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Abstract
The inflammatory response is critical to healing outcome after cutaneous
injury. Our current understanding of the response to injury has been com-
piled from targeted studies on components expected to play a role. It
was hypothesised that an unbiased approach to characterisation of soluble
mediators within the injured tissue might identify additional components,
thereby increasing our understanding of the cellular processes involved. The
aim of this research was to develop and characterise a model of injury with
the potential to identify novel mediators of the early response. Microdial-
ysis was chosen as both the sampling method and the means by which the
tissue was injured as probe insertion causes a single injury that can be
sampled continuously without further damaging the tissue.
Early injury responses were initially characterised in terms of changes in
blood flow and known markers of the inflammatory response, using Laser
Doppler Imaging and a bead-based cytokine flow cytometric assay, respec-
tively. A shotgun proteomic analysis was then undertaken to characterise
of the protein content of the fluid obtained using microdialysis, dialysate.
The phosphorylation status of proteins was also characterised following the
implementation and optimisation of a recently reported method that uses
dendrimer conjugation chemistry to capture phosphopeptides.
Blood flow and cytokine measurements in the dialysate confirmed the oc-
currence of a reproducible inflammatory response to the microdialysis in-
jury. Proteomic analyses of dialysate suggests that it has a relatively sim-
ple protein composition and is dominated by highly abundant components.
The identified proteins originate from both intra- and extracellular loca-
tions and play a range of roles, including regulation of coagulation, cellular
ii
communication, and the immune response. Several are likely to undergo
post-translational phosphorylation and hence their phosphorylation status
was also investigated. Using the phosphopeptide capture method, poten-
tially novel phosphorylation sites were identified in two abundant proteins,
albumin and apolipoprotein L1 at positions S603 and S314, respectively.
Collectively, the data obtained in this investigation increase our knowledge
of the proteins and processes involved in responses to injury, and suggest
that microdialysis may be of some use for studies in this area. Further,
analysis of protein phosphorylation in dialysate suggests that this is an
informative approach that could shed light on extracellular signalling events
that occur during the progression of the response to injury.
iii
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Chapter 1
Introduction
The current understanding of the responses that occur following an injury have so
far failed to lead to efficient interventions in cases of inappropriate healing. It has
been hypothesised that regulation of the inflammatory phase of the injury response is
critical to healing outcome (Eming, Krieg & Davidson, 2007; Stramer, Mori & Martin,
2007). The skin represents an ideal organ in which the early responses, including the
initiation of inflammation can be investigated in humans, in vivo.
1.1 Skin biology and the biology of injury
The skin is the most accessible and largest organ of the human body, accounting
for approximately 15 % of the total adult body mass (Zhao et al., 2008). The function
of the skin is to provide a protective barrier between an organism and its environ-
ment. When this barrier is breached, the skin mounts an inflammatory response to
prevent blood loss, to kill any invading microorganisms and to close any gaps in the
skin barrier (Singer & Clark, 1999). This injury response involves a combination of
resident and infiltrating cellular and molecular mediators from the circulation, which
work together to bring about clearance of the wound and repair. It comprises four
overlapping phases; haemostasis, inflammation, granulation and remodelling. The first
phase, haemostasis, acts to reduce blood loss and plug breakages in the vessel walls
and epidermal barrier with a rudimentary scab, the eschar. The second phase, in-
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flammation, sees the recruitment of the cells necessary to clean the wound and begin
production and remodelling of new tissue and hence arguably represents the most influ-
ential phase in the injury response. Incorrect regulation of the inflammatory response
can lead to a persistent state of chronic, non-healing wounds where the inflammation
is not resolved and tissue destruction continues, while an over-zealous resolution can
lead to fibrosis and loss of function (Diegelmann & Evans, 2004). The goals of wound
healing research are to improve both the speed and efficiency of wound closure and the
aesthetics and functionality of the resultant scar tissue. Furthermore, lessons learned
in uncovering improved wound healing in skin could lead to improved treatments for
chronic inflammation or fibrosis in other tissues. It could also inform diagnostic tests
to predict healing outcome in individual patients, so that appropriate treatment can
be administered in time to prevent the development of such adverse effects.
The histology of the injury response and wound healing has been well characterised,
but the mechanisms which drive these processes are not well understood. Despite ad-
vances in the understanding of growth factor and cytokine influences, therapies guided
by this knowledge have failed to give significant or reliable improvements in wound
outcome. Therefore an alternative approach is required to better characterise these
mechanisms and improve on the current understanding. New analytical technologies,
such as the different proteomic approaches might allow better characterisation of the
optimal response to injury. In principal, they may identify key mediators in control
of the signalling pathways involved in determining the outcome of an injury response.
This potential is likely to be increased further through directly sampling soluble medi-
ators within the injury, locally and specifically.
1.1.1 The skin as an immune organ
The skin is one of the body’s first defences against pathogens, acting as a physical
barrier to infection. Maintenance of the integrity of this barrier is essential and its
structure reflects this protective role. It is composed of two main layers, the outer
epidermis and the inner dermis. The hypodermis, the layer of cushioning subcutaneous
fat immediately below the dermis, containing resident fibroblasts and macrophages,
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is sometimes considered as a third layer of the skin (Kanitakis, 2002). The dermis
and epidermis are further subdivided and are host to a number of key cell types and
structures that contribute to the immune regulation that takes place following an injury,
as shown in Figure 1.1.
The epidermis is divided into four layers, although a fifth, the stratum lucidum, is
present only in palmoplantar skin. The basal layer is composed mainly of epidermal
stem cells, which differentiate into mature keratinocytes during their movement towards
the outer surface of the skin. Once they reach the stratum corneum, these cells, now
known as corneocytes, are highly keratinised, anucleate and dead. From here, they are
sloughed off to be replaced by cells migrating from the stratum granulosum. This cycle
of replenishment ensures that the waterproof barrier is maintained and gives the skin
the regenerative capacity that is so important in recovering from injury.
The dermis consists of two layers, the loose papillary dermis and the more dense
reticular dermis, and is the site of the majority of the cutaneous vasculature. The
papillary dermis is so called due to the finger-like projections or “papillae” formed from
the connective tissue that give the skin its ridged appearance and increases the surface
area for contact across the dermal-epidermal junction and therefore skin strength. It is
comprised mainly of collagen types I and III, with elastin for elasticity and recoil. These
fibres are packed more densely in the reticular dermis, which also contains reticulin
fibres, composed of collagen and fibronectin. Combined, these fibres not only provide
the flexibility required to resist injury, such as by compression, but also provide a
scaffold for infiltrating cells during repair.
Several important structures and cell types reside in the dermis. Tissue macrophages
are situated predominantly in the papillary layer, in order to rapidly intercept any in-
vading pathogens. This removes the time delay that would result from the process of
chemoattraction required to recruit blood monocytes and trigger their differentiation
into mature macrophages. Mast cells are also resident and release vasoactive histamine
in allergic reactions. Sebaceous glands are also located within the dermis and secrete
sebum out onto the skin surface. This is a substance responsible for maintaining the
acidity of the skin which limits microbial growth and therefore reduces the potential
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Figure 1.1: Skin structure. Schematic of the anatomy of human skin. The epider-
mis consists of predominantly keratinocytes, with melanocytes (giving pigmentation),
Merkel (sensory nerve endings) and Langerhan’s (specialised antigen-presenting) cells.
The dermis is composed of connective tissue, predominantly collagen and elastin fibres
and is interspersed with fibroblasts. The connective tissue of the papillary dermis is
loose and forms papillae, finger-like projections (not shown), while that of the reticular
layer is more dense (depicted as a tighter mesh). The dermis is also the site of tissue
macrophages, fibroblasts, hair follicles and associated sebaceous glands, as well as the
dense capillary network termed the dermal vascular plexus. The hypodermis is sub-
cutaneous tissue predominantly composed of adipocytes (yellow ovals) and fibroblasts.
Not to scale. Not all structures shown. Figure adapted from Gray (1918).
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for infection in the event of injury.
Another important structure, the cutaneous vasculature, extends throughout the
dermis (reviewed by Braverman, 2000). It does not reach the epidermis, which is
instead supplied by diffusion from the capillaries imbedded within the dermis. This
capillary network is key to the cutaneous response to injury and responsible for the
visible, cardinal signs of inflammation first recorded by Celsus in the first century, AD.
These signs, the redness, heat, swelling and pain are caused by increased blood flow
to the damaged area and extravasation of its components into the tissue itself. This
extravasation brings the cellular and molecular mediators essential to disinfecting the
wound, further activating resident cells and bringing about repair. Such mediators
include clotting factors to reduce blood loss and seal the wound from the external en-
vironment, proteases to degrade the extracellular matrix and macrophages to phago-
cytose damaged cells. This serves two purposes, to dispose of potentially damaging
agents and to clear the site for the formation of new tissue. Later on, these proteases
are involved in re-modelling the newly formed tissue components to form the mature
scar. These cellular and molecular factors will be discussed in more detail throughout
the course of this research.
Below the dermis lies a layer of adipose tissue involved in insulation and ther-
moregulation, nutrient storage and cushioning against impact injury. It is primarily
composed of adipocytes, but also contains fibroblasts that can become adipocytes, and
possibly vice versa, following acute injury (Andrade, de-Oliveira-Filho & Fernandes,
1998). However, the histological evidence for the latter process is less convincing, as
the investigators were not able to observe changes in specific cells and instead had to in-
fer whether differentiation was in the direction of adipocyte or fibroblast development
from immunohistochemistry data alone. This highlights the importance of studying
temporal changes in the same cells and regions of the injured tissue following such
a response. Differentiation of fibroblasts into adipocytes may represent part of the
re-modelling process, although it has been proposed that adipocytes are an important
source of regulatory cytokines (Pachler et al., 2007; summarised in Klein et al., 2007).
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1.1.2 Overview of the injury response and wound healing in
skin
The response to injury and subsequent healing has been divided into three main
overlapping stages; haemostasis and inflammation, granulation (tissue formation) and
remodelling (Figure 1.2), which will now be considered.
The initial injury generally damages the vasculature, the matrix of the dermis, and
cells within the epidermis - primarily keratinocytes. This damage causes activation of
keratinocytes and vascular endothelial cells, among others, and the subsequent release
of inflammatory mediators. Before the inflammatory response can develop, the con-
dition of the vasculature must first be stabilised and any breaches to the endothelial
layer sealed, until it can replace the missing cells.
Haemostasis is the first stage in the response to injury, its purpose is to seal and
thus prevent excess blood loss from the damaged vessels, while maintaining adequate
blood supply to the injured area. The process of preventing blood loss is induced
by exposure of platelets to extravascular collagen, which occurs as a consequence of
their movement into the tissue through those perforations in the damaged vasculature.
Coagulation is initiated and fibrinogen is cleaved to give active fibrin. This in turn
generates a loose matrix with fibronectin, forming the haemostatic plug that seals
the gaps in the endothelium. Platelets adhere first to the fibrin matrix and then to
each other to complete the seal. They are also involved in early modulation of the
inflammatory response, releasing a great number of protein and lipid mediators once
stimulated by aggregation. Due to their obvious importance as a source of regulatory
compounds, the role of platelets in the response to injury is discussed in greater detail
in Section 1.1.3.3.
Inflammatory mediators released from platelets act in synergy with those released
from the damaged cells of the skin. Blood supply to the damaged tissue is increased,
including a concomitant increase in vascular permeability. Recruitment of leukocytes
is stimulated, to combat infection, remove necrotic tissue and promote repair. Neu-
trophils are the dominant leukocyte sub-type during the early inflammatory phase
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Figure 1.2: Stages of wound healing. Schematic of the time-course of the overlap-
ping stages of the response to injury and subsequent wound healing. The x-axis repre-
sents the time after the injury occurs, the y-axis represents the progress of each stage.
Haemostasis and inflammation are divided into three sub-stages, namely haemostasis
and early and late stages of inflammation, coloured red, orange and yellow, respectively.
Haemostasis typically occurs within minutes, while inflammation can take 24–48 hours,
or more, to resolve. Formation of new tissue, the granulation phase, is shown in green
and the remodelling of this new tissue is represented by the blue section. This remod-
elling may take several months to years, hence the dashed line to indicate this process
continues. Figure adapted from Clark (1988).
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and function to kill and phagocytose any invading pathogens as well as to begin the
breakdown and removal of damaged tissue, discussed further in Section 1.1.4.1. The
“respiratory burst” that releases substances, such as toxic oxygen metabolites for bac-
teriocidal effect, is damaging to the host and so regulation of neutrophil activity must
be closely controlled. They also contribute to the chemoattraction of monocytes, imma-
ture macrophages which proliferate and mature to phagocytose apoptotic neutrophils
and pathogens, and continue the debridement of the wound.
The appearance of macrophages marks the transition into the late inflammatory
stage. Initially, they act to continue the amplification of inflammation, releasing pro-
inflammatory mediators in response to ingestion of pathogens. Once any infection has
been cleared, the phagocytosis of expired neutrophils stimulates a switch to produc-
tion of anti-inflammatory mediators. This switch is critical in the resolution of the
inflammatory response and the progression of repair.
In addition to their phagocytic and inflammatory functions, macrophages release
growth factors, such as vascular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF), epithelial growth factor (EGF) and transforming growth fac-
tors (TGF)α and β. These stimulate the secretion of granulation tissue, including
preliminary matrix components from fibroblasts and the proliferation of endothelial
cells to generate new vasculature (angiogenesis). Re-epithelialisation begins at this
point, with keratinocytes proliferating and migrating along the scaffold provided by
the new matrix. This process displaces the eschar and exposes the replacement tissue.
Fibroblasts first secrete a loose matrix primarily composed of fibronectin and hyalu-
ronic acid which is conducive to the cell migration and proliferation that occurs during
granulation. In the remodelling phase, they switch to production of a collagen and
proteoglycan matrix with a higher tensile strength, required for the mature scar. Matrix
metalloproteinases play a key role in the degradation of excess fibres to leave a matrix
which gives optimal organisation and tension to the new tissue.
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1.1.2.1 Dysregulation of inflammation is responsible for the adverse out-
comes to wound healing
The inflammatory phase of the injury response is arguably the key determinant of
wound outcome (Serhan & Saveill, 2005). A weak inflammatory response risks infection
of the wound, while an excessively strong response leads to delayed healing and the
potential for greater scarring. Furthermore, instances of faster wound healing with less
scarring occur in both foetal and oral tissues in which there is little to no inflammatory
response (Lorenz & Adzick, 1993; Szpaderska, Zuckerman & DiPietro, 2003).
Inflammation is characterised by the progression of leukocyte infiltration, from pre-
dominantly neutrophils to macrophages. These cells not only act to clear the wound of
debris and infection, but release pro- and anti- inflammatory mediators and take part
in both the breakdown of damaged tissue and the formation of its replacement. Hence
the recruitment of these cells is of direct relevance to the later stages, including matrix
deposition and re-epithelialisation (Eming, Krieg & Davidson, 2007). However, it can
also be damaging, in so far as neutrophil-derived proteases and reactive oxygen metabo-
lites degrade both injured and intact tissue (Moraes, Zurawska & Downey, 2006). A
continued release of pro-inflammatory components and neutrophil chemoattractants
will only aggravate the situation further.
Failure to resolve the inflammatory response leads to a chronic wound status in
which tissue destruction by neutrophil proteases continues. This can be a result of
persistent infection causing stimulation of neutrophil activity and the associated release
of cytotoxic components. It can also be a result of a breakdown in signalling, the
causes of which are not yet understood (Menke et al., 2007). Better characterisation
of these signalling mechanisms and comparisons between normal and chronic wound
environments will greatly improve treatments that promote resolution of inflammation.
The converse effect occurs when the resolution of inflammation is too rigourous
and collagen production is not controlled. The deposition of collagen is important, too
little results in a weak scar that may be susceptible to rupture, too much results in
fibrosis. Fibrosis is defined as an excess in matrix deposition that results in alteration
of the tissue architecture and associated reduction or loss of function (Wynn, 2008).
9
1. INTRODUCTION
It is associated not only with disfigurement that occurs with excess scar tissue pro-
duction, but also diseases such as asthma and cirrhosis of the liver. Hence, improved
treatments that prevent disproportionate resolution of inflammation and regulate the
growth factors that cause excessive matrix production would have significant clinical
benefit.
Regulation of the first stages of the injury response, haemostasis and inflammation
is clearly crucial to the wound outcome. It is therefore important to understand how
these stages progress in the normal, successful response to injury.
1.1.3 Injury and Haemostasis - Setting the scene for inflam-
mation
Injury to the skin typically causes damage to the local cells, disruption of the
vasculature and subsequent extravasation of blood components. This disruption of
the vasculature activates the coagulation cascade to restore haemostasis and prevent
excess blood loss, and to generate a provisional fibrin matrix for the migration of
leukocytes and keratinocytes during inflammation and granulation, respectively. The
coagulation process is relatively well understood, so will not be discussed here. Instead,
the reader is referred to the many reviews on the topic, for example, general discussions
on coagulation (Hoffman & Monroe, 2007) and, more specifically, on the role of fibrin
and the fibrinolysis system in wound healing (Clark, 2001; Laurens, Koolwijk & de
Maat, 2006; Takada, Takada & Urano, 1994).
The response to injury also involves the intercommunication between many different
cell types, both resident and from the circulatory system. It involves the activation
of resident cells, such as keratinocytes and vascular endothelial cells. Platelets also
provide a considerable array of inflammatory mediators. The signalling that occurs
as a result of stimulation of these cell types triggers the onset of the inflammatory
response. The contribution of each cell type is discussed in turn.
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1.1.3.1 Keratinocyte response to damage
Keratinocytes are among the first cell types affected by penetrative injury to the
skin and also one of the first to respond. They are also important later on, during gran-
ulation and re-epithelialisation. Keratinocyte activation is relatively well-described, for
example, by Coulombe (1997) and Grinnell (1992). Upon injury, they release stored
interleukin (IL)-1, inducing neighbouring keratinocytes to follow suit and thus ampli-
fying the response. Release of IL-1 then induces the release of other cytokines, such
as IL-6, IL-8 and granulocyte macrophage-colony stimulating factor (GM-CSF) which
initiates an inflammatory response (McKenzie & Sauder, 1990). Table 1.1 shows some
of the cytokines, growth factors and other components released by keratinocytes after
injury and during wound healing, and some of the cell types they target.
Table 1.1: Some examples of inflammatory mediators released by injury-
activated keratinocytes
Mediator Target Cells
GM-CSF∗ Neutrophils, macrophages, Langerhan’s cells, T-cells
ICAM-1∗ T-cells
IL-1α∗ Keratinocytes, fibroblasts, T-cells, B-cells
IL-3∗ Mast cells, basophils
IL-6∗ Neutrophils, macrophages, keratinocytes, T- and B-cells
IL-8∗ Basophils, neutrophils, T-cells
MCP-1† Macrophages
TNF-α∗ Keratinocytes, fibroblasts
IL = interleukin, GM-CSF = granulocyte macrophage-colony stimulating factor, ICAM =
intracellular adhesion molecule, MCP-1, macrophage chemoattractant protein-1, TNF-α =
tumour necrosis factor-alpha, ∗Summarised in McKenzie & Sauder (1990) †Wetzler et al.,
2000.
These mediators cause the up-regulation of chemotactic factors and adhesion molecules,
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leading to recruitment of immune cells and the progression of the inflammatory response
and resolution (Barker et al., 1991; McKenzie & Sauder, 1990). Interleukin-1 is perhaps
the best studied and is involved in the stimulation of over 350 genes, following injury
(Yano et al., 2008). Briefly, it stimulates collagenase secretion from fibroblasts to break
down the existing extracellular matrix, induces expression of leukocyte chemoattrac-
tants and increases adhesion molecule expression on endothelial cells to sequester those
leukocytes from the circulation. These processes will be described in greater detail in
Section 1.1.4. The functions of the remaining cytokines and chemokines within the
injury response and wound healing are described in several reviews (e.g. Gillitzer &
Goebeler, 2001; Werner & Grose, 2003). These have a wide range of effects, but there is
also a large overlap in these functions, to provide back-up mechanisms and to amplify
the signals controlling inflammation.
Regulation of re-epithelialisation by keratinocytes is also under the control of cy-
tokine and growth factor signalling. For example, interferon (IFN)-γ and tumor necro-
sis factor (TNF)-α are involved in the activation of peroxisome proliferator-activated
receptors which stimulate keratinocyte migration to the wound edge (Tan et al., 2001).
GM-CSF is also released from fibroblasts, another cell type, resident within the der-
mis. It it involved in stimulating keratinocyte proliferation, to replace those cells lost or
damaged during the injury. Keratinocytes also stimulate the production of integrins,
expressed on their surface membranes, which form cell–cell and cell–matrix interac-
tions to facilitate cell migration and adhesion in the repairing tissue (Grose et al.,
2002). Re-epithelialisation is not a focus of this research, but further information on
the interactions of keratinocytes with fibroblasts in wound healing can be found in the
several reviews (e.g. Beer et al., 2000; Werner, Krieg & Smola, 2007).
Cytokines and growth factors are clearly important in regulating the recruitment
and activities of both resident and infiltrating cells. However, the degree of pleiotropy
and redundancy, coupled with inter-individual variability in terms of expression levels
of these molecules, makes distinguishing the exact phase of injury very difficult. Alter-
native markers of keratinocyte activation could include anti-microbial peptides, which
are also released following injury and in response to growth factor stimulation, working
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to destroy invading pathogens, in concert with neutrophils (Borregaard et al., 2005).
1.1.3.2 Vascular endothelial cell response to damage
Injury to the vasculature causes activation of the vascular endothelial cells forming
the dermal vascular plexus. These cells play a key role in controlling the delivery of
mediators to the injured site, regulation of leukocyte recruitment and in control of the
extravasation of plasma proteins including immunoglobulins. Later on, in the remod-
elling phase, endothelial cells react to growth factors, including VEGF, to proliferate
and form new vessels to supply the newly formed tissue. This latter function is part of
the later, repair phase in the response to injury, so need not be discussed here.
Disruption of the endothelial cell barrier, as a result of injury, first enables the
passive recruitment of leukocytes and delivery of plasma proteins to the site of injury,
within the clot (Singer & Clark, 1999). Active recruitment of leukocytes to the injury
site is mediated by endothelial cells, however, this will be covered in the relevant
leukocyte sections below (Sections 1.1.4.1 and 1.1.4.2).
Endothelial cells are both responders and activators within the response to injury
and their contribution during inflammation has been extensively reviewed (e.g. Cines
et al., 1998; Contran & Pober, 1990; Cook-Mills & Deem, 2005; Hack & Zeerleder, 2001;
Michiels, 2003). They play an important role in the regulation of inflammatory status
and are key to the recruitment of leukocytes to the site of injury. In response to cy-
tokine stimulation, they release a range of mediators such as cytokines, prostaglandins
and nitric oxide (NO). Cytokine mediators include neutrophil chemoattractants (see
Section 1.1.4.1) and monocyte chemoattactant protein (MCP)-1, thus perpetuating the
inflammatory response. It is interesting to note that the microvascular endothelium
produces MCP-1 in response to TNF-α, but not IFN-γ, stimulation as observed in
macrovascular endothelium (Goebeler et al., 1997). Prostaglandins and NO are both
important regulators of vascular tone, particularly of vasodilatation during very early
inflammation (Goldsmith et al., 1996; Williams & Peck, 1977). NO is also involved in
regulation of a number of additional processes, such as modulation of adhesion molecule
expression and modification of the extracellular matrix, contributing factors in control
13
1. INTRODUCTION
of leukocyte recruitment (reviewed in Bruch-Gerharz, Ruzicka & Kolb-Bachofen, 1998).
In synergy with prostaglandins, NO acts to reduce inflammation, inhibiting platelet
aggregation and expression of adhesion molecules required for leukocyte recruitment
(Kubes, Suzuki & Granger, 1991). The roles of NO and prostaglandins have been
relatively well characterised and widely reviewed, so will not be discussed in further
detail here.
Manipulation of vascular permeability enables regulation of the extravasation of
cells and proteins from the blood into the injured tissue. If extravasation is not con-
trolled it could lead to increased or persistent oedema and the development of a chronic
wound environment. The role of endothelial junctions in the control of vascular perme-
ability in inflammation and the injury response has recently been reviewed (Chanson et
al., 2005), in which several well characterised mechanisms are discussed. TNF-α stimu-
lates a downstream signalling cascade that results in modulation of the actin cytoskele-
ton. The increase in permeability comes from contraction of the endothelial cells, thus
creating gaps between those cells and consequently, within the endothelial barrier (Pe-
trache et al., 2003). A second important regulator of vascular permeability is VEGF,
which mediates phosphorylation of vascular endothelial cadherin (VE-cadherin) and re-
sults in a reduction in adhesion between cells and a subsequent increase in permeability
(Gavard & Gutkind, 2006). Similar activations occur in response to thrombin via pro-
tease activated receptors, through NF-κB signalling (Obreja et al., 2006; Vogel et al.,
2000). Histamine, released from mast cells, causes a transient increase in permeability
that lasts 5-10 minutes, beginning within seconds of release (Wu & Baldwin, 1992).
This permeability increase is thought to occur by both VE-cadherin phosphorylation
and calcium dependant actin modulation mechanisms, as for the previous molecules
considered (van Hinsbergh & van Nieuw Amerongen, 2002). The control of vascular
permeability seems to occur through a few common mechanisms, in response to a wider
variety of mediators. Opportunities for manipulating these mechanisms could therefore
target either components of the common downstream pathways, or the mediators and
their receptors specifically, if one or more are abnormally expressed.
14
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1.1.3.3 Platelets as an important source of mediators
Platelets are the most abundant cell type in the earliest phases of the injury response
(Rozˇman & Bolta, 2007) and perform both haemostatic and inflammatory functions.
As previously mentioned, they begin to aggregate in response to stimuli such as collagen
and thrombin once the vascular endothelial barrier is breached (David et al., 2003).
Platelets are incorporated into the fibrin clot, derived from the cleavage of fibrinogen
by thrombin, where they add to physical structure of the clot itself and act as a
source of cytokines and chemotactic factors that stimulate the infiltration of leukocytes
(Martin, 1997). Chemokines released from platelets and their contribution to the
inflammatory status are reviewed by Gear & Camerini (2003). Briefly, factors such
as ”Regulated upon Activation, Normal T-cell Expressed and Secreted” (RANTES)
stimulate further platelet activation, macrophage inflammatory protein-1α (MIP-1α)
facilitates neutrophil recruitment, and MCP-1, monocyte recruitment. However, these
chemokines are not exclusively involved in those functions mentioned. RANTES, for
example, is also involved in chemoattraction of monocyte, eosinophil and lymphocytes,
MIP-1α also plays a role in monocyte recruitment (reviewed in Rollins, 1997).
It is not just chemokines that are released from platelets. The alpha granules
are a source of approximately 60 growth factors, adhesion proteins, anti-microbials,
proteases, anti-proteases and components of the clotting and fibrinolytic systems and
may represent an important source of novel mediators for therapy. For this reason,
the suitability of platelets as therapeutic agents has been explored, recently reviewed
by Rozˇman & Bolta (2007). Platelet-rich plasma, activated by addition of thrombin,
forms a gel-like substance in which platelets are trapped in a fibrin mesh. This can
be applied to an injury, where the trapped cells can release their granule contents and
initiate healing. The advantage in this technique is that it provides multiple factors
which can act in synergy with each other and thus have a stronger effect than a single
factor alone. Results in diabetic patients and those with chronic ulcers have proved
promising, with some studies reporting almost halving of healing time following the
application of the activated platelet gel-like substance (Hom, Linzie & Huang, 2007;
Mazzucco et al., 2004). The main problems with this method are the variation in
15
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platelet count between donors and the difficulty in storage without activating the cells,
which reduces reliability of the treatment. However, because factors released from
platelets appear to play such an important role in initiating the healing response, they
may act as suitable markers of the normal response to injury. The early success of
platelet gel in therapy would also suggest that the activation of platelets following
injury plays a critical role in outcome and hence that the processes that occur during
the early response, including inflammation, are key.
1.1.4 Inflammation and the cellular infiltrate in injury
The inflammatory component of the injury response consists of an early and late
phase, as previously discussed. The early phase is characterised by the presence of neu-
trophils and the breaking down of existing tissue while the late phase is characterised
by a dominance of macrophages, anti-inflammatory signals and the re-building of the
tissue to heal the wound. Once again, the contributions of the cell types involved will
be discussed in turn.
1.1.4.1 Neutrophils
Neutrophils are the second plasma-derived cell type to infiltrate the wound site,
typically within only a few hours of injury. These cells are recruited early to clean up
the wound by removing any invading pathogens and some of the damaged tissue as
well as regulating cytokine release. Neutrophil involvement following injury involves
several steps; their attraction to the site by chemokines, capture onto endothelial cells
via adhesion molecules, migration between cells to reach the wound site, activation and
then apoptosis once their job is complete.
The primary function of neutrophils is the debridement of the injury site, that
is, removal of necrotic tissue and invading pathogens. This is achieved through the
release of four types of granules - primary (azurophil), secondary (specific), tertiary
(gelatinase) and secretory granules, containing plasma proteins such as albumin, im-
munoglobulins and transferrin. Via these granules, neutrophils release a wide range
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of factors, including antimicrobials, proteases and toxic oxygen metabolites as well
as numerous cytokines and chemokines (Borregaard & Cowland, 1997; Weiss, 1989).
Antimicrobials and toxic oxygen metabolites form part of the armoury against any
invading pathogens, aided by the phagocytic activities of the neutrophils themselves.
This topic is the subject of several reviews (such as Burg & Pillinger, 2001; Levy, 1996;
Witko-Sarsat et al., 2000), to which the reader is referred for further details. Proteases
released, such as elastase and cathepsin G also contribute to bactericidal activity and
their inhibition has been shown to reduce bacterial clearance from wounds (Cole et
al., 2001). Their activity may also contribute to neutrophil infiltration, as targets of
these enzymes include collagen, target of gelatinases, which forms part of the basement
membrane through which neutrophils have to cross. Patients deficient in specific gran-
ules display reduced or absent neutrophil infiltration (Gallin, 1985; Johnston, Boxer &
Berliner, 1992).
An important point to consider with these activities is the damage caused to the
surrounding tissue. Indeed, in several studies of knock-out and knock-down mice, im-
proved healing of sterile wounds has been observed where neutrophils are depleted,
with relative increases of ∼35 % closure of wounds (Dovi, He & DiPietro, 2003). Addi-
tionally, a reduced neutrophil infiltrate is observed in oral mucosa wounds which heal
more quickly than equivalent skin wounds (Szpaderska, Zuckerman & DiPietro, 2003).
Collectively, this suggests that, while neutrophils are important in cleaning the injury,
they are also very harmful. It would be of particular interest to study the stages lead-
ing up to recruitment of neutrophils, to identify if and how their number and activity
are important contributing factors to healing outcome. Considerable progress into the
understanding of neutrophil recruitment, migration and activation has been made over
the past 15 years (Witko-Sarsat et al., 2000).
Neutrophils are attracted to the wound by chemoattractants released from platelets
and resident cells, including keratinocytes and endothelial cells. Such chemoattractants
include IL-8 released from endothelial cells (Utgaard et al., 1998) and Oncostatin M
(OSM) (Kerfoot et al., 2001), released by neutrophils themselves thereby creating a
positive feedback loop (Grenier et al., 1999). These attractant molecules up-regulate
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expression of adhesion molecules on neutrophils that enable them to attach to selectins
on the endothelial cell surface, or up-regulate the selectins themselves. The process
of adhesion has been extensively reviewed (for example, by Ley et al., 2007; Witko-
Sarsat, 2000; Zimmerman, Prescott & McIntyre, 1992), so only key points need be
discussed here. Briefly, release of chemoattractants such as IL-8 causes release of pre-
stored P-selectin from Weibel-Palade bodies within endothelial cells, resulting in its
translocation to the cell surface membrane. P-selectin binds to neutrophils via ligands
such as P-selectin glycoprotein ligand-1 (PSGL-1) which is constitutively expressed
on leukocytes (Sako et al., 1993). This enables transient tethering of neutrophils to
the vascular wall, a process termed ”rolling”, which slows them enough so that they
bind to β2-integrins, forming a more stable attachment. Vessel dilatation assists neu-
trophil attachment as the slower flow rate gives more time for contact to occur. Firm
attachment via β2-integrins may come as a result of neutrophil activation that oc-
curs following binding between, for example, P-selectin and PSGL-1. This triggers a
mitogen activated protein kinase signalling cascade that may regulate integrin speci-
ficity to enable binding to the endothelium, through an as yet unclear mechanism
(Ley, 1996). The exact method by which integrins achieve firm attachment of neu-
trophils to the endothelium is also unclear. Hypotheses include indirect strengthening
of the selectin interactions and the attachment through direct binding to other adhesion
molecules, such as Intracellular Adhesion Molecule-1 (ICAM-1), the latter being the
mechanism employed during T-cell recruitment (McDowall et al., 1998). The attach-
ment of neutrophils represents a bottleneck in the recruitment process, thus providing
an opportunity for intervention. Characterisation of this second stage would increase
the number potential targets for such an intervention, particularly as the increase in
adhesion molecule expression is regulated by several different cytokines.
While such redundancy in the mechanisms bringing neutrophils to the site of injury
offers an obvious evolutionary benefit, it makes identifying critical mediators for ma-
nipulation more difficult. Advances in the understanding of the regulation of neutrophil
recruitment leading to an ability to manipulate this process would be of considerable
clinical benefit.
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1.1.4.2 Monocytes and Macrophages
Monocytes are recruited after neutrophils, usually within 24 hours after injury,
reaching a maximum within 48 hours (Eming, Krieg & Davidson, 2007; Engelhardt
et al., 1998). They perform a number of key functions within the response to injury
and represent the turning point between the pro- and anti-inflammatory stages and
therefore another critical phase with regards to healing outcome. The functions per-
formed include phagocytosis of expired neutrophils and any remaining cellular debris,
presentation of antigens encountered, both amplifying, then dampening, the inflam-
matory response and stimulating repair through the activation of several different cell
types. The role of monocytes/macrophages in the injury response and wound healing
has been reviewed extensively (e.g. DiPietro, 1995; Duffield, 2003; Singer & Clark,
1999), so only a brief summary of their recruitment and functions will be given here.
Monocytes are recruited to the injured tissue following release of chemoattractant
factors, such as MCP-1, IL-8, growth regulated oncogene-α and I-309, although the
latter has more recently been considered to be a lymphocyte chemoattractant instead
(DiPietro et al., 2001; Engelhardt et al., 1998; Miller & Krangel, 1992). Factors such
as RANTES and MIP-1α have been shown to be important in monocyte recruitment
in mice (DiPietro et al., 1998). The involvement of MIP-1α in monocyte recruitment in
humans is unclear. Gaga and colleagues (2008) reported increased recruitment of mono-
cytes following injection of 10 µg of MIP-1α. However, this is a very high concentration
and therefore unlikely to be representative of physiological release. Furthermore, the
authors comment that in some instances, there was in fact a decrease in macrophage
numbers in response to MIP-1α injection. This difference in response highlights the
importance of studying the injury response in humans, as results from animal models
do not always translate.
Monocytes cross the vascular endothelial barrier in a similar manner to neutrophils,
first binding to ligands such as platelet/endothelial cell adhesion molecule-1 (PECAM-
1) and passing between endothelial cells via endothelial cell junctions. This process
has been studied and reviewed extensively, for example, by Liao et al. (1995) and
Muller & Randolph (1999). Following their emigration from the blood to the tissue,
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monocytes mature into their active macrophage form in response to local signals, such
as GRO-α and MCP-1 (Gordon, 2003; Werner & Grose, 2003). Initially, they func-
tion to amplify the inflammatory response through the release of pro-inflammatory
mediators such as TNF-α, IL-1β and IL-6. Later, anti-inflammatory mediators are
released, including IL-10 and TGF-β, to bring about resolution of the inflammatory
response. Macrophages are responsible for the production of new extracellular matrix
and subsequent remodelling to provide a scaffold for replacement tissue to be built,
both directly and through stimulation of other cell types (Hunt et al., 1984; Leibovich
& Ross, 1975). Growth factors are also released to stimulate the recruitment of fibrob-
lasts and the migration of keratinocytes from the wound margin where they can begin
the process of re-epithelialisation (Midwood, Williams & Schwarzbauer, 2004).
Macrophages have been shown to be essential to wound healing in a number of
studies. One of the first to confirm their importance showed delayed wound healing
in response to macrophage anti-sera (Leibovich & Ross, 1975). Mice deficient for two
key modulators of macrophage recruitment and activation, MCP-1 and MIP-1α, also
displayed delayed healing in terms of re-epithelialisation and vessel density (Low et al.,
2001). However, the differences in healing time were not significant from 10 days after
injury, suggesting that a compensatory mechanism may be involved. Studies in mice
deficient for neutrophils and macrophages have been shown to heal at the same rate
as the wild-type equivalents (Martin et al., 2003), although this may be a consequence
of the absence of neutrophils and an inability to mount a ”normal” inflammatory
response. Without these more damaging aspects, the lack of macrophages may have
less of an impact. The authors suggest that there must be a level of compensation
in this situation, with platelet factors fulfilling the stimulatory functions. This model
is therefore unsuitable for demonstrating the necessity of macrophages as it does not
show the effect of their specific depletion or represent an otherwise ”normal” system.
The majority of reports suggest that the action of macrophages is key to the cor-
rect resolution of the inflammatory response and to the initiation of repair. This is
in part regulated by neutrophils, shown by studies in neutropenic mice, in which pro-
inflammatory cytokine release from macrophages is not suppressed (Daley et al., 2005).
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This excess of pro-inflammatory factors means macrophages are often the causal factor
in situations in which fibrosis occurs. This is caused by an over-production of fibrob-
last growth factors and by over-activity of the fibroblasts themselves (Wynn, 2008).
Additionally, timely phagocytosis of neutrophils is of great importance as it prevents
their necrosis and further tissue damage as a result (Vivers, Dransfield & Hart, 2002),
which can lead to the development of chronic wounds. The appropriate recruitment
and regulation of macrophages is therefore critical in ensuring not only stimulation of
repair, but also limitation of damage.
1.1.4.3 Fibroblasts and Mast Cells
The contributions of two additional cell types - mast cells and fibroblasts - should
also be noted, although they are not a focus of the present study.
Mast cells play important roles in the immediate response to injury, although their
necessity for the later stages of normal wound healing is under debate (Artuc et al.,
1999; Egozi et al., 2003; Iba et al., 2004; Weller et al., 2006). They comprise between
2 and 8 % of cells within the dermis, situated close to their targets and sources of
stimulation, such as blood vessels which both supply exogenous signals and respond to
those released by mast cells. Given their location, it is unsurprising that mast cells are
one of the first cell types activated following injury. A large number of pro- and anti-
inflammatory mediators are released, depending on the stage of the injury response. Of
particular interest to the present study is the effect on the vasculature, as mentioned
in the section on vascular endothelial cells 1.1.3.2 above.
Fibroblasts are activated in the later stages of the injury response, that is, during
granulation, matrix secretion and wound contraction (Singer & Clark, 1999). They
are attracted to the wound site by growth factors released by macrophages and ker-
atinocytes, and secrete extracellular matrix components in response, particularly col-
lagen. Following this, they undergo a maturation into myofibroblasts which are re-
sponsible for the contraction of the wound. These cells are not involved in the control
of the initial response to injury and, although their correct regulation is important in
preventing fibrosis, their contribution is not within the focus of this study. However,
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the mechanisms leading to their recruitment is likely to be of interest earlier on. The
role of fibroblasts in wound healing is the subject of a number of reviews, for example,
Eckes et al. (2000) and Werner, Krieg & Smola (2007).
1.1.5 The need for better markers of the injury response
The pleiotropic nature of many cytokines and growth factors means these are inap-
propriate markers of the injury response. They are not present in distinct phases, so
the presence of an individual cytokine will not necessarily be indicative of tissue status.
Comparing changes in levels of a panel of such molecules would improve the accuracy
of characterisation. However, the roles of these in the haemostatic, inflammatory and
proliferative phases makes it very difficult to predict the cellular infiltrate, level of
infection and the progression through inflammation to resolution. The suitability of
cytokines as markers of the inflammatory response are considered further, in Chapter
3.
It is hypothesised that an investigation into the temporal changes in general protein
content of the wound environment could lead to the identification of biomarkers for
distinct stages of the injury response. To achieve this, a method to sample soluble
components from the injury site is required (Sections 1.2 and 1.3), along with methods
to identify unknown targets that are recovered in the sample (Section 1.4).
1.2 Methods of Studying Skin Injury
To date, the majority of investigations into skin injury have focussed on animal
models and human tissue samples, both in vitro in terms of isolated cell populations
and in vivo, in terms of biopsy tissue. More recently, other experiments have assessed
changes in gene expression following an injurious stimulus, using cells obtained from
biopsies (Bryan et al., 2005), or from biological fluids such as plasma and fluid exudate
from the wound surface. The transcriptional control of wound healing was reviewed
recently, by Scha¨fer & Werner (2007). Nucleic acid samples (DNA and RNA molecules)
are typically extracted from tissue or plasma samples, but proteins can also be obtained
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from such body fluids. The proteins themselves, along with their modifications, should
give a more accurate description of the signalling processes in operation, as previously
discussed.
Proteomic technologies offer the chance of identifying novel protein mediators in-
volved in the response to injury. However, the subset of proteins identified will be
reliant on the method by which the injury is sampled. Previous studies of skin injury
have focussed on the use of skin biopsy tissue from both animals and humans, in which
the spatial distribution of cellular infiltrates and specific markers have been targeted
and characterised. The different methods available for sampling the cutaneous response
to injury will now be considered in terms of their suitability for providing a source of
novel markers.
1.2.1 Tissue samples in injury research
Much of the research into the response to cutaneous injury to date has been con-
ducted on solid tissue samples, such as skin biopsies and cell culture models. Im-
munohistochemistry staining of excised tissue samples have shown the location of cells,
cytokines, chemokines and adhesion molecules (e.g. Engelhardt et al., 1998; Juhasz et
al., 1993) at different timed intervals following injury. However, the removal of this
tissue leaves permanent scars, which is undesirable in human studies. Futhermore, it
is also not amenable to more than a few replicates or time-points per individual.
More recently, experiments have been performed using artificial skin constructs
(Speikstra et al., 2007), which avoids the problems of movement and availability en-
countered when using human volunteers, but is unlikely to be truly representative of the
full systemic response. Laser capture microdissection can also been applied, to isolate
specific regions of tissue for later analysis by a wide range of methods, including pro-
teomics, to enable analysis of unknowns (Espina et al., 2007). Along a similar principle,
matrix-assisted laser desorption/ionisation (MALDI) imaging mass spectrometry (MS)
could prove highly informative in terms of spatial analysis of protein expression in tis-
sue sections (Stoeckli et al., 2001), with temporal analysis achieved through sequential
samples. Whole fresh-frozen tissue sections, individual cells or sections produced by
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laser-capture microdissection are coated in an appropriate MALDI matrix and placed
within a modified mass spectrometer containing a mounted camera. The camera pro-
vides a reference to the locations sampled, providing 2-D maps of protein localisation
or molecular mass, with a resolution of 4 µm. However, this method requires specialist
instrumentation that is not yet widely available.
Tissue samples provide a rich source of biomarkers with the potential for novel
identifications, and their analysis has great potential in future studies of the injury
response. However, the vast differences in concentrations of proteins and other com-
ponents within these samples may complicate analysis, masking the identification of
potentially key mediators. Furthermore, they do not allow for continuous sampling in
an in vivo setting and require re-injuring the tissue to gain repeat measures. While
explants and artificial skin constructs might allow for continuous sampling without
re-injury, these samples are not truly representative of the full in vivo response.
1.2.2 Plasma and other biofluids as a source of biomarkers
The most commonly used biological fluids in biomarker discovery experiments are
plasma or serum, and urine. The plasma proteome has been relatively well documented
(Anderson et al., 2004), but its use in injury research has been rather limited. Due to
the systemic nature of serum and plasma samples, these studies tend to be of large-
scale trauma or reperfusion injury instead of a localised, mechanical injury in which
conditions can be controlled and manipulated to better understand the response.
The advantages of using plasma or serum samples are the extent of contact they
have with every cell in the body, the ease of sampling and the abundance of established
and newly developed proteomic analysis protocols. The wide reach of these samples is
also to their disadvantage as a source for biomarker discovery. Proteins released from a
specific population of cells will be in such low quantities relative to the common plasma
proteins as to preclude their detection, a consequence of the large dynamic range of
plasma. The concentrations of different proteins within plasma is thought to exceed
10 orders of magnitude, well beyond the analysis capabilities of current technology of
approximately 2 – 3 in standard MS, 4 – 6 with pre-fractionation (Jacobs et al., 2005).
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One report, as part of the multi-centre collaborative Inflammation and the Host
Response to Injury initiative (http://www.gluegrant.org/index.htm), discusses the dif-
ferent approaches available to reduce this sample complexity, in plasma obtained from
trauma patients. In order to detect potential novel markers of the response to injury,
the 12 most abundant proteins in plasma were first removed using an antibody-based
depletion system, thus reducing the immediate dynamic range of protein concentra-
tions. These proteins constitute an estimated 96 % of the total protein content and
are typically found at high µ – mg/ml levels. Additional fractionations were performed
to enrich for cysteinyl and glycopeptides prior to strong cation exchange chromatog-
raphy, further reducing sample complexity and increasing access to the less abundant
protein components (Liu et al., 2006). These treatments enabled identification of many
proteins involved in inflammatory reactions, including 78 cytokines and cytokine recep-
tors. This is considerably more than the 4 out of an expected 36 found by Anderson
et al. (2004) from 2D-gel electrophoresis-separated, Ig-depleted and low molecular
weight serum fractions. However, these inflammatory markers are often constitutively
expressed in plasma and may be indicative of or confounded by other disease states,
as discussed in Section 1.5.2. Furthermore, these are systemic markers and as such are
unlikely to provide information about the affected, local tissue environment.
Use of cerebrospinal fluid, saliva, sputum and other body fluids is increasing with
demand for a more specific, localised sample, directly representative of the disease en-
vironment of interest. The applications and technical considerations of many different
body fluids in proteomic analysis was recently reviewed by Hu, Loo & Wong (2006).
Analysis of bronchoalveolar lavage (BAL) fluid collected from sclerotic lung was able to
identify the possible involvement of several proteins in protection against inflammation
(e.g. Cu-Zn superoxide dismutase, an antioxidant enzyme) and others (e.g. calumenin,
a calcium-binding protein) in the progression of fibrosis (Fietta et al., 2008). Similarly,
cerebrospinal fluid has been analysed to determine differences between inflicted and
non-inflicted traumatic brain injury in young children, which would of course have im-
portant legal applications (Gao et al., 2007). Both studies highlight the importance of
localised sampling in order to obtain a physiologically relevant subset of protein medi-
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ators. However, with lesser known biofluids comes unexpected problems. In compiling
the sputum proteome, Nicholas et al. (2006) had to overcome the interference of a
high abundance of mucins, highly charged glycoproteins that are highly resistant to
proteolysis.
Unlike the lung (BAL, sputum) or brain (cerebrospinal fluid), the skin doesn’t
immediately appear to have a specifically associated body fluid. Instead, the interstitial
fluid that bathes all cells of the body, including those of the skin, provides a source
of potential biomarkers from this organ. It is formed from plasma filtered from local
capillaries due to hydrostatic pressure, and from the molecular mediators released from
the local cell populations, making it a highly relevant source of protein components.
The use of interstitial fluid and means of collecting it are discussed in the following
section.
1.2.3 Interstitial fluid as the local alternative
The interstitial fluid space is the site of mediator exchange and communication
between cells, therefore interstitial fluid itself is the most appropriate sample for in-
vestigating the signalling processes involved in the response to injury. Sampling of
interstitial fluid directly enables detection of small changes in concentration of cy-
tokines, for example, not detected in plasma samples (Pachler et al., 2007). There
are several methods of sampling interstitial fluid from humans in vivo, including fluid
obtained from skin biopsy samples, suction blisters, capsules, wicks and microdialysis.
Interstitial fluid components can be obtained directly from skin biopsy and other
tissue samples via gentle centrifugation (Bletsa et al., 2006; Wiig, Aukland & Tenstad,
2003). Low speeds of 68-6800 × g are used, to draw off the interstitial fluid without
rupturing the cells and releasing their contents. Validation studies have shown that the
intracellular and plasma contamination levels are negligible (Wiig, Aukland & Tenstad,
2003). Consequently, the interstitial fluid obtained can be assumed to be identical to
that in vivo, with an accurate representation of actual tissue protein concentrations.
While this method enables efficient collection of proteins, it limits the time-course
that can be studied. To study temporal changes, multiple biopsies would need to be
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acquired and this still does not enable continuous sampling. While this is possible in
animal studies, it is inappropriate in human studies where permanent scarring occurs
and less-damaging methods, such as collection of suction blister fluid, are available.
The generation of suction blisters causes an injury response and can be used to
obtain interstitial fluid. Suction blister fluid is obtained by raising blisters on the skin
under negative pressure and removing fluid by aspiration with a needle. It is a very
simple method that has been used extensively for characterisation of skin cytokine
responses to stimuli such as ultraviolet irradiation (e.g. Kuhn et al., 2006) and from
skin disorders such as psoriasis (Reilly et al., 2000). Studies of cutaneous wound repair
utilising skin blisters tend to measure re-epithelialisation rather than the early stages
of inflammation, although interstitial fluid obtained from the blisters would provide
protein components for proteomics analysis. A Pubmed search for suction blister pro-
teomics returns two studies in which several hundred protein spots were detected on
2-D electrophoresis gels from suction blister fluid obtained from both healthy and pso-
riatic skin (Kool et al., 2007; MacDonald et al., 2006). These experiments will be
discussed briefly in the context of the skin proteome in Section 1.5.1 and will be cov-
ered in greater detail in Chapter 4. Unfortunately, despite these successful analyses,
the suction blister method is unsuitable for continuous sampling and therefore tempo-
ral analysis of the injury response. To observe changes over time, several blisters would
need to be raised and then sampled at different timed intervals, but this would still
not give full flexibility of measurement.
Capsules and wicks have also been used as methods for isolating interstitial fluid
components. These devices are implanted into the tissue of interest and interstitial fluid
and soluble components are collected, for example, by absorption in the case of dry
wicks (Wiig et al., 1991). A wide range of solutes can be recovered by either method,
including electrolytes and proteins such as albumin (Zurovsky, Mitchell & Hattingh,
1994) and implantation generates an injury response. To date, there have been no
reports published on the proteome of interstitial fluid obtained by either method, in
humans or other animals, although the ability to measure total protein concentrations
would indicate the possibility exists. However, neither method is likely to be suitable
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for the temporal analysis of the injury response as both suffer the same limitations of
the tissue centrifugation and suction blister techniques. That is, continuous sampling
of interstitial fluid cannot be performed and repeated sampling, with the associated
repeated injury, would be required to obtain temporal data.
Microdialysis is an alternative method for collection of soluble components from
the interstitial fluid that does allow continuous sampling. This involves the insertion
of fine, porous probes which are perfused with physiological saline, mimicking a blood
capillary (Ungerstedt, 1991). Soluble components from the interstitium diffuse into
the probes and are collected as dialysate. The technique has the advantage that it
allows continuous sampling of the interstitium without causing further damage to the
tissue beyond the initial insertion injury, which is of particular benefit in the study
of the early response to injury. Moreover, it enables continuous monitoring of in vivo
processes that will be much closer to the true response than that observed for isolated
tissue or cell samples treated with only a limited subset of those mediators normally
available to the tissue. It was decided that microdialysis was the most appropriate
method of collecting soluble bioactive mediators released from the skin after injury
and this method is discussed in greater detail in the next section.
1.3 In vivo microdialysis for protein recovery
Microdialysis was developed in the 1960s as a method of sampling neurotransmit-
ters from the brains of experimental animals (Bito et al., 1966). Since then it has
been refined and adapted for the sampling of small molecules from many other or-
gans including skin, and more recently for the sampling of larger molecules such as
proteins (Clough, 2005; Rosenbloom, Sipe & Weedn, 2005). The principles and appli-
cations of microdialysis have been extensively reviewed (e.g. Benveniste & Hu¨ttemeier,
1990; Chaurasia et al., 2007; Groth, Ortiz & Benfeldt, 2006; Shippenberg & Thomp-
son, 1997; Stenken, 2006), so only a brief overview of the technique in the context of
protein recovery is necessary here.
Microdialysis operates through the diffusion of soluble molecules from the intersti-
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tial fluid space across the semi-permeable membrane of a probe continuously flushed
with a suitable perfusate (Figure 1.3).
Figure 1.3: Schematic of microdialysis. The probe consists of a tubular semi-
permeable membrane supported by internal guide wire. This is connected to delivery
tubing by a water-tight seal. Perfusion of the probe with an appropriate solution,
termed the “perfusate”, causes solutes to diffuse into the probe, collected as dialysate.
Schematic not to scale.
According to the principles of diffusion, larger molecules will travel more slowly due
to greater impedance by the extracellular matrix environment. Thus, larger molecules
are typically recovered at a lower efficiency than smaller ones. This is represented in
Figure 1.3 by the reduced proportion of the large, green solutes in the probe and in
the vial of dialysate compared to the smaller pink molecules. The continuous flow of
the perfusate through the probe ensures that the concentration gradient is maintained,
enabling uninterrupted sampling of a single region. This is of particular benefit dur-
ing temporal experiments, especially as the collection periods can be varied to suit
the sample volume requirements and time-course of the investigation. The types of
molecules that are recovered can be controlled to some extent by the membrane size,
that is, the molecular mass cut-off (MWCO) of the pores. Smaller MWCO membranes,
for example 5 kDa, will limit recovery to small solutes and exclude most proteins. The
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larger 100 or 3000 kDa membranes should theoretically allow most proteins and protein
complexes to pass into the probe. However, this is rarely the case due to the reduced
diffusion rates of larger molecules, discussed in greater detail in Section 1.3.1.
The 3000 kDa cut-off microdialysis probes used for recovery of larger molecules such
as proteins are constructed from the membranes of renal dialysis capsules. The hollow,
porous fibres are supported by an internal guide wire and fed into fine-bore polythene
tubing, depicted by the black lines in Figure 1.3. This probe is connected to a syringe
pump capable of delivering the perfusate, such as a physiological saline solution, at
microlitre flow rates adjusted to suit the purposes of the experiment. Typical flow
rates range from 0.1 µl/min for studies requiring a higher efficiency of solute recovery
but low volumes of sample to 5 µl/min where larger sample volumes are required at
the expense of solute recovery. The flow rate and sample volume are among the tech-
nical considerations that need to be taken into account in microdialysis experiments,
discussed in the following section.
1.3.1 Technical considerations in in vivo microdialysis exper-
iments
The most important considerations for protein sampling are the efficiency of micro-
dialysis and properties that influence the types of proteins that can be recovered. The
factors affecting the efficiency of solute recovery by microdialysis sampling have been
extensively reviewed (e.g. Shippenberg & Thompson, 1997; Zhou & Gallo, 2005 and
other reviews cited previously), but merit a brief discussion in the context of protein
recovery specifically.
Microdialysis efficiency describes the relationship between the amount of a protein
within the tissue and the amount that is recovered in the dialysate. It is not yet possible
to determine the tissue concentration of a given protein in vivo from the concentration
within the dialysate alone. Instead, a number of different approaches are available by
which this tissue concentration can be approximated. In vitro experiments have shown
the relative efficiency of recovery of large plasma proteins, such as human serum albu-
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min, to be approximately 20 % (Winter et al., 2002). However, it is inappropriate to
extrapolate this to the in vivo environment, because the in vitro experiments typically
dialyse proteins from a free solution. The movements of proteins in free solution are
not inhibited by the presence of extracellular matrix, so there is a tendency to over-
estimate the in vivo concentration based on such experiments. Equally, the osmotic
and physical pressures will be very different within the tissue, which will also influence
the rate of diffusion.
In vivo methods, such as retrograde microdialysis, provide a more appropriate mea-
sure. This method calculates the percentage decrease in concentration of a solute
marker between the perfusate and the collected dialysate. However, these calculations
rely on the assumption that solute uptake is equivalent to the loss of solute within the
perfusate. This seems unlikely given the differences in conditions between the probe
lumen and the extracellular tissue space. Consequently, estimates of tissue concentra-
tion extrapolated from calibration experiments should be confirmed by other means
when possible.
Despite the difficulty in determining actual in vivo concentration, microdialysis re-
mains an invaluable sampling technique for its ability to recover proteins continuously
and without further perturbation of the tissue. Although quantitation of tissue con-
centration would be of great interest, this is not always necessary. Instead, knowledge
of the expected range or degree of change in concentration of a protein in dialysate can
provide sufficient information about the comparative tissue status between conditions.
This continuous sampling has been used for studies over four weeks in length (Borji-
gin & Liu, 2008), however, there a decrease in total recovery is observed with increased
time. Over the course of a dialysis experiment, the pores of the probes can become
blocked, by large protein aggregates for example. In vivo, this is partially a result of the
response to injury but in the short term, blockage occurs passively through adsorption
of solutes to the membrane. Significant blocking of the larger pores was not observed
until three days after implantation of the probe (Wang et al., 2007). However, the
extent of blockage with the smaller pores could not be determined due to limitations
in the resolution of the scanning electron microscope used, so the degree of influence
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remains unknown.
Experiments have shown that there is a reproducible pattern in the change in con-
centration of total protein recovered in dialysate over time (Clough, 2005). An initial
peak in total protein recovered in dialysate is observed immediately after probe inser-
tion. This is followed by a rapid decrease in protein concentration until it reaches a
steady state after a few minutes, reflecting the reduction in protein extravasation from
any damaged vasculature and also the reduction in available protein as it is removed
in the dialysate. The steady-state is hypothesised to occur once the rate of removal
of protein by microdialysis is balanced by rate of the replenishment from the tissue.
Total protein concentration in steady-state dialysate samples from unperturbed skin
and perfused at 3 µl/min is approximately 1 mg/ml (Clough, 2005), compared to skin
interstitial fluid protein content estimated to be >11-30 mg/ml (Fadnes, 1975; Haaver-
stad, Romslo & Myhre, 1997). However, these estimates will vary depending on the
animal, tissue and sampling technique used. Any change in the rate of replenishment
due to biological phenomena will be reflected in a corresponding change in the amount
of protein recovered in the dialysate. Hence, although the tissue concentration of any
specific protein is unknown, the magnitude of change can be determined as percentage
of the total protein recovered in the dialysate and thus provide important information
regarding tissue status.
The effect of tissue depletion is likely to be greatest for larger proteins and con-
sequently, their recovery is often limited, as mentioned in Section 1.3. This is simply
explained by considering that the extracellular matrix exists in the form of a gel and
that larger sized and higher molecular weight proteins will not be able to pass through
the matrix so easily. Hence the low diffusion coefficient for large molecules and the in-
versely proportional relative recovery rate with size (Benveniste & Hu¨ttemeier, 1990).
A compromise between maximal recovery of large proteins and a sufficient volume of
dialysate can be achieved through selection of an optimal perfusion rate. This is one
of the key factors governing the amount of protein that can be recovered by microdial-
ysis, as mentioned in the previous section. Calculations of in vitro protein recovery at
increasing flow rates shows an exponential decrease that reaches steady state at approx-
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imately 5 µl/min. Above this rate, protein recovery is not significantly compromised
and may in fact be increased over longer sampling periods (Clough, 2005). However, a
slower perfusion rate will enable more time for an equilibrium to develop between the
probe lumen and the tissue, giving a dialysate sample that better represents the tissue
concentration of individual proteins.
Finally, only those proteins which are water-soluble and freely able to diffuse within
the extracellular tissue space are available for recovery by microdialysis. However, in-
tracellular and membrane proteins or proteins within complexes bound to the extra-
cellular matrix may be sampled following tissue disruption. Collection of lipid soluble
molecules may be enhanced using different membrane or perfusate compositions (Sun
& Stenken, 2003). The types of molecules that have previously been recovered using
microdialysis are discussed in the following section, with particular emphasis on protein
studies.
1.3.2 Types of molecules recovered by microdialysis
With the importance of microdialysis sampling in neuroscience research, a large
proportion of the molecules targeted for study have been neuropeptides. A list of
neuropeptides, amino acids and other small molecules, such as histamine, that have
been sampled using microdialysis is given in the review by Shippenberg & Thompson
(1997). Since that report, the list of proteins that have been sampled has increased as
larger MWCO probes, new antibodies and new technologies have enabled recovery and
detection of a wider range of large molecules (reviewed in Clough, 2005). However,
these identifications are predominantly due to specific, targeted analyses and will not
generate novel markers.
The past 10 years has seen an increase in popularity of a more global approach to
analysis of biological fluid samples, as proteomic analyses have become more advanced
and more widely available. These techniques enable identification and quantitation of
unknown targets, removing the limitations to those target molecules for which suitable
antibodies have not yet been generated.
Once again, neuroscience was one of the first fields to adopt such technologies
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for use in conjuction with microdialysis sampling in humans. No studies combining
microdialysis in animals with proteomic analysis had been published at the time of
writing. Maurer et al. (2003; 2007) and Haskins et al. (2004) have been among the first
groups to publish on the proteome of cerebral dialysate. In the 2003 paper, Maurer and
colleagues identified 27 proteins, including 10 specific to cerebral dialysate compared
to cerebrospinal fluid. Proteins identified included neuropeptide precursors, structural
proteins and plasma proteins such as neurogenin, fibrinogen and creatine kinase. Thus
demonstrating that this is an informative and successful approach to analysis of the
local tissue environment and dialysate. The range of molecular mass and pI values for
the identified proteins was between 13 – 190 kDa and 4.5 – 7.8, respectively. This is a
broad range of size and a pI range similar to that of the skin (Marro, Guy & Delgado-
Charro, 2001). Several classes of proteins, such as those that are insoluble or bound to
insoluble structures, are excluded by microdialysis sampling for reasons covered in the
previous section. However, it is likely that a large proportion of signalling molecules
are able to diffuse freely through the interstitial fluid space and thus be recovered
by microdialysis. Therefore, it is hypothesised that this microdialysis-injury sampling
model provide a protein-rich sample from which novel markers of the injury response
may be obtained. The methods by which this sample is analysed will determine the
types of markers that can be identified.
1.4 Analytical approaches to characterising the in-
jury model and identifying novel markers
Several approaches are required in characterising the inflammatory response in skin
to the microdialysis model of injury. Preliminary, non-invasive measures are required,
alongside measurements of existing markers, to characterise the injury model and put it
into the context of the existing knowledge. Once the correlation between the sampling
period and the expected progress of the response to injury have been determined, the
presence of novel markers can be investigated.
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1.4.1 Non-invasive quantification of the inflammatory response
to skin injury
The vascular response to injury is an important measure of inflammation as it is
the mechanism behind three of the cardinal signs of inflammation; calor, rubor and
tumor, that is, heat, redness and oedema. The heat comes from an increased flow of
blood from the body core, which is at a higher temperature than the skin circulation.
This increase in blood flow to the area is visualised as the increased redness to the
skin. The oedema comes from increased permeability of the capillaries to plasma and
protein. It is possible to measure inflammation non-invasively, by quantifying these
three properties of the inflammatory response.
1.4.1.1 Quantitation of changes in cutaneous blood flow in the response to
injury
Several methods are available for the measurement of changes in cutaneous blood
flow. These were reviewed by Lima & Bakker, 2005; Swain & Grant, 1989 and Venne-
mann, Lindken & Westerweel, 2007 and so will not be described in detail here. While
skin temperature can be measured and is related to the amount of blood flow, a more
appropriate and accurate measure of inflammation is the redness, that is, the amount
of blood flow at the injury site.
Skin colour can be determined by colorimetric methods, as a measure for erythema
(reviewed by Fullerton et al., 1996). While removing the subjectivity of the human
eye, these methods are better suited to studies into irritant reactions where there is a
well-defined and more pronounced region of inflammation, and more direct measures
of cutaneous perfusion are available.
Methods using radio-labelled tracers give a more accurate measure of skin blood flow
but are invasive. Instead, a commonly used group of non-invasive methods for blood
flow measurement take advantage of the Doppler frequency shift. This is the diffraction
that occurs when low-power red laser light is shone onto moving objects, specifically
erythrocytes within the dermal vascular plexus in this instance. The magnitude of this
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diffraction is a product of the velocity of the erythrocytes, thereby giving a measure
of the rate of blood flow over a given area (Vongsavan & Matthews, 1993). The two
predominant forms of laser Doppler analysis are perfusion monitoring (fluximetry)
and perfusion imaging, reviewed in Rajan et al. (2007). Both forms enable non-
invasive measurements of relative quantification, but only perfusion imaging enables
measurements over a two-dimensional area as opposed to the single point, continuous
measurements of fluximetry. As injury affects the tissue across a three-dimensional
volume as well as over time, perfusion imaging is better suited than fluximetry in this
study.
1.4.1.1.1 Laser Doppler imaging to quantify blood flow Laser Doppler flowme-
try was first used to measure vascular blood flow in humans during the 1970s (Stern,
1975). However, this method measures only at a single fixed point and does not take
into account the local heterogeneity of blood flow in the skin. More recently, the
technique has developed to enable 2-D measurements (Essex & Byrne, 1991), using
a laser Doppler imager. This instrument measures blood flux within both the small,
nutritive capillaries and the underlying arterioles and venules of the skin vasculature
by calculating the degree of refraction of a low power laser light shone onto the skin
(Basic Theory and Operating Principles of Laser Doppler Blood Flow Monitoring and
Imaging (LDF & LDI), Issue 1, 2003). Figure 1.4 shows the components of the Laser
Doppler Imager.
Briefly, low power (∼2 mW) laser light is shone onto the skin, via a scanning mirror
that deflects the light in a raster pattern across the area of interest. On contact with
the skin, the beam scatters. The majority of the light is reflected back along the same
path, either from the skin surface, or from static structures within. Light that hits
moving objects, predominantly erythrocytes, is refracted and returns at a different
frequency. This light penetrates to a depth of between 0.6 and 1 mm below the skin
surface. The returning light is detected by the photodiodes and the signal processed
to produce a 2-D image of flux, the velocity of the erythrocytes as a function of their
number concentration, across the scanned area. This image can then be analysed
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Figure 1.4: Components of the Laser Doppler Imager. Light from a 633 nm, Helium-
Neon laser is shone onto the skin via the scanning mirror. Refracted light is detected by
photodiodes and the signal processed into a 2-dimensional image. The camera takes a black
and white photograph for orientation. Figure adapted from Basic Theory and Operating
Principles of Laser Doppler Blood Flow Monitoring and Imaging (LDF & LDI), Issue 1,
2003.
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off-line to determine mean blood flux over a given area of interest.
Laser Doppler imaging has been successfully combined with microdialysis exper-
iments into inflammatory reactions, as it does not effect the tissue under study. It
has also been used to investigate the vascular response to microdialysis probe inser-
tion (Groth & Serup, 1998), so will provide a useful measure to show that the results
obtained in the present study are comparable with the existing literature and are thus
representative.
The main disadvantage of this method is the time taken to perform the 2-D scan,
because the entire area of interest currently cannot be scanned simultaneously. This
can be somewhat off-set in studies of the vascular response to microdialysis probe
insertion by the necessary staggering of needle insertions. An experienced investigator
can insert the guide needles within the same time frame as the scan, thus avoiding
differences between insertion and scan time between injury sites.
The measurements of changes in cutaneous blood flow during inflammation can be
complemented by measurements of capillary permeability to give a more comprehensive
analysis of vascular responses in inflammation.
1.4.1.2 Quantifying vascular permeability in response to injury
During an inflammatory response, the permeability of dermal capillaries to protein
increases to enable increased delivery of the necessary mediators. One common mea-
sure for quantifying vascular permeability and the associated local swelling, protein
and fluid extravasation is to measure skin thickness, either using calipers, or by ultra-
sound methods. Changes in skin thickness in response to microdialysis probe insertion
have been reported previously (Groth & Serup, 1998). Of the measures explored in
that study, only skin thickness remained constant throughout the duration of the ex-
periment, following probe insertion. While showing that the oedema is present over at
least the first 2 hours after insertion, this does not describe any changes in the content
of this fluid.
The permeability of capillaries to protein has previously been measured using radi-
olabelled tracers (Aschheim & Zweifach, 1961; Graham & Evans, 1991) or dyes such as
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trypan or Evans blue that bind to proteins (Ferrero, 2004; Moitra, Sammani & Garcia,
2007 and references therein). However, if the dye molecules become free, they will lead
to an over-estimate of capillary permeability. Furthermore, these methods are more
invasive and not ideal for human in vivo studies, especially for measurement on a local
scale. Instead, the safest, minimally invasive method would be to measure the recovery
of markers of vascular permeability or of total protein concentration in the dialysate
as a surrogate for extravasation. Total protein concentration can easily be quantified
from 10-20 µl samples using commercially available assay kits. Several studies have
already quantified the protein concentration in dialysate samples from microdialysis at
different perfusion rates (Clough, 2005; Klede, Handwerker & Schmelz, 2003; Sauer-
stein et al., 2000), which will enable comparison of the results obtained in the present
study to the existing literature.
Several mediators involved in increasing macromolecule permeability of the en-
dothelial barrier, including histamine and the cytokines TNF-α and VEGF were dis-
cussed previously, in Section 1.1.3.2. The recovery of histamine in dermal dialysate has
been well characterised in several studies into skin allergy (e.g. Groth, Jørgensen &
Serup, 1998; Petersen, Church & Skov, 1997), so will not be repeated here. TNF-α has
been recovered from skin using microdialysis in several experiments which show only
low levels, < 20 pg/ml for up to 8 hours after injury (Averbeck et al., 2006; Clough
et al., 2007). Recovery of VEGF from the skin by microdialysis has not yet been re-
ported, so quantification of this factor would provide a second measure of endothelial
barrier permeability and contribute to knowledge of the cytokine profile in response to
microdialysis probe insertion.
1.4.2 Measurement of existing markers of inflammation in
dialysate samples
Previously, microdialysis samples have been analysed for specific targets, using
a wide variety of methods such as enzyme-linked immunosorbent assays (ELISAs),
radioimmunoassays (Blakeman, Wiesenfeld-Hallin & Alster, 2001), HPLC (Grabb et
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al., 1998) and Western blotting (Planas et al., 2002).
Western blotting techniques are not easily multiplexed, where more than one target
is being investigated and the method is quite time consuming. Also, unless protein
transfer is optimal, there may be loss of protein during blotting and therefore an
underestimate of protein concentration. Radioimmunoassays have rather been replaced
by the safer, more sensitive ELISA format. ELISAs are currently considered the gold-
standard for quantification of individual target molecules and are increasingly being
used in multiplex experiments (Clough et al., 2007). However, multiplex kits are not
very flexible and custom panels are expensive. Furthermore, the volume requirements
for these assays are high, which limits the temporal resolution that can be achieved.
More recently, bead-based assays have been used to measure the concentration of
multiple cytokines in dialysate samples of as little as 50 (Angst et al., 2008) or 15 µl
(Ao et al., 2005). The two most widely available multiplex bead assay platforms are
the Luminex system, requiring its own analysis instrumentation, and the cytometric
bead array produced by BD Biosciences, which is compatible with most flow cytometer
instruments.
1.4.2.1 Multiplexed cytokine analysis using the BD Biosciences cytometric
bead array assay
The cytometric bead array (CBA) Flex Set consists of a master kit containing all
the necessary buffers, and individual cytokine kits with the specific antibody-coated
beads, detection reagents and standards. This allows the investigator to select a unique
panel of targets, according to the requirements of their experiment.
The assay uses a sandwich principle, in which cytokines within the biological sample
are conjugated first to an antibody coated bead and then to the phycoerythrin (PE)
fluorescent detection reagent, as shown in Figure 1.5. The main advantages of this
method over the alternatives are the effective number of replicates and the ability to
multiplex in very low sample volumes (∼ 50 – 100 µl).
Briefly, protein samples are incubated with the capture beads coated with antibodies
to the target analyte(s), which bind if present. The fluorochrome(s) conjugated to
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(a) (b)
(c) (d)
(e)
Figure 1.5: Principle of the CBA assay. Depiction of the main steps involved in the
conjugation of cytokines from dialysate to the antibody-coated beads and detection reagent.
a) The sample is incubated with the anti-body coated beads. b) Cytokines bind to the appro-
priate antibodies on the bead, while other molecules cannot. c) The antibody-conjugated PE
detection reagent is added, binding to the corresponding cytokine. d) Unbound components
are removed by a wash step. e) Key to the symbols used.
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another antibody against the target analyte(s) are then added and bind to both free
and bead-bound molecules. Excess capture beads and unbound fluorochromes are
removed in a final wash step. Analysis is performed using flow cytometry, where the
instances of the detection of each capture bead and the cumulative fluorescent intensity
of the PE-detection reagent are counted for each analyte captured within the sample.
Each bead is equivalent to one well in an ELISA experiment, so the CBA assay gives
the equivalent of 300 replicates if the recommended settings are used (Human Soluble
Protein Master Buffer Kit Instruction Manual, 2007).
Each capture bead in the Flex set is of a particular size and fluorescence. These
two parameters give each bead population a characteristic profile of forward and side
scatter within the flow cytometer, and therefore occupies a specific location within a
two-dimensional grid. This enables up to 30 different beads to be combined into a
multiplex panel, although sensitivity is reduced as the number of targets in the panel
increases. There is some redundancy within the grid system, so care must be taken to
ensure that bead positions are not duplicated within a multiplex panel.
Use of cytokine multiplex arrays will enable characterisation of an injury model in
terms of the existing wound literature, but additional approaches are required if novel
targets are to be identified.
1.4.3 Global assessment of protein content to enable the dis-
covery of novel markers
To date, the majority of wound healing studies have used a rather piecemeal ap-
proach, investigating the roles of small groups of targets. With the development of
gene microarrays, changes in RNA transcripts in response to injury have now been in-
vestigated, giving a greater view of the molecular events that occur (reviewed recently,
Scha¨fer & Werner, 2007). However, such a global approach has been limited in terms
of protein studies.
While microarrays give an important indication of the genes that are activated in
a response, they cannot give any clues to the activation status of the gene products.
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By studying the proteins themselves, a clearer understanding of their activation and
interactions can be achieved. Furthermore, by using proteomics methods to identify
the protein content of the dialysate samples from injured skin, a panel of potential
markers can be determined for further investigation.
Graves & Haystead (2002) published a comprehensive review on proteomic tech-
nologies and applications in molecular biology, to which the reader is referred for a
more detailed background.
1.5 Shotgun proteomics for surveying the proteome
of biological fluids
Top-down or “shotgun” proteomics enables a survey of the components within a
sample, the most common method being gel electrophoresis-liquid chromatography-
tandem mass spectrometry (GeLC-MS/MS). This comprises an initial 1 or 2-D sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE), “Ge”, separation
step and subsequent band or spot excision. This is followed by in-gel digestion of
proteins with a site-specific endo-protease prior to further separation by liquid chro-
matography (LC) and identification by tandem mass spectrometry (MS/MS). Shotgun
proteomic techniques and their application to biomarker discovery and biological fluid
samples is described in several review articles, including Hu, Loo & Wong (2006),
McDonald & Yates (2002) and Wu & MacCoss (2002).
Two-dimensional gels are traditionally used for the identification of differentially
expressed proteins, in which samples from two conditions are run on two separate gels
and the differences in spot size compared. Differentially expressed protein spots can
then be excised and the proteins identified. It is possible to excise all detected spots
for analysis, but this risks missing proteins that are below the level of detection with
the gel stain used. Instead, use of a 1-D separation provides an initial fractionation
step to reduce sample complexity, without the loss of very low abundance proteins.
The single gel track is divided into 20 – 30 slices of equal size which are then subjected
to in situ digestion a site-specific protease such as trypsin. No proteins should be lost,
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because the entire track is retained, as illustrated in Figure 1.6.
Digested proteins from each excised band are then fractionated further by liquid
chromatography before injection into the tandem mass spectrometer, as previously
described.
No studies combining microdialysis of human skin and shotgun proteomics have yet
been published. However, the proteome of brain dialysate discussed in Section 1.3.2
(Maurer et al. 2003), shows that these technique can be combined successfully. While
the proteome of brain dialysate will bear relatively little resemblance to that of the
skin, extensive investigation is being conducted into the proteome of human plasma,
from which interstitial fluid is partly derived.
One of the most comprehensive studies of the human plasma proteome to date was
published in 2004 as a collaborative project combining three proteomic experiments
with an extensive literature search (Anderson et al., 2004). Whilst this study provided
a vast amount of data, it highlighted the need for care in its interpretation. While 1175
individual components were identified between the four sources, only 46 were shared
by all. A little under 20 % of proteins featured in two or more sources, although the
authors inadvertently admit the literature search was not exhaustive. Indeed, pigment
epithelium derived factor was included in the subset of proteins found in all three exper-
imental datasets and not in the literature dataset, despite it being reported in plasma
in 2003. Differences between experimental datasets are likely due to the different sam-
ple preparation and separation techniques, as well as inter-individual differences due to
the low sample number. Knowledge of the components of plasma will inform which of
those within dialysate are likely to be derived from plasma and which are more likely
to have been produced locally by the injured tissue.
1.5.1 The proteome of skin
Investigations into the skin proteome using different sampling methods should in-
form the types of local proteins that may be recovered using microdialysis. Very few
studies into the proteome of human skin in vivo have been published. Of those, the
majority look at differential expression of proteins between healthy and diseased skin.
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(a) (b)
Figure 1.6: Separation and excision of proteins from 1- and 2-D gels. The entire
track from a 1-D gel (a) is excised into equal-sized bands (blue dashed lines) which are then
subjected to digestion and subsequent mass spectrometry. In contrast, detected protein spots
in 2-D gels (b) are either all excised, or only those which have been differentially regulated
(blue circles) - such as increased or decreased concentration (shown by changes in staining
intensity, or an appearance/absence of a spot in one or other gel) or altered isoelectric point
or mass (indicated by a shift in either the x- or y-axis). Proteins present below the level of
detection for the chosen stain will not be visible on the gel and therefore cannot be removed
and identified.
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Aden et al. (2008) identified 23 proteins that were increased and 3 that were de-
creased between biopsies from healthy human skin and a fibrotic wound healing model,
scleroderma lesional skin. Proteins were separated by 2-D SDS PAGE and those which
demonstrated > 3-fold differences in expression between the two conditions were iden-
tified using peptide mass fingerprinting with MALDI-MS, rather than LC-MS/MS.
The identified proteins included those involved in differentiation of the epidermis (ker-
atins), motility (tropomyosin and vimentin), protein folding and protein metabolism
(e.g. serum amyloid, α-1-anti-trypsin) and extracellular matrix components, such as
α-collagens.
Proteomic analysis of human burn wound biopsies revealed proteins involved in
acute stress, metabolic responses, inflammatory responses, cell migration and prolifer-
ation, structural proteins and those involved in the maintenance of cellular integrity
(Pollins, Friedman & Nanney, 2007). These included keratins, heat shock proteins,
fibrinogen and vimentin, previously identified in skin wounds. However, both this and
the above-mentioned study used solid tissue samples, and so will contain a wider range
of proteins, including intracellular and bound proteins that are unlikely to occur in
interstitial fluid. Two studies looking at the protein content of skin blister fluid have
recently been published.
Macdonald et al. (2006) published on the differences between normal skin and
psoriatic skin in humans, using a suction blister sampling technique (n=1 in each
group). A 2-D gel technique was used, in which only those spots significantly differ-
entially expressed were subsequently identified. The proteins listed were significantly
disease-associated or differentially expressed as a result of treatment with IL-1β, a pro-
inflammatory cytokine. These included common plasma proteins such as complement,
haptoglobin and apoliprotein. However, the authors did note a difference in the overall
spot patterns compared to plasma, suggesting that there are detectable differences in
the identities of proteins expressed in plasma and skin.
The following year, Kool et al. (2007) published on the proteome of suction blister
fluid in healthy human volunteers. Although they were able to identify 401 proteins
in the blister fluid, of which 202 were not found in plasma, only those that have been
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reported as biomarkers or potential biomarkers were listed.
1.5.2 Considerations for biomarker discovery using proteomics.
The suction blister fluid proteome reported by Kool et al. (2007) used depletion of
specific, highly abundant proteins to increase proteome coverage. The proteins removed
included human serum albumin, estimated to comprise 40 – 50 % of the total protein
content of suction blister fluid. Removal of these proteins increases the analysis capacity
for less abundant components, but will reduce the overall protein concentration in a
sample. In comparing the protein content in blister fluid to that in plasma, the authors
report 202 proteins unique to suction blister fluid, 41 unique to plasma and 199 common
to both sources. While the identification of only 240 proteins in plasma initially seems
to be a dramatic underestimate, given the 1175 components identified by Anderson
et al. (2004), each experimental source in that investigation contributed only 283 –
475 proteins once non-human proteins and redundant identifications had been removed.
These differences highlight the influence of sample preparation and the analysis method
chosen on the sub-set of proteins that can be identified.
Protein identities are inferred according to the matching of sequenced peptides ob-
tained from tandem MS analyses. Complications in protein identification arise where
peptide sequences are not unique to a single protein. This is particularly problematic
when trying to distinguish between different isoforms of a protein. Unless a peptide
containing amino acid sequences unique to a particular isoform are identified, this dis-
tinction cannot be made. Equally, where different proteins share identical regions of
sequence, they may contain several identical peptides. Again, an unambiguous identi-
fication cannot be made without a unique peptide that distinguishes the true protein
from the other candidates. Furthermore, there is redundancy in the protein databases,
with many proteins having more than one name and associated entry. It is important
that automatically-assigned identifications be manually examined to check for such
instances. The problems of this inference system for protein identity assignment has
been reviewed in detail (Nesvizhskii & Aebersold, 2005).
One final consideration is particularly important in terms of biomarker discovery.
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It has become increasingly clear that particular groups of proteins appear on lists of
differentially regulated components with surprising frequency. Petrak et al. (2008)
conducted an investigation into reports of differentially regulated proteins, compiling
a list of the most commonly identified proteins in human, rat and mouse experiments
published between 2004 and 2006. Of note to this study, given the identifications in
other skin proteome studies, are the inclusion of keratins and vimentin in the top 15
protein families. Analysis of post-translational modifications may shed light on whether
these proteins are differentially activated in different studies.
1.6 Reversible protein phosphorylation as a crucial
mechanism for regulation of protein function
Another advantage to studying proteins themselves is the ability to identify mod-
ifications and their effects. Reversible protein phosphorylation is the most common
covalent modification in mammalian systems. It is involved in the control of a vast
number of processes including metabolism, signal transduction, cell division, develop-
ment and death, immune responses and inflammation (Berwick & Tavare, 2004).
The role of reversible protein phosphorylation in control of intracellular signalling
has been investigated extensively and has been reviewed comprehensively in organisms
from bacteria to humans (e.g. Hunter, 2000; Pawson & Scott, 2005; Stock, Ninfa
& Stock, 1989), with over 150000 entries for “protein phosphorylation” in Pubmed.
However, extracellular phosphorylation has received far less attention but is likely to
be of equal importance, particularly in relation to plasma proteins and other secreted
components that provide the means by which cells communicate with each other.
The role of ecto-phosphorylation by kinases on the external side of the cell surface
membrane is important in control of the immune response, such as in platelet or com-
plement activation (reviewed in Redegeld, Caldwell & Sitkovsky, 1999). The human
plasma proteome has been reported to contain several extracellularly active kinases
and protein phosphatases (Anderson et al., 2004). This suggests that there are several
sources from which regulators of phosphorylation status can infiltrate an injured tissue
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and influence the function of resident proteins.
In eukaryotes, phosphorylation occurs on serine, threonine and tyrosine residues
(Sickmann & Meyer, 2007), on the oxygen atom of the hydroxyl group on the amino
acid side chain. The negative charge added by the phosphate group can attract pos-
itively charged amino acids within the protein, altering the conformation. This has
an allosteric effect on enzyme action, for example, either activating or inhibiting the
active site. Failure to correctly regulate reversible phosphorylation can lead directly to
the development of diseases including alzheimers, cancer and heart disease (reviewed
in Hunter, 1998, among others). Up to 5 % of the vertebrate genome is predicted
to encode either protein kinases or phosphatases; enzymes that catalyse the addition
or removal of a phosphate group respectively. It is hypothesised that over 30 % of all
proteins can undergo phosphorylation (Schmidt, Schweikart & Andersson, 2007). How-
ever, because protein phosphorylation is a reversible, post-translational modification, it
is impossible to predict accurately if, where and when a protein will be phosphorylated
from the cognate DNA sequence alone. This means the protein itself must be isolated
and investigated. Since many phosphoproteins are present in low numbers and only a
fraction of those available phosphorylation sites are actually phosphorylated at any one
time, pre-enrichment is often required. The available methods for phosphoproteome
analysis, including pre-enrichment are discussed in Chapter 5, along with examples of
protein phosphorylation in the regulation of the response to injury.
1.7 Aims and Objectives of the Study
To date, the sequence of events that occur following an injury and the subsequent
inflammation have been partially characterised in terms of cellular infiltrate and a few
key cytokines and growth factors. However, these have failed to lead to the development
of suitable treatments. It would be of considerable clinical benefit to have a diagnostic
test with which to predict the healing outcome for an individual patient, and in cases
where aberrant responses were expected, a method by which to identify which factors
were altered. The aim of this study was to explore the very early injury environment
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to search for potential markers of the response to injury, particularly those that could
function as targets for improved treatments.
The hypothesis tested in this work was that interstitial fluid represents an important
source of mediators directly involved in the response to injury. Local sampling of
mediators within the interstitial fluid space will provide a novel and relevant insight into
the extracellular signalling processes that are involved in the initiation and development
of the acute inflammatory response following injury.
The combination of dermal microdialysis and proteomics technologies provided a
novel method of biomarker discovery, however, as they had not been used together in
skin research, it was first necessary to conduct studies in healthy volunteers to validate
the suitability of these methods. An improved model of injury is required, as existing
methods are either not well tolerated in temporal or repeat investigations or are un-
suitable for such localised sampling. It was hypothesised that through the use of global
protein analyses, the temporal response to needle injury could be better characterised
in terms of a greater range of mediators and therefore lead to the identification of more
specific markers of the injury response.
The aims of this project were as follows:
1. To develop a model of skin injury suitable for sampling early biomarkers of the
tissue response.
2. To validate the injury model using known biomarkers of the injury response.
3. To identify protein content of interstitial fluid obtained from injured skin.
4. To investigate post-translational modifications of proteins relevant to the early
injury response.
The work conducted to develop and validate the model of injury is covered in
Chapter 3, the protein content of dermal interstitial fluid is covered in Chapter 4 post-
translational modifications are investigated in Chapter 5.
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Materials and Methods
This chapter presents the methods used during the course of this research. The
reagents and instruments used are listed first, followed by the general methods. Specific
alterations to the protocols given in this chapter are included in the appropriate results
chapter.
2.1 Reagents and instrumentation
The reagents used in this study are listed in Table 2.1. Where identical reagents
have been sourced from multiple companies, their use has been noted as appropriate
(within the text). Water used was ultra-pure unless stated, purified using a MilliQ
system (Millipore). All experiments, including incubation and centrifugation steps,
were conducted in a temperature controlled environment at 22◦C, unless otherwise
stated.
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Table 2.1: List of the reagents used during the course of this research and
the supplier from which they were obtained.
Reagent/ Item Company
Acetonitrile Fisher Scientific
Acetyl chloride Fluka
α-cyano-4-hydroxycinnamic Acid Sigma
β-Casein from Bovine Milk Sigma
Bicinchoninic Acid Assay Kit Sigma
Biosafe Coomassie G-250 Stain BioRad
Calibrite Beads BD Biosciences
CBA 30-plex Bead Mixture BD Biosciences
“cOmplete mini” EDTA-free protease inhibitors Roche Diagonostics Limited
Cryo-Vial, 1.0 ml Ult. Security Ext Thd FS Alpha Labs
2,5-Dihydroxybenzoic Acid Aldrich
DTT (Dithiothretiol) Sigma
EMLA Local Anaesthetic Cream Astra Zeneca
FACS tubes (Polystyrene) BD Biosciences
Fine bore polythene tubing (O.D. 1.05 mm, I.D.
0.52 mm)
Portex
Flexifuse tubing Alaris Medical
Glu1–fibrinopeptide B Sigma
Human IFN-γ Flex Set (Bead E7) BD Biosciences
Human IL-10 Flex Set (Bead B7) BD Biosciences
Human IL-6 Flex Set (Bead A7) BD Biosciences
Human MCP-1 Flex Set (Bead D8) BD Biosciences
Human MIP-1α Flex Set (Bead B9) BD Biosciences
Human OSM Flex Set (Bead D5) BD Biosciences
Human Soluble Protein Master Buffer Kit BD Biosciences
Human VEGF Flex Set (Bead B8) BD Biosciences
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Reagent/ Item Company
Hydrochloric Acid Fisher Scientific
Imidazole Sigma
Iodoacetamide Sigma
MES (2-(N-Mopholino) ethanesulfonic acid)
Buffer
Sigma
Methanol (standard) Fisher Scientific
Methanol (anhydrous) Fisher Scientific
Multi affinity removal system column Human 6 Agilent Technologies
N -(3-Dimethylaminopropyl)-N ’-
ethylcarbodiimide
Fluka
NaCl Fisher Scientific
NanoSep Centrifugal Device, 3 kDa MWCO Pall Corporation
NanoSep MF Centrifugal Device, 0.2 µm Pall Corporation
NuPAGE 4-12% Bis-Tris Gels Invitrogen
NuPAGE MOPS SDS running buffer Invitrogen
NuPAGE LDS sample buffer Invitrogen
Orthophosphoric Acid (H3PO4) Fisher Scientific
Paraformaldehyde Fluka
Phosphopeptide Positive Control Set from bovine
casein
Sigma
Phosphorous Pentoxide for dessicators BDH
PhosSTOP phosphotase inhibitor cocktail Roche Diagnostics Limited
PhosTrap Phosphopeptide Enrichment Kit Perkin Elmer
Plasmaphoresis membrane (3000 kDa MWCO,
polyethersulphone)
Asahi Medical
Precision Plus All Blue pre-stained protein stan-
dards
BioRad
ProQ Diamond Phosphoprotein Stain Molecular Probes
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Reagent/ Item Company
“rAPID” Alkaline Phosphatase Roche Applied Science
Rapigest SF surfactant Waters
Ringer’s Saline Baxter
Sanitary Silicone Sealant Bostik
Spin Concentrator, 4 ml, 5 kDa MWCO Agilent Technologies
Stainless Steel Wire Goodfellow
Starburst Dendrimer DNT-128, Generation 5.0, 1,
12-diaminododecane core
Dendritic Nanotechnologies
Sypro Ruby stain for total protein BioRad
Tegaderm R© Transparent Film Dressing - Univer-
sal
3M
Triethylammonium Bicarbonate Buffer Sigma
Trypsin from Bovine Pancreas Sigma
Tygon R© Autoanalysis tubing (ID. 0.015 in, OD.
0.087 in)
Cole Palmer
Ultrafree-MC Biomax Centrifugal Filter Device (5
kDa cut-off)
Millipore
The instruments used in experimentation in the present study are listed in Table
2.2.
Table 2.2: Instrumentation used during the course of this research.
Instrument Company, Location
BD FACSCaliburTMFlow Cytometer (4-colour) BD Biosciences, Oxford, UK.
Biofuge Pico Ultra-centrifuge Heraeus, Hanau, Germany.
CMA 100 Syringe pump CMA, Solna, Sweden.
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Instrument Company, Location
Global Ultima Q-TOF Mass Spectrometer
III and associated equipment (CapLC sys-
tem, µHPLC pump, low volume autosam-
pler, Streamselect µ-column switching module,
nanoLockSpray)
Waters, Manchester, UK.
Laser Doppler blood flow Imager Moor Instruments, Axminster,
UK.
Sorvall LegendRT Centrifuge 120v Thermo Fisher, San Jose, USA.
LTQ-Orbitrap Mass Spectrometer and associ-
ated Surveyor equipment
Thermo Fisher, San Jose, USA.
MALDI-TOF Mass Spectrometer Waters, Manchester, UK.
Microtiter plate reader Dynex Technologies Ltd., Wor-
thing, UK.
Nano-reverse phase C18 PepMap analytical col-
umn (150 mm × 75 µm i.d)
Dionex, Camberley, UK.
Novex Mini-Cell and Powerease 500 Invitrogen, Carlsbad, USA.
PepMap C18 guard column (5 mm × 300 µm
id)
Dionex, Camberley, UK.
pH Meter Jenway, Dunmow, UK.
SpeedVac Savant Instrumentation, Fram-
ingdale, USA.
VersaDoc Model 3000 gel imager BioRad, Hemel Hempstead,
UK.
The methods are divided into three sections covering establishment and character-
isation of the model, analysis of the protein content of dialysate and optimisation of
methods for the analysis of protein phosphorylation in dialysate.
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2.2 Measurements of cutaneous blood flow and dial-
ysate sample collection
Microdialysis was used both as the method of sampling and the method of injuring
the skin of healthy human volunteers. The inflammation that occurred in response to
the insertion injury was quantified, first by non-invasive measurements of blood flow
and then by measuring the changes in concentration of specific inflammatory markers
in dialysate samples.
2.2.1 Microdialysis probe construction
Microdialysis probes were constructed in-house by the insertion of a 7 cm length of
straightened stainless steel guide wire into an equal length of polyethersulphone (PES)
3000 kDa MWCO plasmaphoresis membrane. This probe was then inserted for 1 cm
into a 12 cm length of Tygon R© tubing via a 23G hypodermic needle 1 – 2 cm length
of fine bore polythene tubing inserted into the opposite end to form a connector, both
were then secured with household, silicone-based sealant. Finished probes (Figure 2.1)
were placed in pairs or individually in self-seal sterilisation pouches and sterilised by
ethylene-oxide gas by InHealth Decontamination, Cardiff.
2.2.2 In vivo dialysate sample collection
Healthy human volunteers were recruited from the staff and students of the Uni-
versity of Southampton. Volunteers gave informed written consent and the study was
conducted in the Wellcome Trust Clinical Research Facility at Southampton General
Hospital under ethics granted by South West Hampshire Research Ethics Commitee
(REC 346/03/t and 138/01/w). Volunteers were asked to refrain from excessive alcohol
intake in the 24 hours prior to the study and from caffeine and strenuous exercise for
six hours before. None of the volunteers were on any medication and all were asked
not to take anti-inflammatory preparations in the week leading up to the experiment.
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Figure 2.1: 3000 kDa MWCO Microdialysis Probe. Photograph of a 3000 kDa MWCO
microdialysis probe. All probes were approximately 17 cm in length, with 6 cm of the
strengthened membrane exposed (left-hand section of the probe)
All experiments were conducted in the morning in a quiet, temperature controlled
environment at 22◦C.
The equipment set-up for the in vivo microdialysis experiments is shown in Figure
2.2.
Local anaesthetic cream (EMLA R©, Astra Zeneca) was applied under occlusion
(Tegaderm dressing) to a site no less than 7 cm above the fold of the wrist, 90 minutes
prior to the volunteers’ arrival at the clinical research facility.
On arrival, volunteers were positioned supine on a bed with the dialysis arm raised
to heart level on a pillow and allowed to equilibrate. Anaesthetic was removed on
arrival, 30 minutes before probe insertion, using a damp paper towel and the area was
allowed to air-dry. The area of anaesthesia was checked by gently pressing the skin
with a needle tip and asking the volunteer to report on any sensation.
Microdialysis probes were connected to a syringe pump (CMA 100, CMA) via
flexifuse tubing secured to 1 ml syringes by 19G size hypodermic needles. Syringes
were filled with Ringer’s saline, the perfusate. Perfusion at 3 µl/min was started,
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Figure 2.2: Microdialysis equipment set-up. Photograph of the lay-out of the micro-
dialysis equipment during an experiment. The volunteer is placed on a bed, perpendicular to
the syringe pump and laser doppler scanner, with the non-dominant forearm raised to heart
level. Flexifuse tubing connects the syringes within the pump to the probes.
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before intradermal insertion, to check patency of the probes. Probe insertion was
carried out by Professor Geraldine Clough and is detailed in Figure 2.3.
(a) (b)
(c) (d)
Figure 2.3: Microdialysis probe insertion. Photographs detailing the process of intra-
dermal insertion of microdialysis probes. a) Anaesthetised areas with markings to indicate
each pair of entry and exit points, 2 cm apart. b) Needles in place. c) Probes inserted
through needles. d) Probes in place, with and without collection vials for illustration. In all
photographs, the pairs of dots are 2cm apart, from top to bottom.
Briefly, the insertion sites were marked out by pairs of dots 2 cm apart, within
the anaesthetised area (Figure 2.3a). Hypodermic needles (21G size) were inserted
intradermally for 2 cm (b), beside the marked sites to avoid tattooing the volunteer, and
the probes threaded in through the tip of the needle (c). The needles were then carefully
removed, the probes trimmed with sterile scissors and cryogenic vials positioned to
collect the dialysate (d). Perfusion continued during insertion and collection of the
dialysate began immediately after. The dialysate collection periods are detailed in the
individual results chapters, as different collection times were required for each set of
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experiments. Samples were flash-frozen in liquid nitrogen immediately after collection
and stored on ice until being transferred to -80◦C at the end of the experiment.
2.2.3 Measurement of cutaneous blood flux by laser Doppler
imaging
Changes in microvascular perfusion of the microdialysis probe insertion sites were
quantified as a surrogate measure of inflammation, by laser Doppler imaging using a
Laser Doppler blood flow Imager. Two-dimensional images are created by scanning a
defined area, in a raster pattern.
Single 2-D scans were performed, of a 4 × 8.6 cm area over the microdialysis
probes and at a resolution of 115 × 115 pixels. A baseline scan was performed before
insertion of the microdialysis probes, at 5 minute intervals from 5 – 90 minutes and
120, 150 and 180 minutes post-insertion. Mean blood flux was calculated off-line within
a defined region of interest using the Moor image review software (moorLDI V3.5
Research Software for Laser Doppler Blood Flow Imager, Moor Instruments). Pre-
defined, regular shaped regions of interest could not be used because it was not possible
to place the arm exactly perpendicular to the scanner. Instead, regions had to be
manually defined for each scan. An area of 1.01 ± 0.09 cm2 (mean ± SD) was drawn
around each insertion site, as determined by the image review software, using the black
and white photograph image for reference. This ensured that the probe, and therefore
the injury site, was within the analysis region. Figure 2.4 shows a representative scan,
with its corresponding black and white photograph showing the position of the probes
for comparison, and the regions of interest over which the mean blood flux was recorded
during analysis.
For each image acquired, the mean blood flux at the four injured sites was recorded
and the mean of these calculated.
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Figure 2.4: Representative laser Doppler scan image and corresponding photo-
graph. The rate of blood flow is indicated by coloured pixels, corresponding to the key shown
below the Flux Image (left). The photograph (right) provides a visual record of the scan area,
in which the probes are visible running across the image, with the injury site marked by pairs
of black dots. The numbered boxes represent the regions of interest, approximately 1 cm2,
in which mean blood flux was calculated.
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2.3 BCA Assay to estimate total protein concen-
tration in the dialysate
Protein concentration was estimated using the Bicinchoninic Acid (BCA) assay.
This colourmetric assay relies on the reduction of Cu2+ ions by peptide bonds (and
also cysteine, cystine, tryptophan and tyrosine residues), where the degree of reduction
is proportional to the amount of protein present. Standards of bovine serum albumin in
the appropriate buffer were prepared in 0.1 mg/ml intervals between 0 and 1 mg/ml.
20 µl of standard or sample was added per well to a flat-bottomed 96-well plate.
CuSO4 reagent was added to bicinchoninic acid solution at a ratio of 1:50 and 200 µl
added per well to a 96-well microtiter plate, according to the manufacturer’s protocol.
Plates were read at 570 nm after 30 minutes using a microtiter plate reader. Protein
concentrations were calculated automatically, using the associated analysis software
(Dynex Revelation v 3.2).
2.4 Multiplex cytokine analysis
Cytokine analysis was conducted using a BDTM CBA Flex Set, a bead-based assay
for analysis using flow cytometry (FACS). The Flex Set consisted of a master buffer
kit containing proprietary wash buffers, diluents and set-up beads, and individually
supplied antibody-coated capture beads. Calibrite beads for instrument calibration
and a 30-plex bead set for determining correct resolution were obtained separately.
The conjugation protocol, instrument set up and analysis were conducted accord-
ing to the manufacturers recommended protocol for plasma samples. The alterations
included to adapt the protocol for dialysate samples are discussed in the following
sections.
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2.4.1 Preparation of standards and samples for cytokine quan-
tification
Lyophilised standards were transferred to a single 5 ml polystyrene FACS tube and
equilibrated in 4 ml proprietary assay diluent for 15 minutes to reconstitute. Serial
dilution of this top standard (2500 pg/ml) was performed to give concentrations of
2500, 1250, 625, 312.5, 156, 80, 40, 20, 10, 5 and 0 pg/ml. Dialysate samples were
thawed on ice. Stock solutions of 1 × concentrated pooled capture beads and PE
detection reagents were prepared by dilution with the appropriate diluents, according
to the manufacturer’s protocol. Fifty µl of the capture bead solution was added to
50 µl of each standard or sample mixed gently and incubated for 1 hour at room
temperature. Fifty µl PE detection reagent was then added to each tube for a 2 hour
incubation at room temperature, protected from light. Samples were fixed by addition
of paraformaldehyde at a final concentration of 1% for 20 minutes, then centrifuged at
200 × g for 5 minutes. The supernatant was removed and the pellet re-suspended in
300 µl of wash buffer. All standards and samples were then stored at 4◦C, protected
from light, until analysis no more than one week later.
2.4.2 Instrument set-up for the CBA Flex Set
Instrument set-up was performed according to the manufacturer’s recommended
protocol. Briefly, the FACSCalibur was calibrated by following the FACSComp soft-
ware wizard (BD Biosciences) using positive and negative control Calibrite bead sam-
ples. Next, the recommended template was set up using CellQuest Pro software. Five
calibration samples were prepared as described in the FACS Calibur instrument set-up
manual, using the set-up beads supplied in the master buffer kit. These were used to
adjust the gates within the template and set compensation levels to enable all 30 of
the beads within the 30-plex standard to be resolved. A test sample of the beads to
be used in the multiplex was also analysed to check that those bead populations were
sufficiently well resolved.
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2.4.3 Data acquisition and analysis for the Flex Set
Instrument settings were checked prior to analysis, using the 30-plex standards,
an aliquot of capture beads and the 2500 pg/ml standard. Analysis was conducted
according to the manufacturer’s protocol. Standards and samples were vortexed before
analysis, to re-suspend any settled beads. A total of 300 events per analyte were
aquired for each sample using CellQuest Pro software (BD Biosciences) and analysis
was performed using FCAP array software (Version 1.0.1 for Mac, Soft Flow), following
the analysis Wizard.
2.5 Proteomic analysis of dermal dialysate samples
Two different experiments were performed to identify proteins in dermal dialysate.
The first experiment was conducted to determine the protein content of dermal dialysate.
A second experiment was conducted in which specific highly abundant proteins were
depleted from the dialysate samples, prior to determining protein content. This was
expected to reduce the dynamic range of protein concentrations within the sample and
subsequently increase the identifications of less abundant components. This second
sample required additional preparation steps, described in Section 2.5.2. Subsequent
steps were common to both experiments.
2.5.1 Preparation of dialysate samples for GeLC-MS/MS
Dialysate samples were centrifuged at 16060 × g for 5 minutes to remove insoluble
components. Proteins in the dialysate were separated 1-D SDS PAGE, described in
Section 2.5.3.
2.5.2 Depletion of abundant proteins from dialysate
The highly abundant proteins anti-trypsin, IgA, IgG, haptoglobin, serum albumin
and transferrin were removed from the dialysate using an antibody-based depletion
method. Dialysate samples were thawed on ice, pooled, and concentrated using a 5
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kDa-MWCO spin concentrator device. The protein concentrations of the concentrated
samples were then estimated by BCA assay. Depletion was performed by high perfor-
mance liquid chromatography using a Multi-Affinity Removal System (MARS) column.
Proprietary buffers were supplied with the column, labelled A and B.
Concentrated dialysate was diluted five-fold in Buffer A and injected via a 2 ml loop
onto the MARS column. A gradient was performed with 100 % Buffer A 12 minutes,
18 minutes with 100 % Buffer B and Buffer A again for the final 15 minutes, all at a
flow rate of 200 µl/min. Fractions were collected into a 96-well plate and pooled from
the appropriate wells as shown (Figure 2.5).
Figure 2.5: Example of an HPLC Chromatogram from a Depletion experiment.
HPLC chromatogram showing the high and low abundance fractions obtained following de-
pletion of high abundance proteins from dialysate. Dialysate was injected at time = 0. The
highly abundant proteins anti-trypsin, Immunoglobulins A and G, haptoglobin, serum al-
bumin and transferrin bound to the column in the presence of buffer A during the first 12
minutes, while the low abundance fraction was eluted (left-hand peak, wells 5 –14). Follow-
ing the switch to buffer B, the bound, highly abundant proteins were released and eluted
(right-hand peak, wells 27 – 35).
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Following depletion, the high and low abundance fractions were concentrated to ap-
proximately 50 µl by lyophilisation in vacuo and prepared for MS analysis as described
for non-depleted dialysate above.
2.5.3 One-dimensional SDS polyacrylamide gel electrophore-
sis
Prior to mass spectrometry preparation, proteins were separated using 1D-SDS
PAGE. Samples were prepared by adding protein in solution, of known concentration
as determined by BCA assay, to 1/4 volume NuPAGE LDS sample buffer and 50 mM
dithiothreitol (DTT) reducing agent (final concentration), to a maximum volume of 40
µl. Samples were then heated to 70◦C for 10 minutes before being added to the gel. Ten
µl Precision Plus All Blue pre-stained protein standards were used as molecular mass
markers (range 10 – 250 kDa, molecular masses shown on each gel image presented).
Pre-cast 4-12 % Bis-Tris NuPAGE gels were placed inside the electrophoresis chamber
and MOPS running buffer added, diluted in H2O as appropriate. Protein standards (10
µl) were added to the first well and prepared dialysate samples added to subsequent
wells. Electrophoresis was conducted using a pre-set protocol for NuPAGE gels, at 200
mV, for 45 minutes or until the dye-front reached the bottom of the gel. Gels were
removed from their casing and rinsed in H2O before staining with coomassie blue dye.
2.5.4 Staining of SDS PAGE gels using coomassie blue dye
Colloidal coomassie blue was used to visualise dialysate proteins in the gels to
be prepared for MS analysis. Gels were incubated for one hour in ∼100 ml stain,
then rinsed in water for one hour and again over night to de-stain, all with gentle
rocking. Imaging was performed on a VersaDoc model 3000, using a white-light stage
and PDQuest software version 7.1.0, with pre-set parameters for coomassie-stained
protein gels. The transform function was used to alter the contrast of the whole gel
image, to optimise band visibility. The optimised images were exported as .tiff files.
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2.5.5 Digestion and liquid chromatography-tandem mass spec-
trometry for protein identification.
Once stained, bands were excised from the appropriate track and placed one-per-
well in a 96-well microtiter plate for in situ digestion with trypsin. Digestion and
preparation of the resulting peptides for MS analysis was conducted by Paul Skipp,
according to a standard protocol (Shevchenko et al., 1996). NanoLC-MS/MS analysis
was also performed by Paul Skipp, as follows.
NanoLC separations were performed using a CapLC system, consisting of a µHPLC
pump and low volume autosampler coupled to a Streamselect µ-column switching mod-
ule. Samples, in microtiter plates stored at 10◦C, were loaded via the autosampler onto
a PepMap C18 guard column (5 mm × 300 µm id) for pre-concentration and desalting
using 100 % solvent C (3 % acetonitrile (ACN) + 0.1 % formic acid (FA, in water)
at a flow rate of 20 µl/min. The eluent was diverted to waste. After 6 minutes of
washing, the nano-reverse phase C18 PepMap analytical column (150 mm × 75 µm
i.d) was switched into line using the Streamselect µ-column switching module and a
separation gradient was performed as detailed below. A flow rate of 200 nm/min was
set for all experiments.
All data were acquired using a Q-ToF Global Ultima fitted with a nanoLockSpray
source. [Glu1]-fibrinopeptide B ([M+2H]2+ = 785.8426) was used as the internal lock-
mass calibrant for the nanoLockSpray source. For automated data directed acquisi-
tions, a survey scan was acquired from m/z 375 to 1800 (1.0 sec scan, 0.1 sec inter-scan
delay) in positive ion mode with the switching criteria for MS to MS/MS including (i)
ion intensity (15 counts per second) and (ii) charge state (+2, +3, +4). Product ion
spectra were acquired from m/z 50 to 1800 at 1 scan per second until the data had been
collected for 12 sec or if the ion intensity fell below a threshold of 5 counts per second
before the 12 sec had elapsed. Six channels were available for product ion acquisition.
The collision energy used to perform the MS/MS was automatically varied according
to the mass and charge state of the eluting peptide using a collision energy profile.
Instrument control and data acquisition were provided by the software, MassLynx 4.0
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(Waters).
The data acquired were searched against the NCBI non-redundant human protein
database using Mascot (Matrix Science) and ProteinLynx software (v. 2.05, Waters/
Micromass) to identify matching proteins. Identified proteins were characterised ac-
cording to their functional and locational classifications within the Gene Ontology
database (http://amigo.geneontology.org, release 2008–09–30).
2.6 Methods and optimisation for phosphoproteomic
analysis
Three approaches were investigated to determine the most appropriate method
with which to analyse protein phosphorylation in dialysate. A model phosphopro-
tein, β-casein from bovine milk, was used to optimise each method before analysis of
dialysate. The first method employed a phosphoprotein-specific gel stain to analyse
protein phosphorylation in whole proteins. The other two methods, titanium-dioxide
affinity capture and dendrimer conjugation chemistry, were used to capture phospho-
rylated peptides from protein digests for mass spectrometric analysis.
2.6.1 Sample preparation and staining protocol for the Pro-Q
Diamond phosphoprotein stain
For model protein samples, β-casein was reconstituted in water and serially diluted
to give the required concentration. These were lyophilised in vacuo and resuspended
in 25 µl H2O + 5 µl LDS sample buffer. Standards were prepared by adding 4 µl
Peppermint Stick phosphoprotein standards to 6 µl LDS sample buffer and heating to
95◦C for 4 minutes. Standards comprised two phosphorylated proteins, β-casein and
ovalbumin at 23.6 and 45 kDa respectively, and four non-phosphorylated proteins -
namely lyzozyme (14.4 kDa), avidin (18 kDa) bovine serum albumin (66.2 kDa) and
β-galactosidase (116.2 kDa). Gel electrophoresis was performed as previously described
(Section 2.5.3).
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Once removed from their casing, gels were fixed in a solution of 50 % methanol + 10
% acetic acid for 3 × 30 minute washes, then again overnight. Fixed gels were washed
for 3 × 10 minutes the following morning, in H2O, prior to a 90 minute incubation in
Pro-Q Diamond phosphoprotein stain, protected from light. De-staining was performed
using 20 % ACN + 5 % 1 M sodium acetate (pH 4.0) for 3 × 30 minute washes, also
protected from light and rinsed 3 × 5 minutes in H2O. Imaging was performed using
the UV transilluminator function of the VersaDoc model 3000, with a 520 nm long
pass filter, pre-sets for Sypro Ruby-stained protein gels and a 15 second exposure.
2.6.2 Protocol for Sypro Ruby staining for total protein
After imaging, gels stained for phosphoprotein with ProQ-Diamond stain were in-
cubated in 500 µl Sypro Ruby stain for total protein overnight with gentle rocking,
protected from light. Gels were de-stained for 3 × 30 minutes in 10 % methanol + 7
% acetic acid and rinsed three times in H2O before imaging as for the Pro-Q Diamond
stained gels.
2.6.3 Densitometry analysis of stained gels
Quantitative analysis of staining was performed using Quantity One software (Bio-
Rad). Briefly, lanes were defined manually and the bands of interest selected. Regions
were defined by eye using the rectangular volume tool which calculated staining inten-
sity per mm2 within that region, given as INT*mm2.
2.6.4 Sample preparation for phosphopeptide analysis
Two methods were used for phosphopeptide capture and their subsequent identifi-
cation using mass spectrometry. Neither titanium-dioxide affinity capture or dendrimer
conjugation chemistry were established methods within the Centre for Proteome Re-
search and the latter is a relatively new technique, so both methods required some
optimisation before use with dialysate. Optimisation of these methods were conducted
using increasingly complex model protein samples, followed by preliminary analyses of
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dialysate samples. Sample preparation differed depending on the sample to be anal-
ysed, so each is described separately. When comparisons between the two capture
methods were performed, four samples were prepared from a single digestion, that is,
two sets of 10 µl for digest and methylation analysis, and the remainder divided in
two for capture by each method. The second digestion including Rapigest surfactant
(Section 2.6.4.3) was a later addition to the protocol and while not used in the dialysate
experiment, is strongly recommended for use in future.
2.6.4.1 Control phosphopeptides
Mono and tetraphosphopeptides purified from digests of bovine β-casein were recon-
stituted in H2O to give a final concentration of 0.1 mg/ml for each. This stock solution
was stored at -20◦C. Five µl of each phosphopeptide were pooled and lyophilised in
vacuo to give a total of 1 µg peptide per experiment.
2.6.4.2 Model protein
A 1 mg/ml solution of β-casein in 100 mM triethylammonium bicarbonate buffer
(TEAB) was prepared and 20 µg trypsin, also dissolved in 100 mM TEAB, was added
for an overnight incubation at 37◦C. Either 2.5 µl (100 pmoles) or 25 µl (1 nmole) were
lyophilised in vacuo for each experiment, as specified.
2.6.4.3 Model protein mixture
One mg/ml stock solutions were prepared for each of two phosphorylated (β-casein
and casein) and 3 non-phosphorylated (bovine serum albumin, cytochrome c and myo-
globin) proteins. One hundred µl of each were combined and digested with 20 µg
trypsin per experiment, incubating at 37◦C. A second, 4 hour digestion was performed
in 100 mM TEAB + 0.1 % Rapigest to ensure complete digestion.
2.6.4.4 Dialysate
Dialysate samples, collected as detailed in Section 2.2.2, were thawed on ice and
pooled to give approximately 1-2 mg total protein. Removal of salts and buffer exchange
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were performed simultaneously by filtering the dialysate through a 5 kDa MWCO
spin concentrator. Three washes with 1 ml 100 mM TEAB were completed, keeping
the dialysate proteins in a minimum of 100 µl of liquid at all times. The protein
content of the desalted sample was estimated by BCA assay (Section 2.3). Next, the
dialysate was reduced in 10 mM DTT, incubating for 1 hour at 56◦C. Reduced cysteine
residues were alkylated by the addition of 50 µl 55 mM iodoacetamide, incubating at
room temperature for 30 minutes, in the dark. Trypsin was added in a 1:50 ratio and
incubated at 37◦C overnight to allow complete digestion. Digested dialysate samples
were lyophilised in vacuo and stored at 4◦C until required, although samples were used
immediately when possible.
2.6.5 Methyl-esterification of peptides to prevent non-specific
binding to acidic amino acids
Exposed carboxyl groups are known to interact non-specifically with many affinity-
based phosphopeptide capture methods. Peptides were subjected to methyl-esterification,
the replacement of carboxyl with methyl groups, to block any such non-specific inter-
actions.
Dried samples of peptide were placed in a desiccator with P2O5 under vacuum,
overnight. A methanolic HCl solution was prepared by adding acetyl chloride to anhy-
drous methanol in a 160 µl: 1 ml ratio, as required. Five hundred µl of this solution
were added per mg of the desiccated peptides (to a minimum of 50 µl) and incubated
for 2 hours at 12◦C. The author wishes to acknowledge the assistance of Dr. Bernd
Bodenmiller of the Institute for Molecular Systems Biology, Zurich for suggesting the
use of the desiccator and anhydrous methanol for this process.
2.6.6 Phosphopeptide capture using TiO2-affinity beads
Titanium dioxide (TiO2)-affinity capture was performed using a Phos-Trap
TM
kit
according to the manufacturer’s protocol, with some minor modifications. Briefly,
methylated peptides (Section 2.6.5) were reconstituted in 10 µl H2O + 90 µl proprietary
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binding buffer and captured as follows. A stock of bead solution was prepared by adding
H2O and TiO2 microbead solution at volumes of 190 and 10 µl times the number of
samples, respectively. Two hundred µl of the bead solution were added to each 0.5
ml microcentrifuge tube, vortexing in between to keep the beads suspended evenly.
After 1 minute on the magnet, the supernatant was carefully removed and the beads
re-suspended in 200 µl binding buffer once removed from the magnet. This wash step
was repeated twice further before each 100 µl sample was added per tube to the beads
and incubated for 1 – 2 minutes before placing on the magnet for 1 minute. The
supernatant containing unbound peptide was removed and reserved. The beads were
then washed 3 – 5 times with 200 µl binding buffer, pooling the reserved supernatants
each time. A final wash was performed using 200 µl proprietary washing buffer, and
the supernatant completely removed and discarded. Captured peptides were recovered
by incubating the beads in 10 µl proprietary elution buffer for 1 minute, pipetting up
and down gently to mix. The supernatant was collected and prepared as appropriate
(Sections 2.6.9 and 2.6.10) for analysis.
2.6.7 Phosphopeptide capture using dendrimer conjugation
chemistry
The dendrimer conjugation chemistry method for phosphopeptide enrichment has
been reported only once and had not been established within the Centre for Proteome
Research previously. The protocol consists of four stages, namely preparation of the
samples and lyophilisation of the dendrimers, conjugation of phosphorylated peptides
to the dendrimer, removal of non-bound proteins and hydrolysis and recovery of phos-
phorylated peptides and their subsequent analysis by mass spectrometry. A series
of optimisation experiments were required to improve upon early phosphopeptide en-
richment results. These experiments are described in Chapter 5, while the optimised
method is presented here.
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2.6.7.1 Dendrimer conjugation chemistry
To maintain the necessary pH for conjugation, dendrimers were pH-adjusted prior
to lyophilisation. For each reaction, 80 µl dendrimer solution (DNT-128, Dendritic
Nanotechnologies) was diluted with 400 µl of 100 mM MES buffer and adjusted to pH
5.5 by titration with 1 M HCl. The pH-adjusted dendrimers, approximately 9 mg per
conjugation, were then lyophilised in vacuo to dryness. A reaction solution of 200 mM
MES, 100 mM imidazole and 100 mM EDC was prepared and adjusted to pH 5.5 in the
same manner. Forty µl of this solution per reaction was added to the dried dendrimers
as appropriate and vortexed to solubilise. The dendrimer-reaction solution was then
transferred to the dried, methylated peptides, vortexed to mix, and incubated at room
temperature overnight with strong shaking.
2.6.7.2 Removal of non-bound peptides
Centrifugal filter devices (5 kDa MWCO Ultrafree MC with polyethersulphone
membrane) were pre-washed with 400 µl each of the following; 500 mM NaOH, H2O,
10 % trifluoroacetic acid (TFA) and H2O. Washes were performed by centrifugation
at 4500 × g for approximately 20 minutes or until the liquid had completely passed
through. If the pre-wash was performed the day before use, 400 µl H2O was used
as a storage solution and spun through just before the filter units were needed. The
author wishes to acknowledge Dr. Bernd Bodenmiller for suggesting the inclusion of
this pre-wash step also.
Following the overnight incubation, 400 µl 50 % methanol was added to the dendrimer-
peptide sample, mixed, and the solution transferred to the pre-washed filter device. As
for the pre-wash, centrifugation was performed at 4500 × g in 20-minute intervals,
separated by brief vortexing. This was repeated until the majority of the liquid had
passed through. At this point, the eluate was removed and reserved if needed. Further
washes were performed as follows; 2 × 2 M NaCl in 50 % methanol, 3 × 50 % methanol,
5 × H2O. If necessary, after the second H2O wash, 400 µl H2O was added and the filter
device stored at 4 ◦C overnight with the remainder of the washes performed the next
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day. A minimum of three further H2O washes were performed to remove any polymer
contaminants that may have leached from the filter unit overnight.
2.6.7.3 Hydrolysis and recovery of captured phosphopeptides
After the final H2O wash, 300 µl 10 % TFA was added to the dendrimer-phosphopep-
tide conjugate mixture for a 60 minute incubation at room temperature before cen-
trifugation to elute the released phosphopeptides. Two further washes with H2O were
performed, the eluates pooled with the TFA wash. The pooled sample was lyophilised
in vacuo, to dryness. Samples were analysed by MALDI-TOF (Section 2.6.9) or tan-
dem MS (Section 2.6.10). When necessary, samples were re-methylated to improve
the signal-to-noise ratio where de-methylation, caused by EDC, had occurred. Re-
methylated samples were cleaned using ZipTips (Section 2.6.8) prior to re-analysis.
2.6.8 Zip-Tip clean up for the removal of salts
Re-methylated samples were desalted using C18 ZipTips (Millipore), to remove any
salts that could interfere with MALDI-time-of-flight (TOF) MS analysis. One ZipTip
was used per sample, as follows. Tips were primed by wetting with 10 µl 100 % ACN
three times and the equilibrated three times with 10 µl 0.1 % TFA. Next, lyophilised
samples, reconstituted in 10 µl 0.5 % TFA (pH < 3), were passed through the tip ten
times by gently pipetting up and down to allow peptides to bind to the C18 material
inside the tip. Salts were removed by three washes of the tip with 5 % methanol + 0.1
% TFA and the de-salted peptides were eluted in 10 µl 50 % ACN + 0.1 % TFA.
2.6.9 MALDI-TOF MS analysis of peptide samples
MALDI-TOF MS was used in the optimisation experiments, to check for the pres-
ence of peptides of known mass. MALDI target plates were cleaned in water, then
methanol, and MilliQ-purified water, prior to incubation in a sonicator bath in methanol
+ H3PO4 for 10 minutes. A final rinse with methanol was performed and the plate
allowed to air-dry.
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For phosphorylated peptide samples, a matrix of 2 mg dihydroxybenzoic acid (DHBA)
in methanol + 0.1 % H3PO4 was prepared. For all other samples, the matrix consisted
of 2 mg α-cyanohydroxycinnamic acid (α-CHCA) in 50 % ACN + 0.1 % TFA.
Lyophilised samples were reconstituted in 10 µl H2O and mixed in a 1:1 ratio with
the matrix. De-salted samples for MALDI-TOF MS analysis were eluted in 50 %
elution buffer and 50 % of the appropriate matrix. Reconstituted samples with high
pH were adjusted to a pH < 6 using TFA. 1.4 µl of each sample in matrix was added per
well of the cleaned MALDI target plate. Mass spectrometric analysis was performed
using a MALDI-TOF instrument, with high and medium laser energy for the DHBA
matrix and α-CHCA matrices, respectively. Approximately 5 minutes of scans were
combined for each spectrum and the baseline subtracted. No export function exists for
the spectra images, so a copy of the image was made using the print screen function of
Microsoft Windows and saved as a .jpg file using Microsoft Paint.
2.6.10 Tandem mass spectrometric analysis of phosphopep-
tide samples
Lyophilised phosphopeptide samples were reconstituted in 10 µl 1 % FA. LC-
MS/MS was conducted by Paul Skipp according to the protocol in Section 2.5.5, with
the following modifications. A neutral loss scan was performed from 350 to 1800 (1 sec
per scan) switching between a low collision energy (10 eV) and a high collision energy
(37 eV). When a fragment exhibited a neutral loss of 98, 49 or 33.6 from singly, doubly
or triply charged parent ions respectively, MS/MS was performed on the precursor ion
using a collision energy profile as described above.
2.6.11 Identification of phosphorylation sites using linear trap
quadropole-orbitrap MS
The LC-MS/MS system consisted of a quaternary Surveyor pump, a Surveyor au-
tosampler and LTQ-Orbitrap equipped with a nanospray source. This work was carried
out by Dr. Gary Wolfenden, at Thermo Electron (UK) Ltd.
75
2. MATERIALS AND METHODS
Separation of samples was achieved using a binary gradient from 5 % buffer A (5 %
ACN + 0.1 % FA) to 80 % buffer B (95 % ACN + 0.1 % FA) over 60 minutes using a
C18-RP trap column for desalting and a C18-RP analytical column, prior to injection
into the mass spectrometer. A survey scan (300 – 1400 m/z ) was performed in the
Orbitrap analyser (at R = 60000) and was followed by MS2 of the five most intense
ions in both the Orbitrap and the LTQ analysers. MS3 of all ions showing a neutral
loss of phosphoric acid (98 Da) from the precursor ion was also performed.
Data was processed and searched against the NCBI non-redundant human protein
database using BioWorks (Thermo Fisher). All P-ser and P-thr peptides were required
to show a neutral loss of phosphoric acid (98 Da) from the precursor ion, fragment
ions, and/or trigger the neutral loss-dependent MS3 scan.
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Chapter 3
Characterisation of the Model of
the Injury Response
3.1 Introduction
The purpose of the work described in this chapter was to develop and characterise
a model of injury that would provide samples for proteomic analyses that could po-
tentially allow the identification of biomarkers that predict an individual’s capacity to
resolve an injury. An ideal method of injury should give a reproducible response, be
minimally invasive and well tolerated by the patient, leaving minimal scarring. The
use of microdialysis as the sampling technique within this study provides a method of
injury in that probe insertion via a guide needle is known to cause an injury response
(Ault et al., 1994; Groth & Serup, 1998; Mathy et al., 2003). Particular advantages
of this model are that sampling occurs continuously from the moment of trauma, al-
lowing flexible temporal analysis and causing no further injury, thus preventing any
interference or modulation of inflammation by additional stimuli. Additionally, most
subjects show no signs of scarring within a few weeks (Clough, personal communica-
tion). The response to needle insertion has been well characterised in terms of the
vascular changes and in the release of inflammatory mediators, thus providing a basis
to which the results of this study can be compared to determine the reliability and
reproducibility of this model.
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To characterise the inflammatory status of this model, a panel of additional cy-
tokines was required that represented different aspects of the injury response. It was
therefore appropriate to review the various pro- and anti-inflammatory cytokines, along
with markers of cellular recruitment and of the vascular response, to correlate with
measurements of blood flow. The pro- and anti-inflammatory cytokines needed to be
known markers of the appropriate phase in response to injury and recoverable by micro-
dialysis. IL-6 and IL-10 were chosen as these have been implicated in several processes
within the inflammatory response and measured within dialysate previously (see Sec-
tions 3.1.1 and 3.1.7. Figure 3.1 shows some of the cytokines involved in regulating the
response to injury and some of the effects they cause, including release of additional
mediators and vascular effects.
The typical time course of the injury response would suggest that haemostasis
occurs over a matter of minutes, with inflammation lasting several days. As the early
response is of particular interest in the present study, only those mediators expressed
during haemostasis and early inflammation would be expected. Therefore particular
attention was given to markers of initial damage, such as those released from damaged
keratinocytes and endothelial cells as well as activated platelets. These cells release
cytokines, such as IL-1β, IL-6 that initiate the inflammatory response and IL-8 and
OSM that stimulate the recruitment of neutrophils. To describe the expected cellular
infiltrate, representative chemoattractants or secreted chemokines were chosen for each
of the three most important cell types; platelets (MIP-1α), neutrophils (OSM) and
monocytes/macrophages (MCP-1). Cytokines such as IL-8, IL-6 and IL-1 variants have
been well studied, but the recovery by microdialysis of several of the other markers,
including MIP-1α and OSM have not yet been reported, so it is also of general interest
whether these can be measured in dialysate. The relevance of the chosen mediators as
markers of the inflammatory response are briefly discussed in the following sections.
3.1.1 IL-6 as a pro-inflammatory mediator in injury
Interleukin-6 was selected because it is a pro-inflammatory cytokine and key reg-
ulator of the synthesis of acute phase proteins during inflammation (Castell et al.,
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Figure 3.1: Potential cytokine targets for characterising inflammation in the
injury model. Schematic of the different phases in the injury response, with the
approximate timing of the contributions of different cell types. Stimulatory components
are given in green, their effects, including mediators released, in blue.
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1989; Henrich, Castell & Andus, 1990). It is hypothesised that IL-6 is involved in the
progression of the inflammatory response through to its resolution by regulation of
pro-inflammatory cytokine release. This progression also includes the transition from
neutrophilic infiltrate to one of monocytes (Gabay, 2006). Maturation of monocytes
into phagocytic macrophages eliminates not only the neutrophils, but other debris
within the wound site. IL-6 is also involved in leukocyte recruitment, through stimula-
tion of MCP-1 secretion and production of cellular adhesion molecules such as ICAM-1
(Romano et al., 1997). Of particular interest is the observation that IL-6 levels are
lower in wounds of the oral mucosa, a tissue that tends to heal much faster than the
skin (Szpaderska, Zuckerman & DiPietro, 2003). This suggests that the control of the
magnitude and/ or time-course of IL-6 expression is key in wound outcome.
3.1.2 Oncostatin M as an anti-inflammatory mediator or a
chemoattractant for neutrophils?
Oncostatin M is an IL-6 family cytokine of approximately 28 kDa. Released from
macrophages, T cells and keratinocytes at the wound margin (Goren et al., 2006), it
has been strongly implicated in the attenuation of the inflammatory response after
injury. Here, it has been shown to inhibit TNF-α production and sepsis in response to
common inflammatory stimuli (Wahl & Wallace, 2001) and regulate release of acute
phase proteins from the liver (Richards et al., 1992). The former report also describes
the attenuation of inflammation by OSM in mice with induced rheumatoid arthritis.
However, one study demonstrated the incompatibility between human OSM and the
murine OSM receptor, casting doubt on the validity of these observations (Lindberg et
al., 1998).
In contrast to its reported anti-inflammatory effects, OSM has been found to mod-
ulate expression of IL-6 (Brown et al., 1991). Modur et al. (1997) found that OSM
actually induced inflammation, causing up-regulation of P-selectin and subsequent ad-
hesion and transmigration of neutrophils. This finding has been repeated in a number
of different tissues and cell types, including human dermal microvascular endothelial
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cells (Kerfoot et al., 2001) in which a 96 % selectivity for neutrophils was observed.
This marker was of particular interest, as to the best of the author’s knowledge, it had
not been measured in the context of inflammation induced by mechanical injury prior
to this study.
3.1.3 MCP-1 for the recruitment of monocytes
MCP-1 is produced by a variety of cell types, including keratinocytes, endothelial
cells, Langerhan’s cells and tissue macrophages, in response to an inflammatory stimuli
(Gibran et al., 1997). The primary role of MCP-1 is the chemoattraction of monocytes
to areas of inflammation where they mature into macrophages, the roles of which were
discussed previously, in Section 1.1.4.2. MCP-1 appears to be of particular importance
in wound healing, as MCP-1 -/- mice were unable to compensate for the absence,
exhibiting delayed re-epithelialisation, angiogenesis and collagen formation (Low et
al., 2001). Detection of MCP-1 would indicate both activation of endothelial cells and
the chemoattraction of monocytes to the injury site.
3.1.4 MIP-1α as a marker of platelet degranulation and leuko-
cyte recruitment
The function of MIP-1α in injury is less clear, in that while important in mono-
cyte recruitment (DiPietro et al., 1998), MIP-1α−/− knock-out mice are able develop
alternative, compensatory mechanisms (Low et al., 2001). The level of redundancy
between chemokines meaning that others can fulfil its role. Within the response to
injury, MIP-1α is first released from platelets, then later from various other cell types
which the initial platelet-derived burst recruits (Menten, Wuyts & Van Damme, 2002).
MIP-1α would be expected early in the response to injury as it is constituitively ex-
pressed in the alpha-granules of platelets and released during their activation (Gear &
Camerini, 2003, Klinger et al., 1995), as well as being released later on by macrophages
among other cell types. MIP-1α mRNA was detected within three hours post excisional
wounding in adult mice, remaining elevated until 48 hours (Bryan et al., 2005). MIP-
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1α protein levels were not reported. No human microdialysis studies have looked at
MIP-1α recovery, so it is of general interest whether this chemokine can be detected, as
well as informative in terms of the time course of the response to injury and of platelet
involvement.
3.1.5 VEGF as a regulator of vascular permeability
VEGF was first known as vascular permeability factor, although it has perhaps
become better known for its role in the regulation of angiogenesis. The roles of VEGF in
wound healing and regulation of vascular permeability have been reviewed extensively
(e.g. Bates & Harper, 2002; Bates & Jones, 2003 and Breen, 2007) and it has numerous
functions within inflammation (Angelo & Kurzrock, 2007).
VEGF acts through mediating phosphorylation of junctional proteins such as VE-
cadherin, which leads to a loss of endothelial barrier integrity and thus increasing
permeability (Gavard & Gutkind, 2006). This effect has been confirmed, for example,
through the use of a VEGF antagonist which reduced oedema formation following
ischemia/reperfusion injury within the murine brain (van Bruggen et al., 1999). In the
context of wounds, VEGF was detected in rat skin incisions within the earliest time
point investigated (at 24 hours) and found to be secreted by neutrophils (Nogami et al.,
2007). Clearly, it would be of interest to know if VEGF is expressed during immediate
early responses to skin injury.
3.1.6 IFN-γ in the switch to adaptive immunity and the an-
timicrobial response
The detection of IFN-γ would be significant as it has been reported to be involved
in the switch from innate to adaptive immunity, being a key regulator of macrophage
activation and subsequent antigen presentation (Schroder et al., 2004). High levels
of IFN-γ may indicate that this switch will occur, or the presence of pathogens that
would require removal by the activated macrophages if detected later. Sources of IFN-γ
include leukocytes within the systemic circulation including natural killer cells, T cells
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and antigen-presenting cells as well as cells resident in the dermis, such as dendritic
cells. With a local source, it could be expected to be detected early on in response to
injury.
3.1.7 IL-10 as a marker of the switch from a pro- to an anti-
inflammatory environment
IL-10 was selected because it is an anti-inflammatory mediator and therefore an
indicator of the onset of resolution of inflammation. It is of interest due to the successes
in improved wound resolution observed in animal studies in which IL-10 had been
administered (de Vries, 1995). Additionally, it is resposible for the down-regulation
of several pro-inflammatory cytokines, including TNF-α, IL-6 and IL-8 (Goldman,
Marchant & Schandene´, 1996). IL-10 has been measured in dialysate, falling from ∼
150 pg/ml in samples collected 0 – 8 hours after insertion to just above 0 by the 24 – 32
hour collection (Averbeck et al. 2006). The measurement of IL-10 in the present study,
using shorter collection periods, will improve the temporal resolution and determine
whether IL-10 is released immediately after injury, or increases later on in the response.
3.1.8 Aims
The aims of this chapter were as follows:
• To develop a method of injuring the skin.
• To quantify the vascular responses to this physical trauma.
• To collect and measure known inflammatory mediators.
• To explore the time course of the injury response in this model.
• To inform future study protocols for proteomic analysis of novel markers of the
injury response.
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3.2 Methods
3.2.1 Volunteers
Healthy human volunteers were recruited from the students of the University of
Southampton as described in Section 2.2.2. Four males and one female were recruited
for the experiments discussed in this chapter, with a mean age of 25.2 ± 2.8 years.
3.2.2 Microdialysis
Microdialysis probes were constructed and sterilised as described in Section 2.2.1.
Probe insertion was performed as described in Section 2.2.2. Dialysate was collected
from four probes placed in the dermis of the non-dominant volar forearm and was
sampled over consecutive 30 minute periods for the three hours immediately following
microdialysis probe insertion (shown in Figure 3.2). These periods were chosen based
on the literature, laser Doppler results from preliminary data (not shown) and those
discussed in this chapter.
Figure 3.2: Dialysate collection protocol for cytokine and total protein analy-
sis. Protocol used for the collection of dialysate for analysis of specific markers of injury.
Numbered blue boxes indicate the six dialysate collection periods. Laser Doppler scans were
performed before insertion to represent baseline and then every 5 minutes, starting 5 minutes
after injury.
At the end of each collection, the dialysate from all four probes was pooled, divided
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into aliquots, and flash-frozen in liquid nitrogen, as previously described. One 75 µl
aliquot was used for the quantifying the amount of protein per ml of dialysate and a
second 75 µl for quantifying the recovery of specific markers of injury.
3.2.3 Laser Doppler Imaging to measure blood flow
Laser Doppler imaging was performed to measure the rate of blood flux at the
injury site, as described in Section 2.2.3. Values of mean blood flux are reported in
arbitrary perfusion units (PU).
3.2.4 BCA assay for quantitation of total protein in the dialysate
The concentration of total protein per ml in each dialysate collection was estimated
by BCA assay (Section 2.3). Samples were diluted with an equal volume of Ringer’s
saline. Bovine serum albumin (BSA) standards were prepared in Ringer’s saline in 0.1
mg/ml increments from 0-1 mg/ml. A total of 20 µl of standard or sample was added
per well, in duplicate, and incubated with the prepared assay reagent for 30 minutes,
as per the manufacturers recommended protocol. Absorbance was read at 570 nm
using a microtiter plate reader. The limits of detection were 200-1000 µg/ml. Protein
concentrations were calculated against a standard curve (r2 ≥0.98) constructed by the
analysis software and manually adjusted for dilution factor.
3.2.5 Multiplex cytokine analysis of markers of inflammation
The concentration of selected cytokines was measured using a CBA Flex set, an
antibody-coated bead-based assay from BD Biosciences (Section 1.4.2.1). Samples were
prepared according to the manufacturers recommended protocol and analysed by flow
cytometry, as described in Section 2.4. Data were analysed using the FCAP Array
(Soft Flow Inc.) wizard, using the manufacturers recommended settings. All standard
curves gave an r2 value of 0.98 or greater and gave a detection range of 5-2500 pg/ml
for all cytokines.
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3.2.6 Statistics
The significance of the difference in mean blood flux or mean cytokine concentration
between different time points was determined using a Student’s paired t-test. In all
cases, a probability value of P < 0.05 was taken to be significant. All values are given
in the format Mean ± standard error of the mean (SEM) unless otherwise stated.
Correlations were assessed using the Pearson’s Rank correlation test and repeated
measures analysis of variance (ANOVA) was conducted, where appropriate. All graphs
and statistical analyses were prepared and performed using GraphPad Prism software
version 5.
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3.3 Results
3.3.1 Assessment of the changes in blood flux induced by mi-
crodialysis probe insertion injury
Figure 3.3 shows the typical blood flux response to needle insertion, before and 15
minutes after injury as measured using laser Doppler imaging. All values are given as
mean ± SEM, in perfusion units (PU).
In this example, before insertion, the mean blood flux over the four regions of
interest was 66 ± 4 PU, n = 4. Fifteen minutes after needle insertion, there was a
visible increase in mean blood flux in the vessels and at the insertion sites, to 373 ± 47
PU in the regions of interest. This is representative of those responses seen in the rest
of the volunteer group. Figure 3.4 summarises the changes in mean blood flux over
three hours after needle insertion.
Before injury, baseline mean blood flux was 78 ± 14 PU (n = 4 volunteers). After
insertion, blood flux increased significantly from the baseline value, reaching a peak of
368 ± 67 PU at 10 minutes (p = 0.013, Student’s paired t-test). It then declined over
time, until 70 minutes, where blood flux was no longer significantly above baseline (p
= 0.56, Student’s paired t-test). There was no significant difference between the value
for mean blood flux at 10 minutes and those other measurements taken within the first
30 minutes, as determined by Student’s paired t-test (p > 0.05), so this period of 0 –
30 minutes after injury was defined as the peak phase. The period from 70 minutes to
the end of the experiment was defined as the steady-state phase, during which time a
mean blood flux of 172 ± 3 PU was maintained. The intermediary period of 30 – 70
minutes, over which the mean blood flux decreased, was defined as the decline phase.
These three phases correspond to the proposed 30-minute dialysate collection periods,
with the first collection covering the peak phase, the second sampling over the majority
of the decline period and the four remaining collections corresponding to the time over
which blood flux had reached a steady state and the early phase of the inflammatory
response was underway.
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(a) (b)
(c)
Figure 3.3: Laser Doppler images of blood flow before and after probe in-
sertion Scans of the area around the injury site taken a) 5 minutes before and b) 15
minutes after probe insertion. c) Key denoting the relationship between pixel colour
and blood flux in perfusion units (PU). Dashed lines indicate probe location, white
boxes indicate the region of interest over which area the mean blood flux was calcu-
lated.
88
3. CHARACTERISATION OF THE MODEL
Figure 3.4: Changes in mean blood flux over three hours following microdial-
ysis probe insertion Peak mean blood flux is observed within 15 minutes, followed
by a decline until 65 minutes where a steady state is reached. The dashed line repre-
sents the mean value for baseline. Values are mean ± SEM, n = 4 volunteers. The
first volunteer was excluded due to a change in the measurement protocol from every
30 minutes to every 5 minutes, as a result of data collected in that experiment.
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3.3.2 Analysis of the changes in total protein recovery in the
dialysate over time
The second step in characterising inflammation in response to injury was to assess
the changes in protein concentration in the dialysate as an increase in protein extrava-
sation should result in an increase in protein concentration within the dialysate. The
mean protein concentration of each 30 minute collection is shown below in Figure 3.5.
Figure 3.5: Total protein in the dialysate over time Total protein in the dialysate
in each collection period, denoted by the boxes. Values are Mean ± SEM, n = 5.
Total protein concentration was highest in the first collection, at 2.1 ± 0.4 mg/ml
and decreased over subsequent collections, to 0.59 ± 0.09 mg/ml. Only the first col-
lection contained protein at a significantly higher concentration than the other time-
points (p = 0.0009, repeated measures ANOVA with Bonferroni multiple comparisons
post-test). The changes in protein concentration gave a similar profile to the changes in
blood flux. The relationship between these two parameters is shown in Figure 3.6. The
mean blood flux for all four sites over each 30 minute collection period was compared
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against the protein concentration for that collection.
Figure 3.6: Relationship between mean blood flux and protein concentration
Linear relationship between the mean blood flux and total protein concentration for
each dialysate collection, by volunteer. Each volunteer is indicated by a different colour.
Values are mean ± SEM, n = 5 volunteers. A positive correlation is observed for the
dataset as a whole (Pearson r = 0.817 p < 0.0001, r2 = 0.668). Individual correlations
are as follows, in the format Pearson r value, p value and r2 value; red = 0.96, 0.003
and 0.92, green = 0.96, 0.002 and 0.92, blue = 0.16, 0.759 and 0.03, purple = 0.98,
0.0005 and 0.97 and orange = 0.67, 0.15 and 0.44.
Overall, there was a strong correlation between the total protein concentration in
the dialysate samples and the mean blood flux over the corresponding collection period
(Pearson r = 0.817 p < 0.0001, r2 = 0.668, Pearson’s rank correlation). Individually,
three volunteers gave very strong correlations and the remaining two had no significant
correlation.
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3.3.3 Analysis of changes in markers of inflammation following
needle insertion injury
Four of the seven cytokines in the panel were detected in the dialysate samples.
Those not detected were IL-10, IFN-γ and OSM. IL-6, MCP-1 and VEGF were re-
covered successfully while MIP-1α was only detected in the final collection, above the
negative control of 0 pg/ml but below the lowest standard of 5 pg/ml. Figure 3.7 shows
the concentration of the different markers of inflammation recovered in each dialysate
collection for each volunteer.
MCP-1 (Figure 3.7a) was recovered in the first dialysate collection from two vol-
unteers, at 9.47 ± 4.13 pg/ml (mean ± SEM). The concentration of MCP-1 in the
dialysate increased steadily over time, reaching 279.23 ± 41.89 pg/ml (n = 5) by the
final collection.
VEGF was detected in low concentrations in the first collection from three volun-
teers, at 6.11 ± 0.36 pg/ml. Recovery of VEGF was varied but gave no significant
change over the duration of the experiment. The mean concentration detected ranged
from 2.54 ± 1.15 pg/ml at 45 minutes post injury to 5.53 ± 2.26 pg/ml at 165 minutes,
however this was not a linear increase.
IL-6 was first detected in the third collection, at 21.81 ± 16.10 pg/ml (n = 5). The
concentration of IL-6 increased significantly over subsequent time points, to 195.52 ±
69.98 pg/ml (n = 5) in the final collection (p = 0.03, Student’s paired t-test). The rate
of increase in MCP-1 recovery was greater than that of IL-6 between the fourth and
sixth collections.
MIP-1α was detected in three volunteers in the final collection at 0.97 ± 0.34 pg/ml
(n = 3), above the level of the negative control.
To assess whether a greater hyperaemia or total protein concentration were corre-
lated with an increased expression, and therefore recovery, of cytokines, area under the
curve (AUC) was calculated for each dataset. No correlation was found between total
cytokine concentration and either total blood flux or total protein recovered (Pearson’s
rank = 0.564 and 0.663, r2= 0.318 and 0.439 and p= 0.322 and 0.223, respectively).
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(a) MCP-1 (b) IL-6
(c) VEGF (d) MIP-1α
Figure 3.7: Changes in concentration of specific cytokines in dialysate over
the three hours after insertion Concentrations of a) MCP-1 b) IL-6, C) VEGF
and d) MIP-1α in the dialysate over time from probe insertion. Times represent the
mid-point of the collection periods denoted by the dotted-line boxes. Data are plotted
for each volunteer to show individual responses.
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3.4 Discussion
The aim of the work presented in this chapter was to develope and characterise
a model of injury in skin that was suitable for future proteomic studies into the re-
sponse. The injury needed to be reproducible between volunteers, and to not leave
lasting cosmetic damage. Characterisation of this model involved measurement of the
vascular and inflammatory responses to the injury using established methodology so
that the findings could be compared back to the literature as an additional measure
of reproducibility. The injury caused by the insertion of microdialysis probes was cho-
sen because it enables continuous measurement of a single injury without further the
perturbation that is unavoidable with other combinations of sampling and stimuli.
3.4.1 The vascular response to microdialysis probe insertion
injury
The intradermal insertion of microdialysis probes caused a significant increase in
cutaneous blood flow at the insertion sites, observed in the first measurement after
insertion. This increase was sustained, beginning to decline after 15 minutes. By 70
minutes after the insertion injury, blood flux had stabilised above baseline, although
this was not a significant increase above baseline measurements (Student’s paired t-
test). The increase in blood flow within the superficial capillaries was associated with
an increase in flow in the larger, deeper vessels, visible in the baseline scans as lines of
raised flux.
The responses observed in the present study are supported by those reported pre-
viously (Anderson, Andersson & Wa˙rdell, 1994 and Groth & Serup, 1998). Although
the magnitude of the responses cannot be directly compared as these reports give val-
ues in volts, rather than perfusion units, the peak hyperaemia and decline to steady
state occur within very similar time frames. This suggests that the response is repro-
ducible both between volunteers and between clinical settings and that this method is
appropriate for monitoring the initial vascular response to trauma. However, there are
limits to the information that this technique can provide. Once steady state has been
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reached, there are no further significant changes while blood flux returns to baseline
levels more than 24 hours post injury (Anderson, Andersson & Wa˙rdell, 1994). Ad-
ditional methods are required to understand the mechanisms behind the increases in
cutaneous blood flux and any associated processes involved in the development and
progression of the inflammatory response.
3.4.2 Changes in protein recovery following microdialysis probe
insertion injury
The protein concentration within the dialysate followed the a similar pattern of
decline over time to the blood flux measurements, approximating steady state by the
fourth collection. Protein recovery was slightly higher than previously observed in the
literature, with a mean ± SEM in the first collection of 2.05 ± 0.39 mg/ml compared
to published values of 0.65 and 1.2 mg/ml. This concentration fell to 0.59 ± 0.09
mg/ml in the final collection (150 – 180 minutes post-insertion), compared to 0.43-0.5
mg/ml in previous experiments (Klede, Handwerker & Schmelz, 2003; Sauerstein et
al., 2000). This difference is unlikely to be a result of perfusion rate, as the rate used
in this study was in-between those used in the two published reports. The significance
of this increased recovery is unknown and may be a result of different sensitivities in
the assay methods, or of the reduced dialysis length of 1.5 cm, compared to 2 cm in the
present study. The magnitude of difference in observed concentrations is low enough
that this should not be cause for concern.
Changes in protein extravasation have been measured using microdialysis, partic-
ularly in the context of chemically-induced inflammation. However, it may not be
suitable as a measure as an indicator of inflammatory status in injury. This is partly
because the baseline protein concentration cannot yet be determined, in that sampling
the interstitial fluid space currently requires breaching the skin barrier, thus causing
injury. As a consequence, it is impossible to know whether the steady-state concentra-
tions are representative of a return baseline levels or of an equilibrium between delivery
and removal, by metabolism and microdialysis respectively. Furthermore, these changes
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in protein recovery occur over a very rapid timescale (Clough, 2005) that corresponds
to the time over which proteins can escape via damaged vessels before clotting seals
gaps in the vessel wall, rather than with the progression of the inflammatory response.
Interestingly, a strong positive correlation between protein recovery and mean blood
flux was observed in three volunteers. The volunteer (represented by orange data points
throughout the chapter) who displayed the smallest increase in mean blood flux above
baseline also gave the lowest total protein recovery, although the correlation was only
very weakly positive (Pearson r = 0.67, r2 = 0.44) and not statistically significant (p
= 0.15). The mechanisms responsible for regulating protein extravasation and blood
flux are not known to be related, but the association of these two parameters may be
related to the magnitude of the response to an injury.
3.4.3 Cytokine release after microdialysis probe insertion in-
jury
The third component of the characterisation was the quantification of inflamma-
tory mediators recovered in the dialysate. Of the seven mediators analysed, four were
detected. Those not detected were OSM, IFN-γ and IL-10, the anti-inflammatory
mediator. Although previously measured within the first eight hours after probe in-
sertion (Averbeck et al., 2006), the absence of IL-10 within the three hour time course
was unsurprising as it is more likely to be released later on, towards the end of the
pro-inflammatory phase. The absence of OSM and IFN-γ was a surprising as both
are implicated in the early inflammatory response. IFN-γ has been detected before in
dialysate within the group, reaching between 20 and 100 pg/ml within 2 hours after
probe insertion (Clough et al., 2007), although was undetectable in 8 hour collections
in a study by a different group (Averbeck et al., 2006). When detected, the levels
were highly variable between volunteers and showed no trend over time or increase in
response to allergen (Clough et al., 2007). It is still possible that IFN-γ is released
during this period at concentrations too low to be detected in the dialysate, however,
studies within mice suggest that this is not the case (Bryan et al., 2005). With either
96
3. CHARACTERISATION OF THE MODEL
situation, however, it can be concluded that a switch to an adaptive immune response
is unlikely and that IFN-γ-induced macrophage activation has not yet occurred.
The recovery profile of VEGF was unexpected, in that there was no significant
differences over time and indeed no real trend, with high inter-individual variation
given the low levels recovered (Figure 3.7c). These low values are consistent with
the concentration of VEGF recovered by microdialysis from tumour (2.4 pg/ml) and
unaffected (6.0 pg/ml) breast tissue (Garvin & Dabrosin, 2008).
Predominantly considered to be an angiogenic factor responsible for the prolifer-
ation of endothelial cells, VEGF was first implicated in the modulation of vascular
permeability (Senger et al., 1983). With this in mind, it was hypothesised that VEGF
would be detected early on in the response to injury to enable the extravasation of
cellular or molecular components from the blood and that it would correlate with
protein concentration of the dialysate. No reports have yet been published in which
measurements are taken of VEGF recovered from skin by microdialysis. One study
on human skeletal muscle, in vivo, measured VEGF before and during exercise, from
60 minutes after insertion. VEGF levels remained relatively unchanged in the initial
resting phases before exercise (Ho¨ffner et al., 2003). This observation matches that in
the present study. However, the Ho¨ffner study did not conduct any measurements in
the first hour, in which the effects on vascular permeability would be expected. The
absence of any clear trend in VEGF recovery suggests that another factor or combi-
nation of several mediators may responsible for the increase in vascular permeability
after injury, such as histamine or neuropeptides such as bradykinin.
Recovery of MIP-1α did not occur as would have been expected for a marker of
platelet activation (Figure 3.7d). Very low concentrations were detected only in the
final collection (150 – 180 minutes after insertion) from three of the five volunteers,
compared to the early increases that would be expected from release by activated
platelets. However, this corresponds well with murine mRNA data in which expres-
sion increased from approximately three hours post-injury (Bryan et al., 2005). With
mRNA data however, the effect of pre-generated stores cannot be taken into account,
therefore any protein released from platelets is likely to have been missed. The recov-
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ery of MIP-1α only within the final collection shows that this is not a good marker
for platelet recruitment, at least. Activation of platelets occurs almost immediately
after injury, however the exact time course of the release of alpha granule contents,
including MIP-1α after injury is as yet unclear in this situation. Additional markers
would be required in future to better characterise the action of platelets and a longer
time-course would be needed to characterise the recovery of MIP-1α itself within this
model.
Release of OSM was predicted to occur within one hour of the initiation of an in-
flammatory response. Its absence in this situation would suggest that the inflammation
induced by microdialysis probe insertion injury was not severe enough to require the
IL-6 amplification effects or neutrophil attraction within this time frame. It is also
possible that OSM was released, but not at a great enough concentration to be recov-
ered at a concentration high enough to allow detection. OSM has not been measured
before in an injury situation, however, in patients with sepsis, OSM has been measured
at concentrations of around 45 nM, with levels being low or undetectable in healthy
subjects (Guillet et al., 1995).
Alternatively, the diffusion rate of OSM may be too low or the molecule itself in-
compatible with the microdialysis membrane. OSM has a theoretical pI of 10.7, similar
to that of MCP-1 (10.5), so an incompatibility of molecular charge status between the
protein and the microdialysis membrane is unlikely to be responsible for the absence
of OSM in the dialysate. The time-course of OSM expression following mechanical
injury has also not yet been reported, however polymorphonuclear neutrophils stim-
ulated with bacterial lipopolysaccharide and GM-CSF can produce OSM within one
hour (Grenier et al, 1999) suggesting that it is released rapidly. OSM was detected
within four hours in the equivalent control populations, therefore, if it is released in
response to injury, it may be not be released until after the three hour time course
studied. Early detection of OSM in situations of sepsis and LPS-induced inflammation
suggest a role in anti-bacterial effects consistent with neutrophil chemoattraction, but
the results of the present study indicate it is unlikely to be involved very early on in
injury.
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The macrophage chemoattractant, MCP-1, was observed during the first three hours
after injury. For two of the volunteers, MCP-1 was detected in the very first collection,
albeit at low concentrations. Only one volunteer had detectable levels in the second
collection. This would suggest that this is the result of early, low level release rather
than a constitutive expression. Although this could also be a result of expression
below the concentration required for sufficient recovery to enable detection. Recovery of
MCP-1 greatly increased from the third collection (60-90 minutes post injury) onwards.
MCP-1 has been recovered previously using microdialysis, in human abdominal tis-
sue (Riese et al., 2003), but the collection period in relation to insertion is unclear.
Baseline levels, that is without additional stimuli, were recorded in the range of 2-6000
pg/ml between 60 and 320 minutes post-insertion (Murdolo et al., 2007). These val-
ues were adjusted concentrations, to represent interstitial fluid concentration based on
measurements of relative recovery of approximately 20 %, so the actual levels mea-
sured in the dialysate will be lower (approximately 400-1200 pg/ml). Similar levels
were observed in dialysate obtained from mice within one hour of LPS administra-
tion, un-stimulated values were reported within the low pg/ml range (Ao et al., 2005).
Most volunteers displayed concentrations around 300 pg/ml within the final collection,
slightly lower than the values obtained in dialysate from abdominal tissue but still
comparable. The recovery profile obtained in this study matches that seen in previ-
ous experiments, in which the concentration in response to an inflammatory stimulus
continues to increase over the three hour time frame examined, and beyond (Ao et
al., 2005). This is somewhat surprising, as macrophages are generally not recruited
until after neutrophils. However, the exact time that blood-derived monocytes first
enter the wound is unknown, further than within the first 24 hours (DiPietro, 1995).
An increase in expression this early on suggests that MCP-1 may be involved in other
processes during the earlier stages of the inflammatory response. It is a known stim-
ulator of cytokine production in monocytes (Jiang et al., 1992), however, this would
be expected even later than the initial chemoattraction. Given the multi-functionality
of many cytokines and chemokines, it is probable that MCP-1 fulfils other roles in the
early inflammatory response yet to be determined. It is known to be released from
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keratinocytes (Wetzler et al., 2000) and endothelial cells (Gerritsen & Bloor, 1993)
after injury, and a recent review highlights a possible role in modulation of vascular
permeability (Wallez & Huber, 2008).
IL-6 was recovered in the third dialysate collection, 60 – 90 minutes after injury. The
concentration of IL-6 in the dialysate continued to increase over subsequent collections.
This was very similar to the time course reported by Sjo¨gren, Svensson & Anderson
(2002). In all but one volunteer, IL-6 was first detected at less than 50 pg/ml, increasing
to between 50 – 200 pg/ml by three hours. One volunteer showed considerably higher
release, reaching 456 pg/ml. The concentrations in this study are higher than those
reported by Sjo¨gren and colleagues (10 – 70 pg/ml and one volunteer above the highest
standard of 100 pg/ml). The differences in concentration between the two investigations
is particularly surprising, given the lower perfusion rate (1 µl/min) used. This could
be a result of the dilutions performed in order to obtain enough volume for the assay
or, from the dilution that occurs as a result of the reduced volume loss associated with
the push-pull microdialysis method used. This method removes the dialysate under a
pressure equal to that of the perfusate inflow, reducing the loss of the perfusate to the
tissue surrounding the probe. Alternatively, it could be an consequence of improved
detection methods and sensitivity since the experiments were conducted. The difference
is unlikely to be due to the different microdialysis sampling methods (push-pull versus
the push-only method used in the present study) as little difference is seen for in vivo
recovery of Il-6 reported by Sjo¨gren and colleagues. The concentrations of IL-6 seen
by Clough et al. (2007) were obtained from undiluted samples and are closer to those
observed in this study, reaching a mean of 137 pg/ml by 4.5 hours post insertion. The
increased perfusion rate of 5 µl/min may account for the slightly lower levels and later
time of increase compared to those seen in the present study. IL-6 is not constitutively
expressed in normal skin (Sugawara et al., 2001), so the detection of IL-6 is significant
because it confirms that an inflammatory response has been initiated. As previously
discussed, IL-6 is a key mediator within inflammation with many regulatory roles, so
it would be of particular interest to see how its expression correlates with downstream
targets.
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No correlations were found between cytokine concentration and either measure of
the vascular response to injury, suggesting that the regulation of these parameters are
not closely related (data not shown).
The multiplex cytokine assay worked well with the dialysate samples, both in terms
of volume requirements and sensitivity. In some cases, the dialysis efficiency may not
have been high enough for recovery of a sufficient concentration of cytokine to enable
detection. However, it is not possible to determine whether this is the case, or if no
cytokine was released within the tissue. As explained in Chapter 1, while ex vivo
experiments can give an estimate of dialysis efficiency, these are unreliable estimates
as in vitro dialysis conditions are very different compared to the in vivo environment.
In the present study, the aim was to obtain an overview of the injury environment and
therefore a more comprehensive characterisation. The exact tissue concentration is not
necessarily required as the amount recovered should be equally representative between
volunteers. As long as the recovery is reasonably reproducible, it would still be possible
to differentiate between a normal and an abnormal response on the basis of cytokine
levels relative to each other, and of the time-course by which they are observed in the
dialysate. Figure 3.8 shows those of the panel of cytokines which were detected in
the dialysate, in relation to the cell types either activated or stimulated in the injury
model.
The inflammatory profile obtained from the measures that were detected in the
present study is indicative of the activation of keratinocytes and endothelial cells fol-
lowing injury. This suggests that the three-hour time-course is sampling the early
pro-inflammatory environment just prior to the recruitment of neutrophils, in which
the signals for leukocyte recruitment are being generated. However, the number of pro-
cesses in which these cytokines are involved span four of the five stages of the injury
response. These results highlight the need for more specific markers of injury to better
characterise the response and for more accurate targets for therapeutic intervention.
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3.4.4 Summary
The microdialysis probe insertion method of injury generated a reproducible inflam-
matory response. This response was consistent with the very early stages of inflamma-
tion and measurements of existing markers of inflammation were consistent with those
reported in the literature. While there are some limitations within the sampling tech-
nique, these are far outweighed by the advantages of localised, continuous collection
without causing further injury. The vascular responses, protein recovery and cytokine
profiles obtained were similar to those predicted. However, the involvement of each
mediator in more than one process within the inflammatory response highlights the
problems of using such multifunctional molecules, both as markers of inflammation
and targets for therapy. It is clear that alternative approaches are required. This
work has shown that a sufficient amount of protein-rich fluid can be obtained from
the injury environment using microdialysis, from which novel mediators of the injury
response may be identified. The next chapter describes the analysis of the protein
content of this fluid.
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Figure 3.8: Overview of the results of the characterisation study in the con-
text of injury signalling The measures of inflammation detected (green) are placed
in the context of the signalling overview. Those not detected (red) are also shown.
The x-axis shows the chronology of the stages of the injury response. Cell types are
listed from top to bottom in order of expected involvement, although keratinocytes
and endothelial cells are stimulated simultaneously by the injury itself.
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Chapter 4
Proteomic Profiling of Dermal
Dialysate
4.1 Introduction
Recent research (reviewed in Chapter 1) and the data presented in Chapter 3 have
shown that measurements of cytokines and growth factors are insufficient for charac-
terising responses to injury and to treatment of fibrosis or non-healing wounds. It
is therefore clear that alternative markers are required to give a more comprehensive
understanding of the cutaneous response to injury.
It was hypothesised that the combination of a localised sampling technique and
a more global approach to characterisation of the wound environment would lead to
the identification of novel markers of the injury response. At the time of this study,
the proteome of human dermal dialysate had not been determined, so the first step
was to characterise the protein profile that could be obtained. A baseline survey was
conducted using dialysate samples obtained 30 – 150 minutes after injury, after the
initial peak protein in concentration observed over the first 30 minutes, as shown in
Chapter 3. This survey was conducted using a shotgun proteomics approach, discussed
in Section 1.5, to enable identification of potentially unknown components.
Characterisation of the injury model in Chapter 3 indicated that the three hour
time course chosen covers the activation of resident cell types and of platelets recruited
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to the site of injury. It would be expected that the predominant proteins detected
would be representative of the acute phase and of cell damage. Several studies into the
proteome of the skin have been conducted, as discussed in Section 1.5.1. Although the
proteome obtained will depend on the sampling method, it is likely that there would be
considerable overlap in protein profiles. Two studies (Kool et al., 2007; Macdonald et
al., 2006) reporting on the associations of proteins identified in human suction blister
fluid to various disease states do not list any proteins in common, although different
complement factors are present in both datasets. The seeming absence of shared pro-
teins is likely due to only those proteins of interest to the particular study being listed
and not the entire dataset obtained. Full listings are not available in supplementary
data, so this cannot be confirmed. Several acute phase response proteins were iden-
tified between the two papers, including ceruloplasmin, apolipoprotein, orosomucoid
and haptoglobin related proteins, which would be expected to increase following injury
and hence could be expected in dermal dialysate.
No proteomic analysis of human dermal dialysate samples had been reported to
date, although the combination of microdialysis with proteomics has been applied to
neuroscience research. Analysis of dialysate obtained following microdialysis within the
human brain identified 27 proteins. Of these, the majority were acute phase proteins,
with considerable overlap with those seen in the suction blister skin studies (Maurer
et al., 2003). Ten proteins were apparently specific to brain dialysate, as they had not
been previously identified in cerebrospinal fluid. This suggests that locally produced
components can be detected using these techniques, over and above those systemically
produced components. The total amount of protein in samples used in determining
the cerebral dialysate proteome was between 0.08 and 0.40 mg/ml, compared to the
total protein concentration of 0.59 – 2.1 mg/ml in dermal dialysate samples measured
in Chapter 3. This suggests that there will be sufficient protein in the dermal dialysate
for proteome analysis.
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4.1.1 Specific protein depletion to improve proteome coverage
One concern with the global profiling approach is the abundance of several plasma
proteins, particularly immunoglobulins and serum albumin. With the limited capacity
of the mass spectrometer, these proteins may reduce the detection of less abundant
components. This proves particularly problematic with profiling of plasma/serum,
derived from multiple sources. It is unknown whether this is likely to be a problem in
profiling the proteome of dialysate from skin. However, given that serum albumin is
estimated to comprise approximately 70 % of the total protein in cerebral and dermal
dialysate (Winter et. al., 2002), it is likely to.
Two approaches are employed to improve detection of lower abundance proteins;
the removal of the higher abundance proteins, or fractionation of the sample to reduce
complexity. Depletion appears to be the most common method of reducing the effect
of high abundance proteins with fractionation sometimes used as a secondary step.
Fractionation can either occur in the form of a gel-based methods, such as 1- or 2-D–
SDS PAGE, or through use of liquid chromatography (Faca et al., 2007).
Depletion has previously been conducted using dye-affinity (Ahmed et al., 2003)
and immuno-affinity (Cho et al., 2005) methods. In the former study, a dye-based
depletion method followed by 2-D-gel fractionation was used. Dyes such as Cibacron
Blue used in the Affi-Gel Blue system have a high affinity for serum albumin and are
hypothesised to bind via ionic interactions to a dinucleotide-binding or similar domain,
enabling removal of the protein from complex biological samples (Leatherbarrow &
Dean, 1980). This method is not entirely specific for serum albumin, but can be
used to remove one of the most more highly abundant proteins from serum or plasma
samples. The resulting lower-abundance fraction contained approximately 96 - 99 %
less total protein, with a corresponding 86 - 126 % change in the number of protein
spots identified, compared to untreated serum.
More recently, antibody-based depletion methods have been developed and display
a greater specificity for the target proteins. A comparison of the dye- and immuno-
affinity methods confirmed that a multiaffinity removal column using polyclonal anti-
bodies to the six most abundant proteins in plasma to be the most efficient method
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for depletion (Echan et al., 2005). Accordingly, a Multiple Affinity Removal System
(MARS) column supplied by Agilent was used in the present study. Echan and col-
leagues also stress the need to reduce non-specific loss of proteins, particularly those
bound to the highly abundant proteins that are removed. It was therefore necessary
to analyse the protein content of both depleted and non-depleted dermal dialysate
samples.
4.1.2 Aims
The aim of the research presented in this chapter was to use proteomic analysis to
identify the proteins contained in dermal dialysate from injured skin. This research
was not strictly hypothesis-driven, however it had the potential to generate hypotheses
once the types of proteins present in such samples had been identified.
Specific objectives were as follows:
• To determine whether proteomics technologies were appropriate for the identify-
ing novel proteins within dermal dialysate.
• To determine the effect of depletion of specific highly abundant proteins on the
detection of less abundant components.
• To place the identified proteins in the context of the response to injury through
comparison with reports of injury research in both skin and other tissues.
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4.2 Materials and Methods
4.2.1 Collection of dermal dialysate for proteome profiling
Dermal dialysate was collected as described in Section 2.2.2, using probes produced
as described in Section 2.2.1. Dialysate for the non-depleted analysis was collected
from one healthy male volunteer (aged 34 years) and for the depletion study, from two
healthy male volunteers (mean age = 32.5 ± 6 years). Briefly, four probes were inserted
into the dermis of the non-dominant volar forearm, no less than 7 cm from the fold
of the wrist, as shown in Figure 2.3. Following insertion, probes were perfused with
Ringer’s saline solution for 30 minutes to enable the initial insertion trauma to settle.
This settling period was added to reduce the amount of albumin and haemoglobin,
known to be higher within the first 5 minutes after insertion (Clough, 2005). The
purpose of these profiling experiments was to determine the protein content of dermal
dialysate samples, including proteins that may serve as markers of the injury response.
Due to the predicted >70 % loss off total protein following depletion of highly abundant
components, a larger volume of dialysate was required to determine the protein content
of depleted dialysate. The timing of the study is illustrated in Figure 4.1.
Figure 4.1: Dialysate collection protocol for proteomic profiling of depleted
dialysate. Shaded boxes indicate the collection periods. Dialysate for the non-depleted
sample was collected only during the first collection period, while the depleted sample was
collected from both.
At the end of each one-hour collection period, samples were flash-frozen in liquid
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nitrogen and stored on ice until they could be transferred to -80◦C, on completion of
the experiment. Protease inhibitors were not used in this experiment as they contain
protein components that may influence the proteome obtained.
4.2.2 Preparation of dermal dialysate and estimation of pro-
tein concentration
For the depletion experiment, dialysate samples were thawed on ice and pooled
to give a total 1.8 ml. This was concentrated to 250 µl using a 5 kDa MWCO spin
concentrator and enabled a reduction in the salt content of the sample. Following this,
the protein concentration of the concentrated dialysate was estimated by BCA assay
(Section 2.3). The concentrated sample was taken for depletion, described in the next
section. Dialysate for the initial proteome analysis without depletion was thawed on
ice, but sample concentration prior to separation by 1-D SDS PAGE was not required.
4.2.3 Depletion of the six most abundant proteins in plasma
Depletion was conducted as described in Section 2.5.2. This generated a low abun-
dance fraction containing the proteins that did not bind to the column, and a high
abundance fraction containing those proteins that bound to the column and that were
eluted once the low abundance fraction had been collected. The protein content was
estimated for the low abundance fraction. However, the protein concentration of the
high abundance fraction could not be determined due to the interference of urea in
the elution buffer. The two fractions were concentrated by lyophilisation to 50 µl, 30
µl (approximately 95 µg total protein in the low abundance fraction) was taken from
each for separation by 1-D SDS PAGE.
4.2.4 Protein separation by 1-D SDS PAGE
The non-depleted dialysate and concentrated high and low abundance dialysate
fractions (30 µl) were prepared for SDS PAGE by heating at 70◦C for 10 minutes in
109
4. PROTEOMIC PROFILING OF DERMAL DIALYSATE
25 % sample buffer and 1 % sample reducing agent. 1-D SDS PAGE was conducted as
described in Section 2.5.3, following the protocol for staining with colloidal coomassie.
4.2.5 Shotgun proteomics analysis
For both the non-depleted and low abundance depleted samples, the gel lanes of
interest were excised and cut into approximately 20 even slices. Protein digestion and
mass spectrometry were conducted as described in Section 2.5.
4.2.6 Characterisation of identified proteins using the AmiGO
database classification
The genInfo (gi) number for each protein in turn was cross-referenced using the Pro-
tein Identifier Cross-Reference service (PICR) (http://www.ebi.ac.uk/Tools/picr/searc
h.do) to determine the Uniprot ID. Input parameters were limited to Homo sapiens and
returning only active mappings. The databases used were SwissProt and TrEMBL. In
cases where the gi number produced no results, accession numbers were obtained from
the NCBI protein database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein)
and this number used instead. This Uniprot ID was then used to search the Gene On-
tology (GO) database, found at http://amigo.geneontology.org/cgi-bin/amigo/go.cgi.
Cellular component and biological process terms were collated and terms at Tree Level
Three were determined. Where a protein gave more than one third-level term, all were
collected and all groups reported. Specific functions in the response to injury, focusing
on mechanical injury, were determined through literature searches for the protein name
and “injury” or “wound healing”, using PubMed (http://www.ncbi.nlm.nih.gov/PubM
ed/). Where more than 200 results were found, the search was limited further by spec-
ifying “human” and then “skin”.
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4.3 Results
4.3.1 Proteome analysis of dermal dialysate
The total amount of protein in the non-depleted dialysate was estimated at 1.9
mg/ml by BCA assay. Figure 4.2 shows the 1-D SDS PAGE profile of the separated
dialysate proteins.
Figure 4.2: One-dimensional SDS PAGE of dermal dialysate. The figure shows the
profile of proteins contained in 30 µl dialysate, collected 30 – 90 minutes after injury, from a
single volunteer.
Several distinct bands were detected on the gel, although the profile is dominated
by a large smear at ∼ 50-75 kDa, most likely corresponding to human serum albumin.
The remainder of the track contains clearly distinguished bands ranging from ∼ 15
kDa to > 250 kDa. Six proteins were unambiguously identified within the dialysate
and are listed in Table 4.1. Full information, including the specific peptides identified,
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is provided in Appendix One.
Table 4.1: Proteins identified in non-depleted dermal dialysate collected 30
– 90 minutes after injury
gi Uniprot
ID
Protein Name Mass
(Da)
pI Coverage
(%)
Peptides
4502027 P02768 Albumin 71317 5.92 39.1 21
66932947 P01023 α-2-
Macroglobulin
164614 6.00 5.9 6
4557485 P00450 Ceruloplasmin 122983 5.44 2.3 2
4557385 P01024 Complement
Component 3
188585 6.02 6.0 7
11321561 P02790 Hemopexin 52385 6.55 14.5 4
4557871 P02787 Transferrin 79280 6.81 26.2 11
The proteins identified fell within a mass range of 52 - 189 kDa, showing that
relatively large proteins could be recovered by microdialysis at high enough concentra-
tions to enable analysis by proteomic technologies. No proteins corresponding to the
extremes of the mass range observed in the gel were identified. The most abundant
protein identified was human serum albumin, with 21 different peptides identified over
87 scans and a coverage of 39.1 % of the total protein sequence. Transferrin was the
second most abundant protein, with 11 peptides matched to give a 26.2 % coverage.
Ceruloplasmin was the least abundant in the sample, with two peptides matched and
a 2.3 % coverage of the whole protein. Figure 4.3 shows the cellular component, that
is, the physical structure or compartment, with which each protein is associated.
As expected, all six of the proteins were associated with the extracellular region
and are known to be highly abundant in plasma. Three proteins were also associated
with intracellular components. The biological processes performed by the dialysate
proteins are shown in Figure 4.4. Inexplicably, one protein, transferrin, did not have
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Figure 4.3: Cellular component of the proteins in non-depleted dermal dialysate.
The bar graph shows a summary of the different cellular components from which the proteins
identified in the non-depleted dialysate sample (collected 30 – 90 minutes after injury from a
single volunteer) are associated. Each protein may be active within more than one component,
in which case, all associated components were included. Components correspond to Gene
Ontology tree level 3 terms and are grouped to avoid repetition of very similar terms, e.g.
membrane-bound organelle and intracellular organelle.
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any functional terms associated with its human form. Where a protein had more than
one association, each category was included.
The reported generalised functions of the identified proteins include cellular com-
munication, coagulation, immune response, and the responses to stimulus, to stress
and cell death, indicating a link to the processes that occur in response to injury. Four
classes of biological processes were associated with three or more proteins, including
two terms for general regulation and two in the response to stress or an external stim-
ulus. The remaining terms were associated with only one or two different proteins
each.
While there were no associated terms for human transferrin, the entry for rat trans-
ferrin includes terms such as involvement in acute phase response and homeostasis. It
is also known to be involved in the injury response.
4.3.2 Depletion of highly abundant plasma proteins to in-
crease protein detection in proteomic profiling of dermal
dialysate
The protein concentration in the concentrated dialysate was estimated to be 4.7
mg/ml by BCA assay, equivalent to 1.7 mg as a starting amount. The concentration of
the low abundance fraction was estimated to be 160 µg/ml, giving a total of ∼250 µg
for SDS PAGE. Figure 4.5 shows the 1-D gel profiles of the low and high abundance
fractions of dialysate obtained after depletion of the six most abundant proteins in
plasma; albumin, anti-trypsin, haptoglobin, IgA, IgG and transferrin.
There was a significant difference in profile between the high and low abundance
fractions, with the large smear observed in the non-depleted sample (Figure 4.2) only
present in the high abundance fraction. In place of this smear, the low abundance
fraction contained discrete bands, showing that, as expected, the high abundance pro-
teins were indeed masking other proteins. This was confirmed by the identification of
a total of 29 proteins in the depleted sample (Table 4.2), a 4.8-fold increase on the
number identified in the non-depleted sample. Full details, including peptide sequence
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Figure 4.4: Biological processes performed by the proteins in dermal dialysate.
The bar graph shows the different biological processes for the proteins identified in non-
depleted dialysate (collected 30 – 90 minutes after injury from a single volunteer), according
to the Gene Ontology classification. Processes correspond to level 3 terms within the Gene
Ontology classification, with similar terms e.g. regulation of the response to stimulus and
response to external stimulus grouped appropriately. Regulation is abbreviated to “Reg.” for
aesthetic purposes.
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Figure 4.5: One-dimensional SDS PAGE of Depleted Dialysate. Gel image showing
the two fractions obtained from depletion of dialysate, collected 30 – 150 minutes after injury
and pooled from 2 volunteers. Lane 1 shows pre-stained standards, lane 3 shows the low
abundance fraction (unbound proteins) and lane 5 shows the high abundance protein fraction
(albumin, anti-trypsin, haptoglobin, IgA, IgG and transferrin).
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information is provided in Appendix Two.
Of these 29 proteins, four were previously identified in the non-depleted dialysate;
α-2-Macroglobulin, Ceruloplasmin, Complement Component 3 and Hemopexin. All
protein identifications were made on the basis of two or more different peptides and
only four proteins had less than 10 % protein coverage. In this sample, the mass range
of identified proteins was 16 - 189 kDa, a greater range than non-depleted sample. A
large proportion of the proteins (46 %) were within the 50 - 75 kDa range previously
dominated by the highly abundant proteins. The pI range was 4.93 - 8.34, a similar
range to that observed for proteins in the non-depleted sample.
The associated cellular components of each of the proteins identified in the depleted
sample were determined using the same Gene Ontology database classifications as for
the non-depleted sample and are shown in Figure 4.6.
As expected, the majority of the proteins identified (62 %) were active within the
extracellular region. An identical proportion had intracellular activities, including some
exclusively, such as the keratins. Five proteins had no cellular component associated,
although the two of those are known to act within the intracellular component and the
remainder have been identified in plasma.
The biological processes performed by the 29 proteins identified in the depleted
dialysate sample, according to the gene ontology classifications, are shown in Figure
4.7.
Unsurprisingly, a greater variety of biological processes were represented by the
proteins identified in the depleted sample compared to the non-depleted sample. All
those terms associated with proteins identified in the non-depleted sample were rep-
resented in the depleted sample, along with 12 more. Processes potentially key to
the injury response that were included in this second, depleted sample include cell
adhesion, proliferation, gene expression, secretion and tissue remodelling. The most
common associated function categories were general regulation of biological processes
and also of the response to stress and external stimuli, as for the non-depleted sample.
Metabolic processes were also highly represented, with 10 proteins associated. Three
proteins did not have any biological process terms of level 3 or higher associated with
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Table 4.2: Proteins identified in depleted dermal dialysate.
gi Uniprot
ID
Protein Name Mass
(Da)
pI Coverage
(%)
Peptides
21071030 Q68CK0 α-1B-Glycoprotein 54790 5.56 29.5 9
4502067 P02760 α-1-Microglobulin 39888 5.95 15.9 4
66932947 P01023 α-2-Macroglobulin 164614 6.00 44.4 44
4557287 P01019 Angiotensinogen 53406 5.87 13.4 5
4757756 P07355 Annexin A2 38808 7.57 10.9 3
4557327 P02647 Apolipoprotein A-1 30759 5.56 47.9 17
4557321 P02749 Apolipoprotein H 39598 8.34 17.1 4
4504349 P68871 β-globin 16102 6.75 68.7 8
4502517 P00915 Carbonic Anhydrase 1 28909 6.59 23.0 4
4557485 P00450 Ceruloplasmin 122983 5.44 30.0 23
73858568 P05155 Component 1 inhibitor 55347 6.09 14.4 6
4557385 P01024 Complement Component 3 188585 6.02 19.1 7
67782358 P00751 Complement Factor B 86847 6.67 24.3 12
11321561 P02790 Hemopexin 52385 6.55 40.3 15
4504579 P05156 I Factor (complement) 68120 7.72 3.3 2
17318569 P04264 Keratin 1 66198 8.16 33.1 15
47132620 P35908 Keratin 2a 65678 8.07 13.5 8
17318574 P19013 Keratin 4 57649 6.25 4.3 2
4504919 P05787 Keratin 8 53671 5.52 5.0 2
55956899 P35527 Keratin 9 62255 5.14 21.8 11
9257232 P02763 Orosomucoid 1 23725 4.93 40.8 7
4505529 P19652 Orosomucoid 2 23873 5.03 32.8 7
4505881 P00747 Plasminogen 93247 7.04 10.0 5
4506355 P20742 Pregnancy zone protein 165215 5.97 7.4 7
50659080 P01011 SERPIN A3 47792 5.33 17.3 5
4502261 P01008 SERPIN C1 53025 6.32 27.6 12
39725934 P36955 SERPIN F1 46454 5.97 14.8 6
4507725 P02766 Transthyretin 15991 5.52 49 5
32483410 P02774 Vitamin D-binding protein 54480 5.32 38 15
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Figure 4.6: Cellular origins of the proteins identified in depleted dialysate Bar graph
showing the different cellular components from which the proteins identified in the depleted
dialysate sample (collected 30 – 120 minutes after injury and pooled from 2 volunteers)
originate. Each protein may be derived from more than one component, in which case, all
components were included. Components correspond to tree level 3 terms within the Gene
Ontology classification.
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Figure 4.7: Biological processes performed by the proteins identified in depleted
dialysate. Bar graph showing the different biological processes in which the proteins iden-
tified in dialysate (collected 30 – 150 minutes after injury from 2 volunteers) are involved,
according to the Gene Ontology classification. Each protein may perform more than process,
in which case, all level 3 process terms were included.
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the human form; α-1B-glycoprotein, Annexin A2 and complement I factor. The func-
tion of α-1B-glycoprotein is unclear, but Annexin A2 and I factor are known to be
involved in regulation of the plasmin and complement cascades respectively.
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4.4 Discussion
The aims of the research presented in this chapter were to assess the suitability of
the combination of microdialysis and proteomics for biomarker discovery, to catalogue
the protein content of dermal dialysate from healthy human volunteers and to fit those
proteins into the context of the early response to injury. Finally, any candidate proteins
for further study were to be highlighted. The identification of proteins from non-
depleted dialysate was severely impeded by the abundance of a few proteins. Therefore,
the additional aim of investigating the effect of depletion on protein identification was
also addressed. Removal of these highly abundant proteins was very efficient, with
none of the six proteins identified in the depleted sample. This depletion dramatically
increased the total number of proteins identified in the dermal dialysate samples. A
total of 31 proteins were identified in the two experiments, from both the intra- and
extracellular compartments and involved in a variety of biological processes relevant to
the response to injury.
Although it would be possible to review the relevance of the identified proteins by
intensive reading of the scientific literature, this becomes difficult when more than a
few are under consideration. Furthermore, it is easy to miss trends when using this
approach. For this reason, further analysis exploited the Gene Ontology, in which
keywords from a controlled scientific vocabulary were used to cluster protein features,
including their associated functional categories. The GO approach is useful for spotting
broad trends and circumvents the time-consuming literature searches for obtaining
insights into protein function. However, results must be interpreted with care, as the
system remains rather subjective and the vocabulary is not yet complete.
4.4.1 The effect of depletion on protein identification
None of the six proteins specifically removed by the antibody-based depletion col-
umn were detected, showing that this is a very effective method of depletion. Interest-
ingly, several keratins have been identified which may have been derived from the skin
itself, demonstrating the advantages of a localised sampling method.
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Depletion of the six most abundant plasma proteins from dermal dialysate increased
the number of proteins identified from 6 to 31, a 5–fold increase. This 5–fold increase in
the number of proteins identified is double that observed following depletion of serum
by Ahmed et al. (2003) using dye-based methods and three times the increase in protein
identifications of 1.6-fold observed by Bjo¨rhall, Miliotis and Davidsson (2005), using
a MARS column. This indicates that the highly abundant proteins were impeding
identification of less abundant components in the non-depleted sample.
The starting amount of 1.7 mg total protein was sufficient for proteomic analysis
following the removal of the six most abundant proteins in plasma. However, the total
protein concentrations of 0.5 – 1 mg/ml observed in the later 30 minute collections in
the previous chapter (Chapter 3) would not be enough for this analysis. Therefore a
different method would be required to assess changes in protein content between these
timed collections.
4.4.2 Involvement of identified proteins in the response to in-
jury
The GO associations obtained from the identified proteins were consistent with
several of these proteins being part of the acute response to injury. The biological
process terms associated with the identified proteins give some initial clues as to the
functions of these proteins. The most commonly associated terms were those involved in
regulation of biological processes and the responses to stress and external stimuli. Also
relevant were the associations with the immune response, coagulation, homeostasis
and tissue remodelling, required to maintain or restore the integrity of the tissue.
Proteins associated with these GO terms included α-1-microglobulin, apoliprotein H,
ceruloplasmin, complement factors, hemopexin, keratin 1 and plasminogen. In terms of
cellular component, proteins were derived equally from both the intra- and extracellular
compartments.
The detection of exclusively intracellular proteins is most likely to be a consequence
of damage causing cells to release their contents, while the proteins derived from either
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both or solely extracellular sources may be released or recruited as part of the response
to injury. One example is annexin A2 which, intracellularly, is translocated from the
cytoplasm to the cell membrane following mechanical injury and takes part in the
activation of plasmin, leading to monocyte recruitment (Falcone et al., 2001; Patchell
et al., 2007). Soluble, extracellular, annexin A2 in plasma causes macrophage activation
and subsequent cytokine release (Swisher, Khatri & Feldman, 2007). It is possible that
the exclusively intracellular proteins play a role in the injury response to injury, such
as members of the keratin family which are known to be involved in repair later in the
response (reviewed in DePianto & Coulombe, 2004).
Two proteins, angiotensin and keratin 2a, were associated with cell growth and
proliferation processes, such as those that occur during repair. This is consistent with
reports that angiotensin is involved in regulation of VEGF (Williams et al., 1995). This
indicates that it may be involved in regulation of the repair and replacement of the dam-
aged vasculature. Angiotensinogen had the greatest number of biological process terms
associated (44), so would be expected to perform further functions in the response to
injury. Several forms of angiotensin exist, released from cleavage of angiotensinogen by
neutrophil serine proteases and subsequent processing with angiotensin-converting en-
zyme (ACE) (Ramaha & Patson, 2002; Santos, Campagnole-Santos & Andrade, 2000).
These proteins perform a range of functions, predominantly vasoactive effects, and
have been reported to play an important role in wound healing through modulation of
cell proliferation, differentiation and control of blood pressure and therefore tissue per-
fusion. The discovery of several of the necessary components of the renin-angiotensin
system in cutaneous wounds suggests that angiotensin plays a vital part in the response
to injury.
Many of the other proteins identified in the dermal dialysate samples have been as-
sociated with the response to injury. Table 4.3 summarises some of these roles, where
functions have been reported in the literature.
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Table 4.3: Proteins identified in dermal dialysate and their function within
the response to injury.
Protein Name Function within the response to Injury
α 1B-glycoprotein None known
α-1-microglobulin/
bikunin precursor
Heme scavenger during inflammation, thought to reduce
oxidative stress (Allhorn et al., 2003).
α-2-macroglobulin Down-regulates acute inflammation through binding of
growth factors and cytokines with differential affinity de-
pending on it’s oxidation status (Wu et al., 1998).
albumin Increased at the injury site in response to IL-1α as part
of the acute phase reaction, although this is more likely
to be a result of infiltration of plasma to the damaged
area (Perl et al., 2003).
angiotensinogen Increases the expression of plasminogen activator
inhibitor-1 (PAI-1), an inhibitor of the conversion of plas-
minogen to plasmin (Vaughan, 2001). Also involved in
regulation of VEGF, as has been reported for renal injury
(Sataranatarajan et al., 2008).
annexin A2 Recruitment to the cell surface is increased following me-
chanical injury (Patchell et al., 2007) where it acts as a
co-factor for plasminogen and tissue plasminogen activa-
tor (Ling et al., 2004).
apolipoprotein A-I May play an important role in regulating neutrophil func-
tion during the acute phase of inflammation (Blackburn
et al., 1991).
apolipoprotein H Inhibitor of platelet-von Willebrand factor (vWF) inter-
actions, preventing platelet agglutination (Hulstein et al.,
2007).
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Protein Name Function within the response to Injury
β-globin None reported, although released iron from heme may
result in oxidative stress (Balla et al., 1993).
carbonic anhydrase I None Known
ceruloplasmin May regulate the stress-induced release of IL-1α (Mandi-
nov et al., 2003). Also functions to oxidise Fe2+ to Fe3+,
the form which can bind to transferrin (Patel et al.,
2002).
complement compo-
nent 1 inhibitor
Regulates all three complement pathways and can inhibit
endothelial cell-leukocyte adhesion (Cai & Davis, 2003).
complement compo-
nent 3
Activation of the complement cascade requires cleavage
of complement 3, a proinflammatory mediator respon-
sible for enhancing vascular permeability among other
functions (Sriramarao & DiScipio, 1998).
complement factor B Catalytic component of the C3 convertase enzyme com-
plex involved in activation of the alternative complement
pathway (Le, Abbenante & Fairlie, 2007).
hemopexin Synthesis is increased in response to increased IL-6 levels
in injured peripheral nerves (Madore et al., 1999; Cam-
borieux et al., 2000).
I factor Inhibits the formation of the C3 convertase enzyme com-
plex (Tima´r et al., 2007).
keratin 1 Part of a multi-protein receptor complex that binds
kininogen, leading to bradykinin activation, plasmin ac-
tivation and subsequent vasodilation (Shariat-Madar,
Mahdi & Schmaier, 2002).
keratin 2a None Known
keratin 4 None Known
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Protein Name Function within the response to Injury
keratin 8 May act as a cell-surface receptor for plasminogen and
tissue plasminogen activator (Kralovich et al., 1998).
keratin 9 None Known
orosomucoid 1 & 2 Hypothesised to have a range of anti-inflammatory effects
including maintenance of capillary integrity and inhibi-
tion of neutrophil migration, prostaglandin E2 generation
and platelet aggregation (Matsumoto et al., 2007).
plasminogen Plasma protease involved in controlled degradation of
the extracellular matrix during the remodelling phase of
wound repair (Sha¨fer et al., 1994).
pregnancy zone pro-
tein
Functions as a proteinase inhibitor, including against
proteins of the fibrinolytic system (Takada, Takada &
Urano, 1994).
SERPIN A3 (α1-
antichymotrypsin)
Specifically inhibits superoxide formation by neutrophils
and up-regulates IL-6 expression (Kilpatrick et al., 1991).
SERPIN C1 (anti-
thrombin)
Major anti-coagulant factor that regulates thrombin
among other factors (Roemisch et al., 2002) and may
stimulate release of prostacyclin with the potential to
inhibit release of reactive oxygen species and proteases
from neutrophils (Okajima & Uchiba, 1998).
SERPIN F1 (pig-
ment epithelium-
derived factor)
Displays anti-angiogenic and anti-inflammatory func-
tions including inhibition of macrophage proliferation
(Zamiri et al., 2006) and reduction of VEGF-induced vas-
cular permeability and proinflammatory cytokines such
as MCP-1, TNF-α and ICAM-1 (Zhang et al., 2006).
Transferrin Involved in iron ion homeostasis including its transport,
reducing oxidative damage (Yeoh-Ellerton & Stacey,
2003).
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Protein Name Function within the response to Injury
transthyretin None Known
vitamin D-binding
protein
Responsible for actin clearance after injury, reducing
the occurence of disseminated intravascular coagulation
(Meier et al., 2006).
The majority of the proteins identified in the dialysate samples have known roles
in the response to injury. A significant proportion of the proteins identified are classed
as “acute phase reactants”, reflecting the considerable change in plasma concentration
following the onset of inflammation. Albumin, transferrin and transthyretin are nega-
tive acute phase reactants, that is they are reduced in plasma concentration during
inflammation. Alpha-1-antitrypsin, α-1-antichymotrypsin, α-2-macroglobulin, plas-
minogen, complement factors and ceruloplasmin are positive acute phase proteins and
are thus increased during inflammation. Proteins such as α-2-macroglobulin, albumin,
hemopexin and the orosomucoids are involved in regulation of, or are regulated by,
cytokines. These proteins were associated with response to stimulus and to stress GO
terms. They are known to be involved in the systemic response to injury and infec-
tion with their effects including the modulation of cell responses and mediator release
(reviewed in Ceciliani, Giordano & Spagnolo, 2002; Suffredini et al., 1999). Alpha-2-
macroglobulin is one of the better characterised acute phase components and is known
to function as an anti-protease and as a cytokine-binding protein (Borth, 1992; Borth
& Luger, 1989).
A significant proportion of the proteins identified in the dermal dialysate samples
are involved in the regulation of plasmin, a key protease in the breakdown phase of
remodelling. These include plasminogen, the precursor to plasmin itself, along with
keratins 1 and 8 hypothesised to be involved in a complex that forms the site of
activation. This is in part regulated by plasmin activator inhibitor 1, in turn under the
control of angiotensin. Annexin A2 is also part of a complex that facilitates activation
of plasmin, as discussed previously.
Several of the identified proteins are reported to have roles in the detoxification
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of heme released from infiltrating globin, such as the β-globin detected in this study.
Ceruloplasmin oxidises iron from the form in which it is most commonly bound to
hemoglobin in the absence of oxygen, to the form in which it can bind to transferrin,
another protein identified here, to be removed (Osaki, Johnson & Frieden, 1966). This
process is well documented, particularly in response to damage to the central nervous
system (Patel et al., 2002; Rathore et al., 2008). Alpha-1-microglobulin also acts as a
heme scavanger, further reducing potential iron-induced oxidant damage (Table 4.3).
The proteins identified in dialysate within this study are put into the context of
the injury model in Figure 4.8, where functions in injury are known.
All proteins with known functions in the response to injury map onto the overview
diagram, with only the iron-detoxification processes unrelated to markers previously
given on the schematic. The identification of these proteins within dialysate after injury
is consistent with the cytokine data from Chapter 3, however the protein data give a
much clearer view of the processes involved and which pathways may be activated.
4.4.3 The suitability of combining microdialysis and shotgun
proteomics technologies
This is the first report of the proteome of dermal dialysate and as such, it is not
possible to compare these data to those of previous studies. The best comparison
would be between proteomic studies of other skin samples, such as skin biopsies or
suction blister experiments, or of microdialysis in other human tissues. Compared
to proteomic studies of alternative skin samples, the number of proteins identified in
dermal dialysate was very low; 31 compared to 401 in suction blister fluid (Kool et al.,
2007), although that study reported only 240 proteins in plasma samples analysed in
parallel. This is one fifth of the identifications made in the human plasma proteome
study (Anderson et al., 2004), so both numbers may be an underestimate.
The relatively low number of protein identifications in the dialysate sample is most
likely a consequence of the sampling technique. The proteome of cerebral micro-
dialysate contained 27 proteins, including three different forms of both tubulin and
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Figure 4.8: Overview of the involvement of proteins identified in dialysate in the
injury response. Proteins identified within dialysate in this study are given in dark blue.
Inhibitory interactions are shown by red arrows, activating interactions are shown with green
arrows. Factors characterised in the previous chapter (Chapter 3) are shown circled, in green
if detected and red if not. ∗ Plasminogen is involved in stimulation of cytokine expression from
macrophages and in control of the fibrinolytic system, along with pregnancy zone protein,
not pictured.
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haptoglobin proteins (Maurer et al., 2003), slightly fewer than detected in dermal
dialysate. The number may be limited by the method sampling, or of separation,
as proteins were resolved on 2-D gels and only proteins detected by the presence of
stained spots were removed for analysis, a problem from which the present study did
not suffer. In addition, no depletion methods were employed to remove albumin. While
this cerebral dialysate proteome shares many components with dermal dialysate (35
%, Table 4.4) that indicate a common response to probe insertion may occur, it is not
representative of the skin.
Table 4.4: Proteins common to both dermal and cerebral dialysate
Protein Name Dermal
Dialysate
(Uniprot
ID)
Cerebral
Dialysate
(Uniprot
ID)
α-1B-glycoprotein Q68CK0 P04217
α-1-microglobulin P02760 P02760
albumin P02768 P02768
apolipoprotein A-1 P02647 P02647
β-globin P68871 P02023
complement compo-
nent 3
P01024 P01024
plasminogen P00747 P00747
serpin A3 P01011 P01011
transthyretin P02766 P02766
transferrin P02787 P02787
vitamin D binding
protein
P02774 P02774
No proteins common to the human skin proteome study of Kool et al. (2007) were
found, presumably due to only an incomplete list being reported. Of the few proteins
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reported as identified in Macdonald et al. (2006), four are shared with dermal dialysate;
apolipoprotein A1, ceruloplasmin, complement factor B and vitamin D binding protein.
It is likely that there are many more common proteins, but without access to the full
list of identifications, this cannot be confirmed.
Kool et al. (2007) used a different method of categorising proteins to that used in
the present study, although they still exploited the Gene Ontology terminology. The
Gene Ontology strategy, reviewed recently by Dimmer et al. (2008), was established
in 1998 (Ashburner et al., 2000) to provide a standardised classification system for
gene and protein annotation. It enables clearer comparisons between different datasets
and experiments conducted in unrelated laboratories. AmiGO is one of the primary
search and browse tools provided by The Gene Ontology Consortium and is updated
frequently, thus representing the most straight-forward method for determining GO
associations for the dialysate dataset. Tools such as DAVID used by Kool et al. enable
more automated annotation. However, these are primarily intended for gene expression
or microrray analysis and are more appropriate for large datasets for which manual
searching is not practical. The advantage of manual searching being the researcher’s
direct input, allowing associations to be made that may not be made by a computer.
The majority of GO terms associated with the proteins identified in dialysate were
relevant to the injury response and the method by which it was created, showing this
to be an appropriate classification system.
Several skin-specific proteins were identified in this study, namely keratin variants,
which suggest that this is a suitable method for analysis of the local tissue environment.
However, care should be taken when confirming identification of keratins in proteomics,
particularly in studies of the skin. It is not possible to determine whether keratins
are derived from the sample or from contamination during processing and depletion
will only increase the detection of contaminants. Precautions were taken to minimise
contamination, e.g. the use of filtered air in the Centre for Proteome Research (CPR).
Furthermore, keratin contamination within the CPR has not been a problem previously
and the direct involvement of two of the six identified keratins in the response to injury
suggests that these are likely to be genuine identifications from the dialysate sample
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itself. Proteome profiling of murine skin revealed several different keratins (Huang
et al., 2003), while profiling of other murine organs did not identify any (Cutillas &
Vanhaesebroeck, 2007). This was rather surprising as keratins are within the top 15
protein families identified in proteomic profiling experiments, with keratin 8 the tenth
most commonly identified protein in differential expression experiments (Petrak et al.,
2008). Apolipoprotein A1 is frequently identified in rodent experiments, but is not
one of the top 10 proteins identified in human profiling studies. Annexins are also
very common, highlighting the fact that protein identifications should be examined in
context before additional or novel functions are attributed.
While the combination of microdialysis and proteomics appears to be compatible,
the proteins identified represent only a small fraction of the total protein complement
of the response to injury. This was to be expected, given the experimental conditions,
such as solubility and diffusion rate, imposed by the microdialysis sampling method.
Depletion of the most highly abundant proteins significantly increased the number of
less abundant proteins identified but the dynamic range of concentrations remains too
large for comprehensive characterisation. For example, no cytokines were detected in
the proteome study, despite their measurement in samples from equivalent time points
after injury. This is likely to be a result of sub-optimal sensitivity in terms of the mass
spectrometer and its analysis capacity for complex samples, although this will improve
as the technology becomes more sophisticated and more mature.
4.4.4 Summary
This is the first report combining dermal microdialysis and proteomics with deple-
tion of highly abundant proteins. Depletion enabled a 5–fold increase in the number
of proteins identified in dermal dialysate. A starting concentration of 1.7 mg, obtained
from 1.8 ml dialysate, was sufficient for this analysis. However, this is a very large
volume and is not practical for the higher resolution analysis required in investigating
30-minute timed samples as 12 probes would be required to collect that amount within
the specified time period. For temporal analysis of protein content, a different method
with lower volume requirements is needed.
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The majority of proteins identified within dermal dialysate appear to be abundant
plasma proteins. However, this does not mean that they cannot play an important
role in the early response to injury. Rather than investigating the changes in con-
centration of these proteins, it may be of greater benefit to characterise reversible
post-translational modifications, such as protein phosphorylation. To date, however,
such studies have been restricted by technological limitations which need to be over-
come if comprehensive information on this aspect of the response to tissue injury is to
be obtained.
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Chapter 5
Optimisation of phosphopeptide
capture methods for analysis of
protein phosphorylation in dermal
dialysates
5.1 Introduction
The importance of the reversible phosphorylation of proteins in the regulation of
many intracellular processes is well known and well studied. However, its role in regu-
lation of extracellular processes has received considerably less attention. The discovery
of many extracellular protein kinases, e.g. in plasma and from cells such as platelets has
lead to an understanding that proteins can be modified within the tissue space, thereby
potentially altering their function after release, as discussed in Chapter 1. Although
no kinases or phosphatases were identified in dermal dialysate (Chapter 4), more than
one-half of those proteins identified have been reported to contain phosphorylation
sites, as discussed in the following section.
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5.1.1 Identification of proteins that may undergo post-transla-
tional modification due to regulation or response to in-
jury
Sixteen of the proteins identified in dermal dialysate samples (Chapter 4) have
reported phosphorylation sites (Table 5.1). Some of these have known regulatory func-
tions related to responses to injury.
Many phosphorylation sites within these proteins have been identified by global
profiling studies. While the functions of the majority of these phosphorylation events
remain unknown, some have been assigned a role in specific cellular processes. For
example, complement component 3 is phosphorylated following the local decrease in
pH that occurs after an injury (Forsberg et al., 1989). This phosphorylation prevents
the inhibitory cleavage of C3 by complement factors H and I (Ekdahl & Nilsson, 1995)
indicating that the complement cascade is actively maintained.
Differential phosphorylation of serpin f1 (pigment epithelium derived factor), in-
volved in VEGF regulation, switches the protein between its anti-angiogenic and neu-
rotrophic roles. Phosphorylation on the S24 and S114 residues causes a conforma-
tional change that prevents phosphorylation of S227 and preserves the anti-angiogenic,
anti-neurotrophic form. Phosphorylation of all three of these sites yields a stronger
anti-angiogenic form (Maik-Rachline & Seger, 2006).
Annexin A2 is also of interest as it has been directly implicated in the response
to injury. Phosphorylation of S25 is involved in regulation of the cell cycle, molecular
associations and in the intracellular location of the protein.
5.1.2 Methods for investigating the phosphoproteome
There are several methods for analysing phosphoproteins, ranging from radio-isotope
labelling of metabolically active cells and western blotting with phospho-specific an-
tibodies, to the use of immobilised metal affinity (IMAC) and other chromatographic
techniques to isolate phosphoproteins and phosphopeptides. Most of these methods
employ mass spectrometry to identify phosphoproteins of interest. For recent reviews
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Table 5.1: Published phosphorylation sites for proteins identified in the der-
mal dialysate samples
Protein Reported∗ Phosphorylation Sites
α-1-microglobulin T198
α-2-macroglobulin Y497, Y695, Y708
albumin S82, Y108, Y162, Y164, Y365, Y377, Y394
annexin A2 T2, S11, S17, T18, Y23, S25, Y29, Y74, Y108, T122, S126,
Y187, Y198, Y234, Y237, Y274, Y315, Y316, Y317
apolipoprotein A1 S201‡
β-globin Y35, S44, Y130, Y145
ceruloplasmin S204, T674, Y784, Y787
complement 3 Y489, S742
keratin 1 S20, Y374, S501, T506, Y565
keratin 4 Y329, Y344
keratin 8 S9, S21, S22, S24, Y25, S27, S34, S35, S36, S37, S39, S43,
S74, Y204, S240, S243, S251, S253, S258, Y267, S274,
Y282, S330, S400, S410, S424, Y427, T431, S432, S436,
Y437, S438, S441, S442, S445, S451, S475, S477, S478
keratin 9 Y485
plasminogen S597
pregnancy zone Y700, Y701
protein
SERPIN f1 S24, S114, T226, S227
transferrin Y536, Y666
∗ As listed at www.phosphosite.org, October 2008, unless otherwise stated. ‡ Beg et al.,
(1989). S = serine, T = threonine and Y = tyrosine phosphorylated.
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on current methods for analysis of the phosphoproteome, see Delom & Chevet, (2006),
Paradela & Albar, (2008), Raggiaschi, Gotta & Terstappen, (2005) and Schmidt,
Schweikart & Andersson, (2006). Of particular interest in these reviews are the more
recent methods in which phosphopeptides are linked to molecules that can be readily
isolated from a sample solution. These methods impart increased specificity due to
the direct interactions with the phosphate group. Two key strategies in this respect
are the use of biotinylation and phosphoramidate chemistry. The biotinylation tech-
nique replaces phosphate groups with a biotin tag, thereby allowing phospho-serine,
-tyrosine or -threonine-containing peptides to be isolated on an immobilised avidin
support (Oda, Nagasu & Chait, 2001). However, there are a high proportion of side-
reactions as cysteine residues can also bind the biotin tag if efficient blocking steps
are not carried out. Furthermore, the removal of the phosphate groups that occurs
during the process makes the identification of the site of phosphorylation difficult to
confirm. The presence of the biotin tag indicates the site of modification, but it is
difficult to determine whether the site is a true phosphorylation site or uncovered due
to non-specific reactions with the biotin tag.
Of direct relevance to this study is the phosphoramidate chemistry scheme devel-
oped by Tao et al., (2005). This method involves covalent binding of phosphopeptides
to the amine groups of a synthetic polyamine dendrimer via the formation of phospho-
ramidate bonds and is discussed in greater detail in Section 5.1.4.
To investigate changes in the phosphoproteome of the interstitium as sampled by
microdialysis, the method of analysis must obviously be sufficiently sensitive to recog-
nise the fraction of proteins that are phosphorylated within it. Radio-isotope labelling
is not applicable to dialysate, as the sample is not metabolically active. Gel-based
methods, such as a western blotting in conjugation with phospho-specific antibodies,
are also unsuitable. While sensitive enough to detect femtomolar levels of phosphory-
lated proteins, the antibodies have varying specificity, as they are raised against specific
epitopes and may not recognise phosphorylation at sites where the amino acid sequence
differs. Antibodies against the rarest form of phosphorylation, phospho-tyrosine, are
considered most effective. The more common phospho-serine and phospho-threonine
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forms are less immunogenic, so efficient antibodies are harder to generate (Kauffman,
Bailey & Fussenegger, 2001). In addition to the limitations posed by the antibodies,
western blotting itself may not be ideally suited to comprehensive phosphoproteome
analysis. Even in two dimensions, it is difficult to resolve every protein clearly in a gel
and, as noted in the previous chapter, highly abundant proteins frequently obscure less
abundant components. Moreover, proteins transferred to a membrane will be limited
to those within the pI range of the 2-D gel and not all proteins will be transferred
equally during blotting, preventing accurate qualitative analysis. Finally, removal of
the antibodies requires harsh chemical conditions that may disrupt phosphorylation,
complicating later analyses to identify the phosphoprotein and the phosphorylated
residue(s). An alternative approach would be to stain the gel directly with a reversible
phospho-specific dye. While this has improved sensitivity and specificity, it suffers
similar limitations to western blotting with regards to protein separation and is bi-
ased towards multiply phosphorylated and highly abundant proteins. This method
could prove useful as a simple “first look” to determine whether a sample contains
phosphorylated proteins, in conjunction with another method with which to identify
those proteins. It would also provide a good comparison with the proteome data from
Chapter 4, as identical separation techniques, that is 1-D SDS PAGE, would be used.
The low abundance of the phosphorylated form of many proteins hinders their
identification within complex samples. Furthermore, the acidic nature of the phos-
phate group means that phosphorylated proteins have a higher affinity for certain
metal and plastic surfaces and may be lost by adsorption. This, along with low ion-
isation efficiency, makes mass spectrometric analysis of phosphorylated proteins and
peptides difficult. Immunoprecipitation with anti-phosphoprotein antibodies has been
used to enrich for phosphorylated proteins in a small number of studies (Gronborg et
al., 2002). However, as discussed above, the limitations of epitope recognition make
this an unsuitable technique. Methods taking advantage of the affinity for metals have
proven more successful in reducing sample complexity.
Affinity chromatography methods have been extensively employed and are cur-
rently the most popular methods of enriching for phosphorylated proteins. These
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methods take advantage of the shift in pI resulting from the addition of the acidic phos-
phate group as it increases protein affinity for positively charged moieties. Schmidt,
Schweikart & Andersson, (2006) recently published a comprehensive review of chro-
matographic methods in phosphoproteome analysis, in which the principle and exam-
ples were discussed. Andersson & Porath, (1986) first observed that phosphopeptides
displayed an affinity for metal ions, particularly Fe(III). Using immobilised Fe3+ ions
on a chromatographic support, they were able to fractionate hen egg-derived ovalbumin
into three differentially phosphorylated fractions by elution with solvents at varying pH
and phosphate concentrations. While non-specific binding and the narrow pH range
of operation still limit the IMAC technique, improvements are published on a regular
basis. For example, dioxides of both titanium and zirconium have recently emerged as
better alternatives.
5.1.3 Titanium dioxide affinity chromatography for capture of
phosphopeptides
The use of TiO2 for isolation of phosphopeptides from complex mixtures was first
reported in 2004 (Pinkse et al., 2004). Two main formats have been used, namely
chromatography columns and coated magnetic beads. The chromatography column
format is advantageous in that it enables online MS analysis. However, the initial set-up
is complex, requiring specialist equipment, and the experiment itself is time-consuming
in terms of machine use. In contrast, TiO2-coated magnetic beads are commercially
available and allow phosphopeptide isolation within 30 minutes or less. The captured
sample can then be processed as appropriate for analysis or further preparation.
This method is more specific than IMAC, reportedly giving a phosphopeptide re-
covery of >90 % (Klemm et al., 2006) compared to 70 – 90 % for IMAC (Dubrovska
& Souchelnytskyi, 2005). Specificity has been increased to 100 % in low-complexity
samples, through the addition of 200 mg/ml dihydroxybenzoic acid (DHBA) to peptide
samples, prior to separation (Larsen et al., 2005). This level of specificity is unlikely in
more complex samples and the high affinity of TiO2 for phosphopeptides may prove a
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problem when eluting multiply phosphorylated peptides, accounting for the low level
of their detection in other studies (Thingholm et al., 2008).
5.1.4 Dendrimer-conjugation chemistry
A new method for phosphopeptide capture was recently reported by Tao et al.
(2005). The dendrimer conjugation chemistry method involves the covalent and re-
versible binding of the phosphate group to the amine group on a synthetic branched
compound (dendrimer) that functions as a soluble polymer support. Peptide samples
containing both phosphorylated and non-phosphorylated peptides are mixed with the
dendrimers, in the presence of imidazole and carbodiimide catalysts at pH 5.5. Under
these conditions, the dendrimers conjugate with the phosphate groups on phosphopep-
tides in the sample. Non-bound peptides can then be removed in a simple washing step.
Phosphorylated peptides are subsequently removed from the dendrimer by hydrolysis
and can be analysed by mass spectrometry to identify the parent protein and the site
of phosphorylation. Figure 5.1 shows the structure of the polyamidoamine (PAMAM)
dendrimer molecule used for phosphopeptide capture in the present study.
The dendrimer molecule is highly branched, with the long 12-carbon chains making
the separation between amine groups great enough to enable more than one phospho-
peptide to bind per dendrimer. The many amine groups exposed are available to bind
covalently to the phosphate groups of serine, threonine or tyrosine-containing phospho-
peptides. The chemistry of the conjugation reaction between the dendrimer and the
phosphate group of a phosphopeptide is detailed in Figure 5.2.
Under acidic conditions, the carbon of the carbodiimide (EDC) performs an elec-
trophilic attack on the oxygen atom (O−) within the phosphate group. This complex
is extremely unstable and is replaced by the imidazole in a substitution reaction. A
second substitution reaction occurs as the imidazole is replaced by the dendrimer.
Hydrolysis with TFA releases the phosphopeptides for analysis.
The benefit of this phosphoramidate chemistry method over other derivatisation
techniques is that it enables retention of the phosphate group, allowing the phospho-
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Figure 5.1: Schematic of a dendrimer molecule. Generation 5.0 1, 12-diaminododecane
core PAMAM dendrimer with terminal amine groups exposed. Image created by Joseph
Heinzelmann of Dendritic Nanotechnologies.
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Figure 5.2: Schematic of the chemistry of the conjugation between dendrimer
and phosphopeptides. The phosphate group on a phosphopeptide (R-PO3H) undergoes
electrophilic attack (represented by the horizontal dotted line) by the EDC catalyst (R2CN2),
subsequently replaced by imidazole (C3H2N2). A final substitution occurs when the amine
group of the dendrimer (RNH2) displaces the imidazole, binding to the phosphopeptide via
the phosphate group.
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rylation site to be identified (Bodenmiller et al., 2007). As this is a relatively new
method, it was not well established and required considerable optimisation before use
with dialysate samples. The low complexity of dialysate compared to cell lysate sam-
ples would suggest that prior immunoprecipitation may not be required. This may
facilitate the detection of unknown phosphorylation sites as the components that can
be detected will not be limited to those proteins that are recognised by existing an-
tibodies. Finally, the approach should avoid problems with the elution of multiply
phosphorylated peptides reported for TiO2, as peptides are eluted by hydrolysis rather
than relying on affinity changes.
5.1.5 Specific objectives
The aim of the research described in this chapter was to investigate post-translational
modifications of those proteins identified in dermal dialysate and their relevance to the
injury response. Specific objectives were as follows:
• To evaluate the suitability of existing methods for protein phosphorylation anal-
ysis.
• To optimise methods of phosphopeptide isolation and enrichment for use with
dialysate samples.
• To identify phosphorylated proteins in dermal dialysate obtained from injured
skin.
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5.2 Materials and Methods
Three methods were employed for phosphoproteome analysis of dermal dialysate.
The first method used a dye specific for phosphorylation which could be used to stain
phosphorylated proteins within a 1-D SDS PAGE gel. Two further methods were re-
quired, an affinity-based method using TiO2-coated microbeads and a chemical derivati-
sation method using dendrimers as a soluble support.
5.2.1 Samples used in optimisation studies
Evaluation of the phosphoprotein gel stain was performed using bovine β-casein,
a model phosphoprotein. This is method is described in the relevant section (Sec-
tion 5.2.2). Initial optimisation of the TiO2 and dendrimer methods was performed
using tryptic digests of β-casein, containing a singly phosphorylated peptide of 2062
Da (mono-phosphopeptide), a quadruply phosphorylated peptide of 3122 Da (tetra-
phosphopeptide) and other, non-phosphorylated peptides. The full sequence along
with sites for trypsin cleavage is given in Figure 5.3 below.
Figure 5.3: Amino acid sequence of bovine β-casein. Single-letter code amino acid
sequence of bovine β-casein, UNIPROT ID P02666. Vertical lines (green) represent expected
trypsin cleavage sites, red text indicates phosphorylated amino acids.
Table 5.2 lists the peptides resulting from a theoretical digest of β-casein that are
within the range of 750-3500 Da. One missed cleavage was allowed in case of incomplete
digestion.
Initial experiments also used 0.5 µg each of the purified mono- and tetra- phospho-
peptides. For later optimisations, the starting amounts of β-casein digest was 2.5 µg
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Table 5.2: List of Peptides obtained from a theoretical digest of β-casein
Peptide Sequence Predicted
peptide
mass† (Da)
Predicted
methylated
mass (Da)
EMLEMEMLNVPGEMIVEMSPLSPSPSPEMEM 3321.4 3433.4
SITRINKM (17–43)
AVPYPQRDMMPIQAFLLYQEMPVLGPVRM (192–
217)
2997.6 3039.6
DMMPIQAFLLYQEMPVLGPVRGPFPIIVM (199–224) 2909.6 2951.6
REMLEMEMLNVPGEMIVEMSPLSPSPSPEM 3122.3 3234.3
EMSITRM (16–40)
EMLEMEMLNVPGEMIVEMSPLSPSPSPEMEM 2966.2 3078.2
SITRM (17–40)
IEMKFQSPEMEMQQQTEMDMEMLQDMKM (45–
63)
2432.1 2544.1
DMMPIQAFLLYQEMPVLGPVRM (199–217) 2186.2 2228.2
FQSPEMEMQQQTEMDMEMLQDMKM (48–63) 2061.9 2159.9
VLPVPQKAVPYPQRM (185–198) 1591.9 1605.9
VLILACLVALALARM (3–16) 1438.9 1452.9
HKEMMPFPKM (121–128) 1013.5 1041.5
EMAMAPKHKM (115–122) 911.4 939.4
VKEMAMAPKM (113–120) 830.5 844.5
P Phosphorylated residue, M Residue available for methylation, † Mass includes
phosphorylation where appropriate. Bold text highlights the phosphopeptides. Digest
conditions were; untreated cysteines, monoisotopic mass ([M+H]+), maximum 1 missed
cleavage, only peptides larger than 750 Da included. Peptides over 3500 were excluded.
Numbers in brackets indicate the position of that peptide in the sequence.
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(100 pmoles). The data presented in this chapter were obtained from β-casein digests
unless stated otherwise.
Further optimisation was made using a more complex sample, namely a tryptic di-
gest of five proteins; bovine β-casein, casein and serum albumin, and equine cytochrome
C and myoglobin. The expected peptides were determined by theoretical digestion
using the PeptideMass tool (http://ca.expasy.org/tools/peptide-mass.html). Sites of
phosphorylation were determined according to the respective entry on www.phosphosite
.org. Protein accession numbers were entered into the NCBI protein database http://ww
w.ncbi.nlm.nih.gov/sites/entrez?db=protein to obtain the protein sequence. The pro-
tein sequence was entered into the PeptideMass tool and peptide treatment variables
were selected. Peptide masses were set to [M+H]+ and monoisotopic values. Cysteines
were untreated, one missed cleavage was allowed and the option for peptide size to be
displayed was set to >750 Da. The phosphopeptides expected from this mixture, their
parent protein name and accession number are listed in Table 5.3.
Once optimisation using model samples were completed, preliminary analyses of
protein phosphorylation in dialysate were conducted to confirm that phosphorylated
peptides could be captured.
Dialysate samples used were obtained during the first 30 minutes after injury and
were pooled from two volunteers. Samples were collected as detailed in Section 2.2.2,
according to the protocol depicted in Figure 5.4.
The protein content of these optimisation samples was estimated by BCA assay.
The samples for dendrimer and TiO2-affinity capture contained 872 µg and 780 µg total
protein, respectively. Highly abundant proteins were not removed, because phospho-
peptides from these proteins were also of interest. Samples from the first 30 minutes
after insertion were used due to their higher protein concentration. Phosphatase in-
hibitors were not used in these preliminary studies. Dialysate samples were desalted,
reduced, alkylated and digested as described in Section 2.6.4.4.
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Table 5.3: Phosphopeptides expected in the 5–protein mix
Phosphopeptide Sequence Predicted
peptide
mass†
(Da)
Predicted
modified
peptide‡
mass (Da)
Casein α-S1 subunit (P02662)
QMEMAEMSISPSPSPEMEM IVPNSPVEMQKHIQKM 2827.4 3231.4
VNEMLSKDM IGSPEMSPTEMDMQAMEMDM IKM 2438.1 2790.1
QMEMAEMSISPSPSPEMEM IVPNSPVEMQKM 2321.1 2725.1
VPQLEM IVPNSPAEMEMRLHSMKM 2177.1 2313.1
YKVPQLEM IVPNSPAEMEMRM 1872.0 2008.0
DM IGSPEMPSTEMDMQAMEMDM IKM 1767.8 2025.8
VPQLEM IVPNSPAEMEMRM 1580.8 1761.8
Casein α-S2 subunit (P02663)
NANEMEMEMYSIGSPSPSPEMEMSPAEMVATEMEMVKM 2688.2 3134.2
NTMEMHVSPSPSPEMEMSP IISQEMTYKQEMKM 2684.2 3088.2
NAVPITPTLNREMQLSPTPSEMEMNSKM 2428.2 2644.2
NTMEMHVSPSPSPEMEMSP IISQEMTYKM 2299.0 2689.0
KTVDMMEMSPTEMVFTKM 1514.7 1650.7
TVDMMEMSPTEMVFTKKM 1514.7 1650.7
TVDMMEMSPTEMVFTKM 1386.6 1522.6
EMQLSPTSPEMEMNSKKM 1379.7 1595.7
EMQLSPTSPEMEMNSKM 1251.6 1467.6
Casein β subunit (β-casein) (P02666)
REMLEMEMLNVPGEM IVEMSPLSPSPSPEMEMSITRM 2803.5 3235.5
EMLEMEMLNVPGEM IVEMSPLSPSPSPEMEMSITRM 2647.3 3079.3
IEMKFQSPEMEMQQQTEMDMEMLQDMKM 2352.1 2544.1
FQSPEMEMQQQTEMDMEMLQDMKM 1981.9 2159.9
P Phosphorylated, M Methylated, † Unmodified mass. ‡ Assumes full methylation and
phosphorylation. Theoretical digest conditions; untreated cysteines, monoisotopic mass
([M+H]+), maximum 1 missed cleavage, peptides > 750 Da included. Peptides over 3500
and under 1000 Da excluded.
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Figure 5.4: Dialysate collection protocol for phosphopeptide enrichment optimisa-
tion. The figure shows the timescale of the microdialysis experiment used to collect dialysate
for the optimisation of phosphopeptide capture. Samples were collected over 30 minutes im-
mediately after probe insertion. Pooled dialysate from two different volunteers was used for
each experiment in this study.
5.2.2 Detection of phosphorylation using ProQ Diamond phos-
phoprotein stain
The sample preparation, electrophoresis, staining procedures and analysis are de-
scribed in full in Sections 2.5.3, 2.6.1 and 2.6.2. Briefly, lyophilised β-casein was solu-
bilised in 25 µl H2O + 5 µl LDS sample buffer to give samples of the following total
protein amounts: 40, 20, 10, 5, 2.5, 1.25, 0.63, 0.31 and 0.15 µg. One-dimensional SDS
PAGE was performed and the resulting gel stained first with ProQ Diamond phos-
phoprotein stain and secondly with Sypro Ruby total protein stain. Following image
capture (Section 2.5.3), the staining intensity was measured by densitometry analysis
using Quantity One software as previously described (Section 2.6.3). The mean inten-
sity for each β-casein band was plotted against concentration, using GraphPad Prism
software (GraphPad Software).
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5.2.3 Titanium dioxide affinity for capture of phosphopep-
tides
Samples were prepared and methylated as described in Section 2.6.4. Initial ex-
periments used 0.5 µg each of the purified mono- and tetra-phosphopeptides. Starting
amounts of β-casein digest were 2.5 µg (100 pmoles) unless stated. Captures were
performed as detailed in Section 2.6.6.
The limits of detection were investigated by attempting to capture phosphopeptides
from a doubling dilution series (40, 20, 10, 5, 2.5, 1.25, 0.63, 0.31, 0.15 and 0.08 µg).
To compare the TiO2 and dendrimer methods, a digest containing 5 µg of each protein
was prepared by incubation with 1.5 µg of trypsin at 37◦C overnight. A second 4 hour
digestion was performed with the addition of 0.1 % RapiGest and 1 µg trypsin. Half
of this digest, equivalent to 100 pmoles β-casein, was taken for TiO2 affinity capture
and the other half for dendrimer conjugation capture.
5.2.4 Optimisations of phosphopeptide capture by dendrimer
conjugation chemistry
Initial experiments following the protocol published by Tao et al. (2005) were
unsuccessful (data not shown). It was therefore necessary to conduct a series of op-
timisation experiments to enable the efficient and specific capture of phosphorylated
peptides from complex mixtures. Table 5.4 summarises the differences between the
original conjugation protocol and the final optimised method developed during the
course of the project. The methods used during optimisation are described over the
remainder of this section and the results obtained form a significant proportion of this
chapter.
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Table 5.4: Changes made to the original dendrimer protocol∗
Protocol
Stage
Published method Optimised method
Digestion of
protein sam-
ple
Digestion using 1 µg trypsin. Digestion improved with use of 0.1 %
RapiGest SF surfactant (Waters) and
trypsin in 1:20 ratio with total protein.
Methylation
of peptides
Peptides reconstituted in 75
µl methanolic HCl (100 µl
acetyl chloride + 500 µl an-
hydrous methanol). Incu-
bated at 12 ◦C for 90 min-
utes.
Peptides reconstituted in methanolic HCl
prepared by the addition of 160 µl acetyl
chloride to 1 ml pre-cooled anhydrous
methanol at a ratio of 500 µl per mg pro-
tein, to a minimum of 100 µl. Incubated
at 12 ◦C for 2 hours.
Conjugation
of phospho-
peptides to
the den-
drimer
Reaction solution contain-
ing 50 mM EDC, 100 mM
imidazole, 200 mM MES
buffer and 9 mg dendrimer
(Sigma). Forty µl reaction
solution added to dried pep-
tides and incubated for 10
hours.
Reaction solution containing 100 mM
EDC, 100 mM imidazole and 200 mM
MES buffer all adjusted to pH 5.5, and 9
mg of pH-adjusted dendrimer (Dendritic
Nanotechnologies). Forty µl reaction so-
lution added to dried peptides and incu-
bated for 16 hours.
Removal of
non-bound
peptides
Several washes with 3 M
NaCl in 30 % methanol in
water
Sequence of 1 × 50 % methanol, 2 × 2
M NaCl in 50 % methanol, 3 × 50 %
methanol and 5 × water.
Recovery of
phosphopep-
tides
10 % TFA for 30 minutes,
washed through with 30 %
methanol.
10 % TFA for 60 minutes, washed through
with water.
MALDI
Analysis
Matrix unspecified Improved matrix using dihydroxybenzoic
acid and orthophosphoric acid.
∗ Original published method is that found in Tao et al. (2005).
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The methods used to achieve these optimisations are described below. The opti-
mised methods are reported in Sections 2.6.4 – 2.6.10.
5.2.4.1 Methylation to prevent non-specific binding
Peptides were methylated to block non-specific binding due to the carboxyl groups
of acidic amino acid residues. Initially, a methanolic HCl solution was prepared from
160 µl acetyl chloride added dropwise to 1 ml methanol pre-cooled to -20◦C. Peptides
were incubated with 75 µl of this solution for 90 minutes at 12◦C. It was subsequently
discovered that although there was full methylation of the peptides prior to capture,
some methyl groups were lost during capture. This resulted in multiple peaks for
each peptide, due to different methylation variants. The method was therefore im-
proved through the use of anhydrous methanol and a two hour incubation with 500
µl methanolic HCl per 1 mg peptide, to a minimum of 100 µl. Dried peptides were
desiccated overnight in the presence of P2O5 prior to methylation.
5.2.4.2 Optimisation of the conjugation stage
The first experiments using the original conjugation protocol were unsuccessful.
One explanation was that addition of the dendrimer caused an adverse change in pH
– when the dried dendrimers were added to the reaction solution of approximately pH
6, the overall pH increased. This problem was solved by independently adjusting the
pH of the dendrimers prior to lyophilisation. Three hundred and fifty µl of 100 mM
MES buffer solution was added to 80 µl dendrimer, as supplied in methanol and the pH
adjusted to 5.5 by titration with 1 M HCl before lyophilisation in vacuo. The reaction
solution (200 mM MES, 100 mM EDC and 100 mM imidazole) was adjusted to pH
5.5, again by titration with 1 M HCl and added to the dried, pH-adjusted dendrimers.
This solution in turn was added to dried, methylated peptides and incubated at room
temperature for 16 hours with strong shaking.
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5.2.4.3 Reduction of co-purifying contaminants
Early experiments indicated that the captured phosphopeptides were contaminated
with polymers that had leached from the filter membrane. Accordingly, alternative
filters were tested to determine whether different membrane compositions released fewer
contaminants and different solvent conditions were investigated to see if it was possible
to reduce polymer solubilisation.
The original 5 kDa MWCO Ultrafree MC polyethersulphone (PES) filter was com-
pared against a 3 kDa MWCO NanoSep filter with Omega, modified PES membrane
and a NanoSep with BioInert modified nylon membrane (kindly donated by VWR In-
ternational). Regenerated cellulose membranes were not tested as these had been found
to be inappropriate in earlier stages of the optimisation (data not shown). Filters were
subjected to the original wash procedure of 1 × 50 % methanol, 4 × 2 M NaCl in 50 %
methanol and 4 × 50 % methanol, followed by 60 minutes incubation with 10 % TFA
and two further washes with 50 % methanol. The final filtrate, combining the TFA
wash and subsequent methanol washes, was lyophilised and analysed by MALDI-TOF
MS (Section 2.6.9).
A panel of different solvents were prepared (Table 5.5) to determine which would
cause the least polymer contamination.
Table 5.5: Different solvents tested for their effect on leaching of polymer
contaminants from the filter membrane
20 % ethanol 40 % ethanol
60 % ethanol 10 % acetonitrile
20 % acetonitrile 10 % methanol
50 % methanol water
Filters were washed 6 times with 400 µl solvent, incubated for one hour with 10 %
TFA and washed twice further with solvent. Washes were performed by centrifugation
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at 5000 × g for 15 minutes or until all the liquid had passed through. The TFA and
subsequent washes were combined to form the final filtrate equivalent to the eluted
phosphopeptide sample. Each wash filtrate was lyophilised and analysed for polymer
content by MALDI-TOF MS (Section 2.6.9). The five most commonly found peaks
were determined manually and the intensity of those peaks recorded for each of the
final filtrates obtained from each solvent.
A pre-wash step was also added in which filters were washed prior to use, to remove
any loose polymer. Washes were performed using 400 µl of 500 mM NaOH, water, 10
% TFA and water again. Centrifugation was at 5000 × g for 15 minutes or until all
the liquid had passed through. Cleaned filters were stored at 4 ◦C with 400 µl water
overnight, or used immediately. This step was added at the suggestion of Dr. Bernd
Bodenmiller.
5.2.4.4 Investigation into the effect of different matrix compositions
Phosphorylation is an acidic modification, making phosphorylated peptides harder
to ionise when using a positive ion analysis mode. Additionally, phosphopeptides have
a high affinity for metal and so can bind to the MALDI target plate, further reducing
ionisation efficiency.
To improve the ionisation of these negatively charged peptides, two modifications
were made. First, the target plates were washed with orthophosphoric acid (H3PO4) in
methanol to block potential phosphate binding sites on the plate. Secondly, an alternate
matrix was used to improve phosphopeptide ionisation. DHBA is known to improve
capture of phosphopeptides in TiO2 chromatography systems (Larsen et al., 2005), but
was shown to be unnecessary in IMAC (Imanishi, Kochin & Eriksson, 2007). It has
also been used as a matrix for phosphopeptide analysis by MALDI MS in a limited
number of studies (Kjellstro¨m & Jensen, 2004). It was hypothesised that together
with orthophosphoric acid, DHBA could enhance the detection of phosphopeptides in
positive ion mode. Three DHBA-based matrix solutions were prepared as detailed
in Table 5.6 and the effect on signal intensity of the two purified phosphopeptides
determined.
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Table 5.6: Different solvents tested for their effect on leaching of polymer
contaminants from the filter membrane
Matrix 1 2 mg α-cyano-4-hydroxycinnamic acid + 1 ml 50 % acetonitrile + 0.2 %
TFA
Matrix 2 2 mg dihydroxybenzoic acid + 1 ml 100 % methanol + 1 % H3PO4
Matrix 3 2 mg dihydroxybenzoic acid + 1 ml 50 % methanol + 1 % H3PO4
Matrix 4 2 mg dihydroxybenzoic acid + 1 ml 50 % acetonitrile + 1 % H3PO4
One µl of each phosphopeptide was mixed in a 1:1 ratio with each matrix and
1.4 µl per sample spotted onto separate wells of a cleaned MALDI plate for analysis
by MALDI-TOF MS. High laser energy was required for the DHBA-based matrix
preparations.
5.2.4.5 Remethylation of captured samples to improve detection of phos-
phopeptides
The recovered peptides consistently displayed a reduction in methylation status fol-
lowing dendrimer conjugation, later attributed to the presence of EDC. This increased
the complexity of the sample, as several methylation variants were detected for each
peptide, and reduced the signal intensities of individual peaks of interest. With a bio-
logical sample, this additional variation would complicate LC-MS/MS analysis, giving
a higher incidence of false-positive identifications. Accordingly, an additional methy-
lation step was added after the capture stage to replace any methyl groups lost during
conjugation. Captured peptide samples were lyophilised, dessicated and methylated as
described in Section 2.6.5.
5.2.4.6 Mass spectrometry for identifying the captured phosphopeptides
Three different types of mass spectrometry were used to analyse the captured phos-
phopeptides, namely matrix-assisted laser desorption/ionisation-time of flight (MALDI-
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TOF), liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a quadr-
opole-time of flight instrument, and tandem mass spectrometry with an ion trap for
ion selection and fragmentation, using an LTQ Orbitrap XL (linear trap quadropole-
orbitrap) instrument. Details of these are given in Sections 2.6.9, 2.6.10 and 2.6.11.
Estimates of relative abundance for the MALDI-TOF MS experiments were measured
in arbitrary units (AU), based on the intensity of the tallest peak, given on each spec-
trum.
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5.3 Results
5.3.1 Use of a phosphoprotein-specific gel stain to quantify
protein phosphorylation
Initially, a phospho-specific gel stain was used to analyse post-translational protein
phosphorylation in dialysate. Figure 5.5 shows the intensity of staining obtained from
different concentrations of a known phosphorylated protein, β-casein.
Figure 5.5: Limits of detection of phosphorylated proteins by phosphoprotein and
total protein stains. The staining intensity of the ProQ Diamond phosphoprotein stain
(red) and Sypro Ruby total protein stain (black) for different concentrations (40, 20, 10, 5,
2.5, 1.25, 0.63, 0.3 and 0.15 µg) of the phosphorylated protein β-casein (n = 2).
The lowest concentration of β-casein detected with the stain for total protein was
0.31 µg whereas the phosphoprotein stain detected β-casein at 1.25 µg and higher.
Staining intensity with ProQ Diamond was variable, especially with large amounts of
protein and demonstrated very little linear relationship between the amount of phos-
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phorylated protein and staining intensity. Staining with Sypro Ruby was also variable
but the staining intensity was more proportional to the protein concentration. In
summary, the phospho-specific stain had limited sensitivity and relatively poor quan-
tification for large concentrations of a known phosphorylated protein. Furthermore,
the stain would not enrich for phosphorylated proteins and additional methods would
be required. It was therefore decided that it was not sensible to pursue this staining
approach.
5.3.2 Phosphopeptide enrichment using titanium-dioxide (TiO2)
beads
A trypsin digest of the model phosphorylated protein β-casein should produce two
phosphopeptides: a singly phosphoryated peptide at m/z 2160 [M+H]+ and a quadru-
ply phosphorylated peptide at m/z 3236 [M+H]+ when both are fully methylated.
The ability of TiO2-coated beads to capture and enrich these phosphopeptides was
therefore investigated. Figure 5.6 shows a representative MALDI-TOF MS spectrum
of the β-casein peptides captured by the TiO2 beads.
The two β-casein phosphopeptides were detected (seen as m/z 2160 and 3237
[M+H]+), but the spectrum was dominated by larger peaks at m/z 1595, 2042 and 2707
[M+H]+. No matches were found for m/z 2042 and 2707 [M+H]+. The peak at m/z
1595 [M+H]+ corresponds to the mass of an α s2 casein peptide, EMQLSPTSPEMEMNS
KKM , although its identification could not be confirmed by LC-MS/MS. This is a con-
taminant and part of the parent protein from which β-casein is derived. The peak at
m/z 1553 [M+H]+ matches the mass of a methylation variant of that at m/z 1595
[M+H]+, as the difference is equivalent to the loss of three of the four methyl groups.
Additionally, peaks at m/z 2707 and 2696 [M+H]+ correspond to predicted mass of
the peptide VNEMLSKDM IGSPEMSPTEMDMQAMEMDM IKM from α-S1-casein, mi-
nus one phosphate group and both one phosphate and one methyl group, respectively.
No potential match could be determined for m/z 2042 [M+H]+. LC-MS/MS analysis
(data not shown) was only able to identify the mono-phosphopeptide from β-casein.
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Figure 5.6: Peptides captured from 100 pmoles β-casein by TiO2 beads. Known
peptides captured include those at m/z 1595 – α s2 casein, 2160 – mono-phosphopeptide β-
casein, 3137 – α s1 casein, 3235 – tetra-phosphopeptide β-casein. Peptides at m/z 2042, 2707
and 2835 [M+H]+ did not correspond to any predicted phosphopeptides.
Experiments to determine the minimum detection limit were successful for the
lowest amount of β-casein, 80 ng (data not shown). This confirmed that the TiO2
bead capture is a sensitive method, but the detection of the other unidentified peaks
shows that it is not necessarily specific. While this method would reduce sample
complexity and enrich for phosphorylated peptides, there remains a need for a more
specific method.
5.3.3 Optimisation of phosphopeptide capture and enrichment
by dendrimer conjugation chemistry
Figure 5.7 shows a representative spectrum obtained from the initial successful cap-
ture of phosphopeptides from a tryptic digest of β-casein using dendrimer conjugation
chemistry.
While successful, these captures were not optimal. Firstly, the mono-phosphopeptide
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Figure 5.7: Example of a spectrum obtained from early attempts at phosphopep-
tide capture using dendrimer conjugation chemistry. Peptides captured from 100
pmoles of a tryptic digest of β-casein. The mono-phosphopeptide peak with sub-optimal
methylation is circled in red, the tetra-phosphopeptide peak was absent (circled in blue) and
the contamination is circled in green.
peak (red circle in the Figure) was split between several methylation variants where
there was sub-optimal, or loss of, methylation. Secondly, the tetra-phosphopeptide
was not detected (blue circle), possibly due to inefficient ionsation during MS analysis.
Finally, and most notably, there was considerable contamination (green circle) obscur-
ing identification of true peptides. The captured mono-phosphopeptide peak was 25
% the height of the tallest contaminant peak. The regularity of the m/z values of the
contaminants strongly suggested that the problem was due to polymer leaching, e.g.
from the filter membrane.
5.3.3.1 Optimisation of the filtration stages to reduce polymer contamina-
tion in the captured sample
With the discovery that polymer contaminants were derived from the membrane
of the filter device, an alternative was required. Three membrane compositions were
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compared; the original PES membrane, modified PES “Omega” and a modified nylon
“Bioinert” membrane. Several other filter constructs had been deemed unsuitable in
earlier optimisation steps. Figure 5.8 shows the amount of contamination obtained
from each filter type.
The Omega membrane released the most contaminants (Figure 5.8b) whereas the
Bioinert membrane (Figure 5.8c) gave the fewest. The remaining contaminants in the
latter were highly abundant compared to those generated by the Omega membrane
(5710 AU compared to 1350 AU) but were still half that of the tallest peak obtained
from the original Ultrafree membrane (10500 AU). Unfortunately, the Bioinert mem-
brane was later found to be incompatible with the dendrimer and hence could not be
used.
The original Ultrafree MC filter with the standard polyethersulphone membrane
(Figure 5.8a) was the best compromise, despite the high abundance of the contaminant
peaks. However, an alternative method of reducing contamination was still required.
Therefore, the effect of different solvents on the membrane was assessed to determine
whether polymer leaching could be reduced by using different wash solutions. Table
5.7 shows the intensity of contaminants detected in the final filtrate obtained from each
solvent.
Two solvents exhibited the highest contamination giving the highest intensity for
two of the most common peaks each, 10 % methanol and 60 % ethanol. Water alone
gave the least contamination with four of the five most common peaks not detected.
The one contaminant peak detected was at the lowest intensity for that peak. Twenty
percent acetonitrile appeared to cause the least leaching of polymer. However, it caused
leaching of a large number of less common contaminants not included in the table. Of
the remaining solvents, 50 % methanol gave the least contamination. This was the sol-
vent originally used and none of the other solvents presented a better alternative, apart
from water alone. As an organic solvent was required, it was decided that a two-step
wash procedure was necessary. The combination of 50 % methanol followed by water
enabled optimal removal of non-bound peptides and reduced polymer contamination.
Contamination was further reduced by a pre-wash protocol added at the suggestion
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(a)
(b)
(c)
Figure 5.8: Comparison of contamination from different types of filter membrane.
Contaminant peaks contained in the final wash filtrate (10 % TFA and 2 × 50 % methanol,
equivalent to eluted phosphopeptide samples) were analysed by MALDI-TOF MS. Samples
were generated using the following wash sequence (5× 2 M NaCl, 5× 50 % methanol) through
a) Ultrafree MC filter with polyethersulphone membrane, b) NanoSep with Omega modified
polyethersulphone membrane and c) NanoSep with Bioinert modified nylon membrane.
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Table 5.7: Polymer peak intensities under different solvent conditions
Signal Intensity of Contaminant Peak∗ (AU)
Solvent 996 Da 1165 Da 1279 Da 1733 Da 2016 Da
10 % acetonitrile 2230 2360 3220 795 302
20 % acetonitrile 246 443 321 138 131
20 % ethanol 2710 3880 3720† 995 503
40 % ethanol 3160 4760 2430 606 410
60 % ethanol 2510 3000 2800 1550 984
10 % methanol 5450 6480 1980 nd‡ nd
50 % methanol 1040 1350 1120 748 394
H2O nd nd 119 nd nd
∗ Peak values given as m/z [M+H]+, † Bold type indicates the highest value in each
column, ‡ indicates where the peak was not detected under those conditions.
of Dr. Bernd Bodenmiller of the Institute for Molecular Systems Biology, Zurich.
Filters were washed with NaOH, TFA and water as described previously (Sections
2.6.7.2 and 5.2.4.3). Figure 5.9 shows the reduced contamination achieved.
The most dominant peak is that of the captured mono-phosphopeptide, with con-
taminants at 20 % or lower compared to the size of the mono-phosphopeptide peak.
This was a significant improvement on the 400 % observed in the initial capture pro-
tocol (Figure 5.7).
5.3.3.2 Optimisation of MALDI-TOF MS analysis conditions to improve
detection of phosphopeptides
Table 5.8 shows the signal intensity obtained for the mono- and tetra- phosphopep-
tides analysed using different matrix compositions for MALDI-TOF MS.
The tetra-phosphopeptide was not detected with the α-CHCA matrix and mono-
phosphopeptide detection was poor compared to the alternatives. In contrast, all three
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Figure 5.9: Reduced polymer contamination with optimised wash protocols. Den-
drimer capture of methylated mono-phosphopeptide (main peak cluster) from 100 pmoles
β-casein digest. Contaminant peaks (left) fall below 20 % of the highest peak.
DHBA-based matrix preparations enabled the detection of the tetra-phosphopeptide.
Matrix 2 gave the highest signal intensity for the mono-phosphopeptide (13200 AU)
while matrix 4 gave the highest signal intensity for the tetra-phosphopeptide (3520
AU). Matrix 2 was chosen as the best preparation to use as it gave the greatest increase
(6.8–fold) in detection of the mono-phosphopeptide and performed better in subsequent
tests (data not shown).
5.3.3.3 Re-methylation of captured samples to improve signal intensity
and reduce unnecessary sample complexity
Re-methylation of lyophilised samples after phosphopeptide capture increased the
signal intensity of the fully methylated form of the mono-phosphopeptide (Figure 5.10).
The captured mono-phosphopeptide was detected in eight methylation variants
(Figure 5.10a). The most predominant peak was the 4×methylated mono-phosphopep-
tide at m/z 2117 [M+H]+ with an intensity of 904 AU. Remethylating the captured
sample reduced the profile to one large and two small peaks, representing the fully
methylated (m/z 2159 [M+H]+) and the 6 and 5 × methylated (m/z 2145 and 2131
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(a)
(b)
Figure 5.10: The effect of re-methylation on sample complexity. a) Profile of mono-
phosphopeptide captured by dendrimer conjugation from 100 pmoles β-casein. Methylation
variants observed were 6, 5, 4, 3, 2, 1 and 0 × methylated (m/z 2145, 2131, 2117, 2103,
2089, 2075 and 2061 [M+H]+, respectively) b) Dendrimer-captured mono-phosphopeptide
from β-casein, after re-methylation to improve signal intensity and reduce complexity. The
fully (7 ×) methylated form was predominant (m/z 2159 [M+H]+). Small peaks were present
for the 6 and 5 × methylated forms.
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Table 5.8: Signal intensities of the mono- and tetra- phosphopeptide peaks
for each matrix
Signal Intensity (AU)
Mono- Tetra-
Matrix phosphopeptide phosphopeptide
Matrix 1 1950 not detected
Matrix 2 13200† 2730
Matrix 3 4570 2110
Matrix 4 8090 3520
† Bold text indicates the highest values in each column. Matrix 1 = α-CHCA in 50 % ACN
+ 0.2 % TFA. Matrix 2 = DHBA in methanol + 1 % H3PO4. Matrix 3 = DHBA in 50 %
methanol + 1 % H3PO4. Matrix 4 = DHBA in 50 % ACN + 1 % H3PO4.
[M+H]+, respectively) forms. The predominant peak in the remethylated sample, the
fully methylated variant, was double the intensity of that observed prior to remethyla-
tion, at 1770 AU. Analysis of the limits of detection, as conducted for the TiO2 bead
method, showed that dendrimer conjugation could also capture the mono-phosphopepti-
de from the lowest concentration investigated, 80 ng.
5.3.3.4 Identification of phosphopeptides from β-casein captured using den-
drimer conjugation and LC-MS/MS
Figure 5.11 shows the tandem mass spectrometry data obtained for the mono-
phosphopeptide identified from capture using the dendrimer method.
The spectrum in Figure 5.11a shows the loss of phosphoric acid from b and y ions,
equivalent to 98 Da. Figure 5.11b shows the ions detected in this experiment, indicated
in red. This fragmentation data confirms the peptide sequence and the identification
of the known phosphorylation site on the serine residue, for example on the b3 ion at
345.16.
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(a)
(b)
Figure 5.11: Peptide results for the mono-phosphopeptide identified by LC-
MS/MS following dendrimer capture from 1 nmole β-casein digest. a) LC-MS/MS
spectrum showing the loss of phosphoric acid (98 Da) from both b and y ion series b) Table
of results showing the peptide sequence determined. Red text indicates ions matched in this
experiment.
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5.3.4 Comparison of phosphopeptide capture by the optimised
TiO2 bead and dendrimer conjugation chemistry meth-
ods
The two optimised phosphopeptide capture methods were compared directly using
a common starting sample. Figure 5.12 shows the peptide profiles obtained following
MALDI-TOF MS analysis of the captured samples.
The two phosphopeptides from β-casein were captured by both methods. The
mono-phosphopeptide was most prominent in the TiO2–captured sample, with an in-
tensity of 2940 AU. In the dendrimer capture, the mono-phosphopeptide was only
30 % of the tallest peak, but was detected with an approximate intensity of 5900
AU. This was double the intensity of the mono-phosphopeptide in the TiO2–captured
sample. The tetra-phosphopeptide was detected in its fully methylated (m/z 3235
[M+H]+) form in the TiO2–captured sample. The peak at m/z 3122 [M+H]+ ob-
served in both captures corresponds to the m/z value of the unmethylated form of the
tetra-phosphopeptide.
The largest peak detected in the dendrimer capture, at m/z 1634 [M+H]+ did not
correspond to any of the expected phosphopeptides. It most likely represents either
KTVDMMEMSPTEMVFTKM or TVDMMEMSPTEMVFTKKM from α-S2-casein, mi-
nus one methyl group.
LC-MS/MS analysis identified only the mono-phosphopeptide from β-casein, pro-
ducing spectra similar to that shown in Figure 5.11.
5.3.5 Orbitrap analysis of phosphopeptides captured from β-
casein using dendrimer-conjugation
It was possible that the type of mass spectrometer used also had an influence on
the type of phosphopeptide detected from the captured sample. Table 5.9 shows the
peptides identified from a dendrimer capture of 100 pmoles β-casein using an LTQ
linear ion trap-orbitrap (LTQ-orbitrap) mass spectrometer to avoid the bias against
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(a)
(b)
Figure 5.12: Comparison of phosphopeptide captures by TiO2 and dendrimer
methods. MALDI-TOF MS spectra showing the phosphopeptides captured from a tryptic
digest of the 5-protein mix by a) TiO2 and b) dendrimer methods. The β-casein mono–
(m/z 2161 [M+H]+) and tetra-phosphopeptides are present with the tetra– in both fully
methylated and unmethylated forms (m/z 3122 and 3235 [M+H]+ respectively). Captures
were from a common sample containing 25 µg total protein, 5 µg of each peptide, giving 100
pmoles β-casein available per capture.
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multiply phosphorylated peptides experienced with LC-MS/MS (this work was carried
out by Dr. Gary Wolfenden, at Thermo Electron (UK) Ltd.).
Table 5.9: Peptides identified from a dendrimer capture of β-casein by Orbi-
trap analysis
Peptide Mass (Da) Charge
β-casein
K. FQSPEMEMQQQTEMDMEMLQDMKM 2159.9377 3
K. FQSPEMEMQQQTEMDMEMLQDMKM 2159.9377 2
K. FQSEMEMQQQTEMDMEMLQDMKM 2061.9614 2
K.IEMKFQSPEMEMQQQTEMDMEMLQDMKM 2544.1749 3
α-S2-casein
R.EMQLSPTSPEMEMNSKM 1467.5650 2
K.TVDMEMSPTEMVFTKKM 1650.7695 2
K.TVDMEMSTEMVFTKKM 1552.7931 2
Sequences in single letter amino acid code. M = methylated residue, P = phosphorylated
residue.
The mono-phosphopeptide from β-casein was detected in several forms. The fully
digested peptide was detected in both phosphorylated and unphosphorylated forms
and the phosphorylated form in both doubly and triply charged variants. One peptide
was the result of an incomplete digest (2544.1749 Da) and is the fully methylated,
phosphorylated, triply charged form. Two different peptides were detected from α-
casein. This is a contaminant derived from casein, the parent protein to both β and α-
casein. A singly phosphorylated peptide of 1650.7695 Da and a doubly phosphorylated
peptide of 1467.5650 Da were detected. From these data, it can be concluded that use
of more advanced mass spectrometry techniques significantly improves the number and
type of captured phosphopeptides that can be detected.
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5.3.6 Identification of phosphorylated proteins in dialysate
A preliminary analysis was conducted to determine whether phosphorylated pep-
tides could be captured from dialysate. Figure 5.13 shows a representative MALDI-
TOF MS profile obtained from 1 mg methylated trypsin-digests of dialysate collected
during the first 30 minutes after injury.
The MALDI-TOF MS profiles of peptides from methylated dialysate were domi-
nated by a peak at m/z 1927 [M+H]+. The abundance of this peptide and other peaks,
at m/z 1495, 1665, 1728 [M+H]+ have suppressed the detection of less abundant com-
ponents. In Figure 5.13b, there are more higher molecular mass peptides such as those
at m/z 2356, 2656 and 2864 [M+H]+. Those lower molecular mass peaks shared with
the first sample (Figure 5.13a) are less abundant, but still present.
Figure 5.14 shows the peptide profiles of dialysate captured by the two phospho-
peptide enrichment methods.
The peak at m/z 1927 [M+H]+ which dominated the methylated dialysate spectrum
was not present in either captured sample. Many more peaks were detected in the
captured samples, demonstrating the suppressive effects of the abundant ions seen in
the methylated spectra, prior to capture. Peaks detected from both capture methods
include those at m/z 955, 1028, 1177, 1571, 1653, 1667, 2655, 2669 and 2683 [M+H]+.
The latter three are likely to be methylation variants of the same peptide as they are
each 14 Da apart.
No peptides were identified using electrospray ionisation (ESI) LC-MS/MS on the
Q-TOF Global Ultima, so the phosphopeptides captured by dendrimer conjugation
from a second sample of dialysate were identified using an LTQ-orbitrap mass spec-
trometer. Table 5.10 lists those peptides in which potentially novel phosphorylation
sites were identified.
Three phosphopeptides were confirmed in dialysate, one from an albumin variant,
at S277, and two from apolipoprotein L1 at S311 and S314. MS3 data provided con-
firmatory information for the apolipoprotein L1 phosphorylation site identifications
(Figure 5.15 and Table 5.11).
MS2 analysis shows the position of the y ion terminating in a phosphorylated serine.
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(a)
(b)
Figure 5.13: MALDI-TOF MS profile of methylated peptides from dialysate.
Methylated peptides derived from a tryptic digest of dialysate pooled from two volunteers
prior to a) TiO2 and b) dendrimer capture. The starting concentrations were ∼ 800 µg total
protein.
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(a)
(b)
Figure 5.14: MALDI-TOF MS profiles of peptides captured from dialysate by
TiO2 and dendrimer methods. Peptides captured from methylated trypsin digest of
dialysate samples, shown in Figure 5.13, by a) TiO2 beads and b) dendrimer conjugation.
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(a)
(b)
Figure 5.15: LTQ-orbitrap mass spectra showing fragmentation of the phosphory-
lated apolipoprotein L1 peptide. Mass spectrum showing the y and b ion series obtained
from fragmentation of the apolipoprotein L1 phosphopeptide, in (a) MS2 and (b) MS3. The
MS2 data shows the predicted position of peaks for y ions with terminal phosphorylated
serine residues. MS3 confirms the presence of the y7 and y10 ions, the former having lost
phosphoric acid (98 Da) and the latter retaining its phosphate (see Table 5.11).
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Table 5.10: Phosphopeptides identified from a dendrimer capture of dermal
dialysate by Orbitrap analysis containing novel phosphorylation sites
Peptide Mass (Da) Charge
Apolipoprotein L1
R.VTEMPISPAEMSPGEMQVEMRM .V (306 – 320) 1860.8028 2
R.VTEMPISPAEMSGEMQVEMRM .V(306 – 320) 1762.8265 2
Serum Albumin
K.LVAASPQAALGLM (273 – 283) 1027.6146 2
Sequences in single letter amino acid code. M = methylated residue, P = phosphorylated
residue. Data obtained from a demonstration experiment so may not be the full list of
identifications.
Fragmentation of the y14 ion at m/z 881.8 [M+2H]2+ in MS3 showed evidence of two
phosphorylated serine residues. The difference of 167 Da between the y10 and y9
fragment ions corresponds to the loss of a phosphorylated serine. In contrast, the
difference of 69 Da between the y8 and y7 fragment ions corresponds to the loss of a
serine residue that had previously lost phosphoric acid (98 Da), for example, during
MS2 fragmentation.
The phosphopeptide identified from the albumin variant also corresponds to the full
sequence of human serum albumin. This entire variant sequence was found to comprise
residues 333 – 609, placing the phosphorylation site at S603. The albumin phospho-
rylation site is not listed within the corresponding entry on www.phosphosite.org, and
hence represents a novel phosphorylation site. Phosphorylation at S311 of apolipopro-
tein L1 has previously been confirmed, while the site at S314 has not (Mancone et al.,
2007). This is a second novel phosphorylation site detected in dermal dialysate.
The 3-D structure of apolipoprotein L1 has not yet been solved, so it is not possible
to show the location of the phosphorylation site. However, such data is available for
the albumin peptide. Figure 5.16 shows the location of the novel phosphorylation site
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Table 5.11: Ion series obtained from MS2 and MS3 analysis of captured
dialysate proteins using an LTQ-orbitrap mass spectrometer
MS2 MS3
† b ion End y ion b ion End y ion
(m/z ) Residue m/z (m/z ) Residue m/z
1 50.5415 V — 15 1 100.757 V — 15
2 101.0653 T 881.3708 14 2 201.1234 T 1663.7580 14
3 172.5944 EM 830.8470 13 3 344.1816 EM 1562.7103 13
4 221.1208 P 759.3179 12 4 441.2344 P 1419.6521 12
5 277.6629 I 710.7915 11 5 554.3184 I 1322.5993 11
6 361.1620 SP 654.2494 10 6 721.3168 SP 1209.5153 10
7 396.6806 A 570.7503 9 7 792.3539 A 1042.5169 9
8 468.2097 EM 535.2317 8 8 935.4121 EM 971.4798 8
9 551.7089 SP 463.7026 7 9 1004.4342 SP 828.4216 7
10 580.2196 G 380.2034 6 10 1061.4556 G 759.3995 6
11 651.7487 EM 351.6927 5 11 1204.5139 EM 702.3781 5
12 715.7780 Q 280.1636 4 12 1332.5725 Q 559.3198 4
13 765.3122 V 216.1343 3 13 1431.6409 V 431.2613 3
14 836.8414 EM 166.6001 2 14 1574.6991 EM 332.1928 2
15 — RM 95.0709 1 15 — RM 189.1346 1
† = Residue number, P = potentially phosphorylated residue, M = methylated
residue. Blue text indicates confirmed y ions, red text indicates confirmed b ions,
green text indicates loss of 98 Da corresponding to phosphoric acid.
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within the 3-D structure of the serum albumin.
Figure 5.16: Three-dimensional structure of human serum albumin protein show-
ing the novel phosphorylation site. The image shows the carbon backbone of the protein,
coloured from dark blue at the N’ terminus through to green at the C’ terminus. The serine
found to be phosphorylated in the present study, S603, is shown in a ball structure near the
C’ terminus. Image generated using Rasmol.
The figure shows the 3-D structure of serum albumin, with the binding-site indi-
cated by the cleft between the two sides of the molecule. The newly-identified phos-
phorylation site, serine 603, is shown in a ball format, close to the C’ terminus on the
outside of the molecule. The significance of the location of this phosphorylation site
will be considered in Section 5.4.5.
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5.4 Discussion
Reversible protein phosphorylation is a key regulatory process that to date has
primarily focused on studies within cells, as opposed to the extracellular environment.
This chapter describes studies to compare three methods for the identification of phos-
phorylated proteins; it also describes the first attempts to study protein phosphoryla-
tion in dermal dialysate samples. One method for studying protein phosphorylation
was found to be unsuitable, while the remaining two were found to be complemen-
tary. Using these two methods to enrich for phosphopeptides within dermal dialysate
samples, two novel phosphorylation sites were detected.
5.4.1 Use of ProQ Diamond staining for phosphoprotein de-
tection
The results of the phosphoprotein staining experiments were rather disappointing,
but not unexpected. There was a 32–fold difference between the highest and lowest
protein concentrations detected (1.25 – 40 µg), but only a ∼3–fold difference in staining
intensity with ProQ Diamond across that range. This is in contrast to the ∼5 – fold
difference in staining intensity with Sypro Ruby with equivalent concentrations. The
minimum detection limit of 1.25 µg phosphoprotein with ProQ Diamond is high in
biological terms and was unlikely to be encountered in dialysate samples.
The very low intensity values obtained for ProQ Diamond staining compared to
measurements of total protein by Sypro Ruby are unlikely to be due to loss of phos-
phorylation. Mass spectrometric analysis of a sample of β-casein from the same batch
indicated that the protein is found almost exclusively in its phosphorylated form from
this source. The non-phosphorylated form is easier to ionise and hence is likely to
be easier to detect than the phosphorylated form. Therefore, partial phosphorylation
of the β-casein is unlikely to explain the discrepancy between the amount of protein
detected by ProQ Diamond and Sypro Ruby. The low staining efficiency could be a
consequence of the differing accessibility of the phosphate group. However, within the
gel, the protein is unlikely to be folded such that the phosphate group is obscured from
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a molecule as small as a dye.
Several reviews, including that by Delom & Chevet (2006), have concluded that
in-gel phosphoprotein stains such as ProQ Diamond are not sensitive enough for com-
prehensive phosphoproteome analysis. Furthermore, recent reports suggest that the
stain may not be absolutely specific for phosphoproteins, for example El-Khatib, Good
& Muench, (2007), Gorg, Weiss & Dunn, (2004) and Murray et al., (2004). Taken with
the results from this study, it appeared that more efficient methods were required.
5.4.2 Phosphopeptide enrichment by TiO2-affinity capture
Phosphopeptide enrichment using the TiO2-affinity method was a significant im-
provement on the use of a phosphoprotein stain for detection of β-casein phosphoryla-
tion. This method was able to detect phosphopeptides from the lowest concentration
tested, 80 ng, confirming it to be more sensitive. At face value, however, it did not
appear to be very specific, with several unexpected and unidentified peaks dominat-
ing the spectrum. Peptide sequence data could not be obtained using MALDI-TOF
MS, but potential matches could be manually assigned to almost all of these pep-
tides when methylation variants were considered. Significantly, the peak at m/z 2042
[M+H]+ could not be assigned to any variants of any of the expected phosphopeptides
or non-phosphorylated peptides. While it is possible that the unidentified components
represent novel phosphopeptides, it is equally possible that they are not phosphory-
lated. The existance of methylation variants supports the points raised by Larsen et
al. (2005) regarding the complexity introduced by incomplete methylation.
Overall, four different potential phosphopeptides were identified out of 20 possible
matches, if the contaminant proteins are included. In comparison, Larsen et al. (2005)
found 9 different phosphopeptide variants from a list of 23 potential sequences, with
an additional 9 peptides that were not thought to be phosphorylated. In the present
study, the mono- and tetra- phosphopeptides from β-casein were present as expected,
although at surprisingly low abundance. The other two were potential matches for
phosphopeptides from α-S1 and S2-casein, contaminants derived from the purification
process. Four peaks could not be assigned, one large and three small in intensity.
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The detection of contaminants derived from the parent protein suggests that this
method is very sensitive. However, the detection of equal numbers of unidentifiable
peptides compared to known phosphopeptides also indicates that it may not be very
specific. The TiO2 technique is discussed further, in comparison to the dendrimer
method and with regards to LC-MS/MS analysis in Section 5.4.4.
5.4.3 Optimisation of dendrimer conjugation chemistry for
phosphopeptide enrichment
Initial experiments to capture purified phosphopeptides using the original, pub-
lished dendrimer conjugation chemistry method were unsuccessful. Through a series
of optimisation experiments, the method has been improved and successfully applied
to both purified phosphopeptides and more complex samples containing a mixture of
several proteins, as well as for the preliminary analysis of biological samples.
Two early optimisation steps to reduce the amount of dendrimer lost through the
filter unit were not presented in the results section, but merit a brief consideration
here. Lyophilisation of the first wash filtrate revealed dendrimer (Sigma) present in
the wash-through. The filter unit’s molecular weight cut-off value of 5 kDa reflects
the average, rather than the maximum size of molecule that can pass through. It
can generally be expected that molecules up to three times this value can cross the
membrane. However, the mass of the dendrimer compound should have been 29 kDa,
which meant they should not have been able to pass through. Several different filter
units were tested, with the same result. One-dimensional SDS PAGE revealed that the
dendrimer had degraded and was present in two forms, including a band at 15 kDa
which could potentially pass through the filter. As an alternative source, Dendritic
Nanotechnologies, the original manufacturer, were able to supply the dendrimers direct.
These were a great improvement, with little to no dendrimer found in the wash-through.
One of the most significant problems with the published method was that it pro-
duced highly abundant contaminant peaks within the low m/z range of the MALDI-
TOF MS spectra of captured peptides. The regular spacing of these peaks suggested
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that they might be polymers and their appearance solely in the captured samples sug-
gested that the source was most likely to be the filter unit or the dendrimer. Further
studies confirmed this hypothesis and showed that alternative filter units gave worse
results. Although alternative solvent combinations were not exhaustively tested, fur-
ther experimentation is likely to only give slight improvements. The combination of
the methanol and water solvent wash scheme and incorporation of a pre-wash step gave
a satisfactory resolution to this problem.
Use of the DHBA-based matrix improved the detection of the mono-phosphopeptide
and enabled detection of the tetra-phosphopeptide by MALDI-TOF MS. The reasons
for this improvement are unknown, highlighting the present lack of knowledge about
suitable matrix preparations and an inability to rationally predict behaviour of such
compounds. Recently, Jaskolla et al. (2008) attained a significantly improved sensi-
tivity and peptide recovery through use of a modified α-cyanocinnamic acid matrix.
Sequence coverage of bovine serum albumin was increased from 4 % with the α-cyano-4-
hydroxycinnamic acid matrix to 48 % with the 4-chloro-α-cyanocinnamic acid matrix.
The authors suggest that the lower proton affinity of the latter preparation improve
the ionisation of basic peptides. It is possible that the low coverage of phosphopep-
tides captured from β-casein and the five-protein mix is a consequence of sub-optimal
matrix conditions. These observations suggest that further work to optimise matrices
for peptide and phosphopeptide analyses are likely to prove worthwhile.
The final problem with the initial dendrimer method was the loss of methylation
after the conjugation reaction. Re-methylation of captured samples reduced the com-
plexity of the mass spectra and hence increased the signal intensity of the fully methy-
lated peptides by approximately 2–fold. The loss of methylation can be explained by
reports that the carbodiimide component can hydrolyse the methyl esters (Guo, Galan
& Tao, 2007). This loss of methylation is important, as the carboxyl groups may be-
come available for non-specific binding. It was not, however, limited to the dendrimer
technique – loss of methylation was also observed in the TiO2-captured samples. That
re-methylation improves this situation suggests that this is an actual loss of methyl
groups, not a bias towards peptides without full methylation. Methylation neutralises
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the charge associated with the carboxyl groups, which should also improve ionisation.
However, the additional lyophilisation steps that are necessary to the re-methylation
process lead to loss of peptide by adsorption. Consequently, this step is only recom-
mended for cases where the fully methylated peptide is not dominant or where there
is clear spreading of the signal over peaks differing by units of 14 Da.
It appears that the optimised dendrimer method has improved on the original
method (Tao et al., 2005), in terms of reduced contaminants and detection of the
tetra-phosphopeptide shown in the comparison with TiO2. However, as highlighted by
the differences in results obtained from different mass spectrometers, it is not appro-
priate to compare the results directly. The different analysis conditions and machine
used will have influenced the spectra obtained. Instead, the type of mass spectrometer
employed is a more appropriate consideration. The use of MALDI-TOF-MS provided
a simple method of confirming that known peptides were being captured. Once vari-
ables were introduced, including even the methylated peptides from β-casein or the
five-protein mix discussed in the next section, peak assignment became more ambigu-
ous and further analysis to confirm the peptide identity and phosphorylation site or
sites was required. Liquid chromatography coupled with tandem mass spectrometry
on a Q-TOF instrument identified only the mono-phosphopeptide in both samples of
β-casein alone, or in the five-protein mix. The use of an LTQ-orbitrap system sig-
nificantly increased the number of phosphopeptides identified in the captured sample.
This was most likely due to the improved ionisation methods, additional MS dimen-
sions and the dynamic exclusion technique that prevents re-analysis of abundant peaks
in the same MS/MS scan. These factors mean that the LTQ-orbitrap is currently the
most efficient method for analysis of protein phosphorylation of those examined.
5.4.4 Assessment of the comparison of TiO2 and dendrimer
captures
The dendrimer method clearly benefits from less non-specific binding and less con-
tamination than the TiO2-affinity method, with only expected phosphopeptides or
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their methylation variants detected. It also appears to be more efficient as recovery
of the mono-phosphopeptide from β-casein was approximately 2.3–fold higher for the
dendrimer method; ≈5900 AU compared to ≈2940 AU with TiO2. Very few of the
different expected phosphopeptides were detected in either capture. This may be a
result of there being twice the concentration of peptides from the β subunit of casein,
as it was included as both a subunit of whole casein and in the purified form. However,
this explanation seems unlikely given that the largest peak in the dendrimer-captured
profile corresponds to a methylation variant of an α-S2-casein phosphopeptide.
The TiO2–affinity method did capture the fully methylated form of the tetra-
phosphopeptide from β-casein and hence may be more effective at capturing multiply
phosphorylated proteins. This observed difference between the capture profiles from
the two methods may be a chance occurence, that is, a consequence of the low ion-
isation efficiency of multiply phosphorylated peptides in particular. The capture of
multiply phosphorylated peptides was not improved by LC-MS/MS analysis, which
also biases against such peptides, due to the ionisation process favouring positive ions.
Only the mono-phosphopeptide from β-casein was detected from both capture samples
by this analysis. Unfortunately, it was not possible to analyse these samples using the
LTQ-orbitrap mass spectrometer, which potentially would have been useful given the
additional identifications made from the dendrimer-captured β-casein sample (Table
5.9). The results obtained from both MALDI-TOF and LC-MS/MS analyses suggest
that both capture methods should be used to gain a more comprehensive coverage of
the phosphoproteome.
Bodenmiller et al. (2007) published a comparison between TiO2 affinity, phos-
phoramidate chemistry and IMAC for phosphopeptide capture. The phosphoramidate
chemistry that was used was a variation on the dendrimer technique used by Tao et
al. (2005), in which cystamine was used in place of the dendrimer. Assessment of the
reproducibility showed phosphoramidate chemistry to be slightly more reproducible
(96.2 % internal similarity, compared to 95.7 % for TiO2 and 93.9 % for IMAC) in
terms of retention and intensity. It also displayed the highest overlapping of features;
80 %, compared to 76, 74 and 85 % for TiO2, IMAC and the starting sample respec-
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tively. Importantly, overlap between the three methods was relatively low at ∼35 %.
This difference could not be accounted for by inclusion of non-phosphorylated peptides
isolated by non-specific binding, suggesting that a combination of methods is required
for comprehensive phosphoproteome analysis.
5.4.5 Preliminary analyses of protein phosphorylation in der-
mal dialysate samples
Analysis of protein phosphorylation in dermal dialysate revealed two novel phospho-
rylation sites; S314 in apolipoprotein L1 and S603 in serum albumin. Dialysate samples
obtained during the first 30 minutes after injury were digested, methylated and sub-
jected to phosphopeptide enrichment by either TiO2-affinity or dendrimer capture. The
captured samples were analysed by MALDI-TOF MS to determine whether there were
peptides present. Identification of phosphopeptides captured from dialysate using the
dendrimer conjugation method was performed using LTQ-orbitrap mass spectrometry.
The two pooled dialysate samples produced similar digest profiles. The same dom-
inant peaks were observed in each sample, but at different relative intensities. This
appears to suggest that the profiles of peptides in the digests are consistent between
volunteers. However, due to the high abundance of albumin, these profiles are likely
to show predominantly albumin peptides and hence appear very similar. The other
components will be at a lower abundance and therefore suppressed by the higher abun-
dance components. This should not have presented a problem with the captures, as
only those peptides that are phosphorylated should bind.
A theoretical digest of human serum albumin shows that at least three of the
dominant peptides could be derived from albumin. Those at m/z 1495, 1665 and 1927
[M+H]+ correspond to the mass of the fully methylated forms of RHPDMYSVVLLLRM
(residues 361 – 372), KVPQVSTPTLVEMVSRM (438 – 452) and RHPYFYAPEM
LLFFAKM or HPYFYAPEM LLFFAKRM (169 – 183/ 170 –184), respectively. Neither
are known to be phosphorylated.
The number of peaks in the captured dialysate spectra was increased compared to
184
5. ANALYSES OF PROTEIN PHOSPHORYLATION
before capture, for both methods. None of those peaks dominant in the methylated
dialysate spectra prior to capture were present in the captured samples. The peak at
m/z 1667 [M+H]+ could either have been revealed by the removal of the one at m/z
1665 [M+H]+, or could be the same peptide shifted slightly due to day-to-day machine
variation.
The profiles of the captured samples contained many more peaks than observed
in the methylated digests before enrichment. They shared several features, as listed
previously, but showed more differences than similarities. This could be the result of
several factors. First, the two different capture methods will have different specificities
and differing abilities to access phosphorylation sites (see Bodenmiller et al., 2007).
Secondly, these captures were not from a common starting sample and although the
starting profiles contained very similar components, it is likely that the less abundant
components differed slightly. Finally, the samples were analysed on different days.
Day-to-day variability in the MALDI-TOF MS instrumentation means that there is
the possibility of slight differences (<2 Da) in the m/z values of a peptide on different
days, depending on the calibration.
It is not possible, from the MALDI spectra, to be certain that all the peptides cap-
tured were actually phosphorylated. A common method of confirming phosphorylation
status is to treat the sample with a phosphatase enzyme to remove the phosphate group
prior to re-analysis, looking for the corresponding loss of 80 Da (phosphate) or 98 Da
(phosphoric acid). Experiments to dephosphorylate the captured samples had mixed
success (data not shown). The main problem was the loss of signal caused by the
additional processing and lyophilisation steps on an already small amount of sample.
However, further work in this area together with LTQ-orbitrap analysis would help
assign the unknown peaks.
Analysis of dendrimer-captured dermal dialysate samples using LTQ-orbitrap en-
abled identification of potentially novel phosphorylation sites in both serum albumin
and apolipoprotein L1. Unfortunately, due to the analysis using the LTQ-orbitrap in-
strument being part of a demonstration, only select data were obtained. It is therefore
not known whether additional phosphopeptides or any of the other albumin phospho-
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rylation sites were detected. None of the phosphorylation sites listed in Table 5.1 were
detected. This is most likely a consequence of the relative abundance of serum albumin
and the very small sample sizes used. However, the samples used were selected for their
high protein content, including serum albumin which was known to contain phospho-
rylation sites. Another factor which is likely to have contributed to the low number
of phosphopeptides was that phosphatase inhibitors were not used in this preliminary
study. Their use in future experiments could increase the number of phosphopeptides
captured.
The novel phosphorylation sites identified in this study could represent modifica-
tions that occur specifically within the skin, or in response to injury. However, as novel
identifications, their functions and related kinases are not yet known. Apolipoprotein
L1 has previously been classed as a potential biomarker for fibrosis, due its reduced
expression in serum samples from liver cirrhosis patients, compared to healthy con-
trols (Gangadharan et al., 2007). Within the last few months, it has emerged as an
inducer of cell death, itself induced by cytokines IFN-γ and TNF-α (Zhaorigetu et al.,
2008). However, the function of the phosphorylation is unknown, and the absence of
a solved 3-D structure makes it difficult to predict any potential functions. The loca-
tion of S603 of serum albumin on the external face of the molecule suggests that it is
unlikely to be involved in regulation of protein binding from within the binding site
itself. It could alter protein binding through allosteric interactions. The identification
of novel phosphorylation sites in plasma proteins sampled from a non-plasma source
makes it tempting to speculate that these proteins are phosphorylated within the skin
in response to injury. Further work is needed to better characterise these and other
phosphorylation sites from proteins identified in dermal dialysate, as well as potential
interaction partners, to determine the significance of these findings.
5.4.6 Summary
The aim of the research presented in this chapter was to investigate post-translational
modifications, specifically protein phosphorylation, in dermal dialysate collected dur-
ing the response to injury. To achieve this, three leading methods of phosphorylation
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analysis were evaluated, in-gel staining, TiO2-affinity chromatography and a chemi-
cal derivatisation method, dendrimer conjugation chemistry. The phosphoprotein gel
stain was found to be unsuitable, but the remaining two methods were complimen-
tary, once optimised. Optimisation of the dendrimer conjugation chemistry method
gave improved specificity over the TiO2 bead method, although it has not been con-
firmed whether the tetra-phosphopeptide could be captured using this technique. The
LTQ-orbitrap mass spectrometry system was found to be the most effective method for
phosphopeptide characterisation, giving the highest number of phosphopeptides iden-
tified. Preliminary analysis of protein phosphorylation in dermal dialysate samples was
successful and two potentially novel phosphorylation sites were discovered. The iden-
tification of these novel phosphorylation sites provides scope for further investigation
to determine whether these modifications serve a purpose specific to the cutaneous
response to injury.
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Chapter 6
General Discussion
It is becoming increasingly clear that the inflammatory phase of the injury response
is critical to healing outcome. The mediators that control the progression of the in-
flammatory response have been partially characterised, such as cytokines and growth
factors, but this has failed to lead to satisfactory therapeutic interventions.
The current understanding of the response to injury has been developed incremen-
tally by studying specific markers that are predicted to identify a current stage in the
progression of the response, or to have an involvement in the regulation. The present
research tested the hypothesis that a more global approach to the characterisation of
soluble components present within the wound environment, using shotgun proteomics,
could potentially identify novel biomarkers of the injury response.
Existing injury models can provide protein-containing fluids for analysis, but are
limited in that one injury gives only one sample for analysis. Instead, a model was
required in which the same injury could be sampled more than once in order to study
the progression of the inflammatory response over time. Therefore, one of the pri-
mary aims of this research was to develop and characterise a model of skin injury
from which unknown components could be sampled continuously, and catalogued in
order to identify potentially novel markers of the injury response. The microdialysis
injury model was chosen for its ability to combine injury and sampling, as well as its
applicability to other tissues. With this method, it was possible to sample the injured
tissue continuously without causing additional trauma, which could potential modify
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the response.
Characterisation of the microdialysis injury model using known markers of inflam-
mation fulfilled the second aim of this thesis, showing that it produced a response
comparable to existing models and that a protein-rich fluid could be obtained. Dermal
microdialysis and proteomics had not been combined previously, so it was first nec-
essary to determine the types of proteins contained within dialysate. Thus, the third
aim of this research was to catalogue the proteins that could be identified using these
techniques. The proteins identified were predominantly abundant plasma proteins with
roles in different aspects of the response to injury and inflammation. Further character-
isation was achieved by investigating post-translational protein phosphorylation, the
final aim, in which potentially novel phosphorylation sites were discovered.
6.1 Is microdialysis probe insertion an appropriate
model of injury?
Much of the research into the response to injury and subsequent wound healing has
been conducted in animals. While this provides an important insight into conserved
responses, there still remain subtle differences between model animals, and human
patients. It is therefore beneficial to develop models of studying injury responses in
human volunteers. Existing models, such as the incisions and skin biopsies used in
animal experiments, have seen limited use in human studies. Several disadvantages for
each model, e.g. discontinuous sample, has prompted a search for an alternative. The
first aim of this project was to develop and characterise a model of injury in skin that
would provide a protein-rich fluid, representative of the interstitium, for analysis.
Microdialysis was chosen as the method by which solutes from the interstitium
could be sampled continuously, for reasons detailed in Chapter 1. This also provided
the means of injuring the skin and removed the potential for additional damage asso-
ciated with isolating the injured tissue for analysis, as with incisional and excisional
wound models. The main advantages of the microdialysis injury model over existing
methods is that it generates a reproducible trauma whilst incorporating a sampling
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method that is both local and minimally invasive. This method also enables a flex-
ibility in the time-course that can be sampled, to balance protein requirements with
temporal resolution. Furthermore, the injury caused by the probe insertion process
is relatively small and most volunteers heal without visible scarring (Clough, personal
communication; personal observation), an advantage in human studies where cosmetic
outcome is of importance.
The three hour time course was chosen for the present study because it was known
that cytokines were recovered in dialysate samples within this time, thus indicating
that the inflammatory response was underway. This meant that haemostasis and the
initiation of the inflammatory response, and therefore potential markers of these pro-
cesses, would be sampled. The temporal flexibility of microdialysis sampling means
that this time course could be extended or altered in future experiments, either to
follow the progression of the response further, or to increase the temporal resolution.
Changing temporal resolution will have no impact on the tissue, but the injury response
is likely to have an impact on the recovery of solutes over time. This is initially due to
blockage of the pores of the probe by larger solutes or complexes. Over the following
days, the tissue remodels itself and further blocks pores with new connective tissue
(Wang et al., 2007).
The vascular response to the injury was very similar to that seen in previous mi-
crodialysis experiments (Anderson, Andersson & Wa¨rdell, 1994 and Groth & Serup,
1998), although data on the vascular response to other incision models are unavailable.
Therefore, it was more informative to consider the content of the dialysate samples to
determine whether microdialysis is an appropriate model of injury.
6.2 Is dialysate an appropriate source of potential
biomarkers of the response to injury?
Physically, the injury caused by microdialysis probe insertion is similar to an inci-
sion, because no tissue is removed. The difference between the microdialysis insertion
model and incisional wounds is that the insertion of the guide needle primarily damages
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the dermis. The epidermis is only damaged at the entrance and exit sites, compared
to a typical incision which bisects the epidermis across the full length of the wound.
This may reduce the number of damaged keratinocytes, and therefore the release of
stored cytokines necessary for initiating the injury response. The concentration of IL-6
measured in the present study was comparable to levels found in murine incisional
wound studies (Bryan et al., 2005) and other human microdialysis studies (Angst et
al., 2008; Clough et al., 2007), but higher than in excisional wounds in human suction
blister and skin biopsy controls (Deerman et al., 2004; Van Der Laan, de Leij & ten
Duis, 2001).
Analysis of the cytokine content of dialysate showed that there was an inflammatory
response to microdialysis probe insertion (Chapter 3). However, cytokines are not the
only mediators involved, and cannot give a complete picture of the processes that
occur. A survey of the protein content of dialysate was performed to give a broader
characterisation of the components that may be active within the injury environment.
The shotgun proteomic analysis of dermal dialysate conducted as part of this research
shows that it contained many proteins relevant to the processes that occur as part of
the injury response, both extra- and intracellular in origin, as discussed in Chapter 4.
Considerably fewer proteins were identified in the dermal dialysate, even after de-
pletion of highly abundant proteins. Since the same shotgun approach and instrumen-
tation have yielded many more components in other biofluids, the difference in the
number of proteins identified is likely due to the differences in the protein content of
the sample, and the types of proteins recovered by each approach. Also, the generation
of blisters causes greater stress on the tissue and hence an increased leakage of plasma
proteins that contaminate the interstitial fluid (Kool et al., 2007). Their collection in
the blister fluid is not inhibited by diffusion into a probe, as is the case with microdial-
ysis. The number of proteins found in dermal dialysate was comparable to the number
found in cerebral dialysate (Maurer et al., 2003). The 14 % increase in dermal dialysate
identifications may be due to the use of 1-D SDS-PAGE as a primary separation tech-
nique in the present study, rather than 2-D gel electrophoresis used in the brain study,
which may bias against insoluble proteins or those that exist below the sensitivity level
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of the staining. However, the latter is unlikely to have been a major problem, given
that the sensitivity of the silver stain used is within the nanogram range (Blum, Beier
& Gross, 1987). It is most likely that this difference is a function of either the mass
spectrometry used or the protein content of the different tissues analysed.
Despite the apparent simplicity of dermal dialysate proteome the list is unlikely to
be comprehensive. This is shown by the detection of cytokines in the present study
when using antibody detection methods (Chapter 3), but not when using mass spec-
trometry.
Additional work with dermal dialysate conducted within the Centre for Proteome
Research has used a gel-free method for identification of proteins, known as iTRAQ
(Applied Biosystems). With this approach, more than 60 additional proteins were
identified, without using depletion (Parkinson, personal communication). Many are
variants of proteins found in the present study; for example, two additional apolipopro-
teins and seven further keratins. This increase is also due, in part, to the larger sample
number and differences in the processing and analysis, including the omission of the
depletion and gel stages, and the different mass spectrometry experiments performed.
The experiments showed the presence of further relevant proteins including fibrinogen
and vitronectin, involved in promoting coagulation, and kininogen-1, a precursor to
bradykinin, also known to have a variety of effects in inflammation, including mod-
ulation of vascular permeability. Also identified were some of the highly abundant
proteins specifically depleted in the present study, including serum albumin, transfer-
rin and several immunoglobulin variants.
While the protein content of the dialysate samples (Chapter 4) was compiled from
only two experiments, the overlap between this and the iTRAQ study shows that the
proteome collated in the present study is representative of the types of proteins found in
the wider population. Furthermore, the iTRAQ analysis was able to quantify changes
in recovery of the identified proteins in dialysate collected in sequential samples. Quan-
titative data were available for one-third of the proteins, showing 1 – 2-fold changes in
the amounts recovered for each (Parkinson, personal communication).
Now that some of the components of interstitial fluid are known, more sensitive
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quantification methods, e.g. ELISAs or Western blotting, could be used to follow
changes in the concentration of a protein recovered in dialysate samples from con-
secutive time-periods. However, such methods require specific antibodies and multiple
experiments, which can prove very time consuming. Recent developments in proteomic
methods provide an interesting alternative. Multiple reaction monitoring (MRM, also
known in the singular as selected reaction monitoring, SRM) enables the absolute quan-
titation of large numbers of proteins using mass spectrometry (Anderson & Hunter,
2006). A similar approach has been used previously in microdialysis-mass spectrome-
try studies, for the measurement of metabolites, such as the neurotransmitter acetyl-
choline (Fu et al., 2008), but has not yet been used for quantifying peptides recovered
in dialysate.
The MRM technique involves defining the m/z value of a target peptide and cor-
responding fragment ion, which the mass spectrometer is able to detect and quantify
between samples. Peptide specificity is ensured by the combination of a first-dimension
MS (MS1) step which selects the target peptide and a second, MS2, step which selects
for the particular compoment that is characteristic of the fragmentation spectrum.
Peptide selection lists for targets are compiled either from in silico prediction pro-
grams, or using known peptides from proteome profiling experiments, such as those
performed in the present study. The presence of highly abundant proteins does not
seem to be detrimental to the detection of lower abundance components, with proteins
at concentrations as low as 0.67 µg/ml (Anderson & Hunter, 2006) identified without
depletion. However, fractionation or immunodepletion of the sample prior to analysis
would enable greater access to the dynamic range of protein concentrations.
Quantifying changes in protein recovery will show whether any proteins are sig-
nificantly up- or down-regulated over the course of the response to injury and from
this, an importance to the progression of inflammation can be inferred. However, a
change in concentration is not the only determinant of a role. In fact, changes in
post-translational modifications are more likely to be indicative of protein activation
or function within a response. Examples of the proteins found in dermal dialysate
that are known to be differentially phosphorylated in response to injury were given
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in Section 5.1.1. None of these were reported in the preliminary investigation into
phosphorylation in dialysate, most likely due to the limited dataset that could be re-
ported, but also to the presence of relatively abundant albumin and apolipoprotein
phosphopeptides obscuring further identifications. However, the two potentially novel
sites suggest that the analysis of post-translation modifications in proteins recovered
in dialysate will provide novel insights into protein function and signalling during the
injury response.
Collectively, these data suggest that microdialysis has the potential to recover rel-
evant, novel markers of the injury response, provided the analysis techniques used are
sensitive enough to detect relatively low abundance components. Thus, it is likely to
be a useful tool in furthering our understanding of the signalling processes that occur
following injury.
6.3 What new insights into the injury response have
been gained?
This research originally set out to find novel markers of the response to injury
using cutaneous microdialysis and shotgun proteomics. However, it was first neces-
sary to explore the suitability of this combination of technologies for the recovery and
identification of proteins relevant to the injury response.
Data from this study expanded on previous characterisations of the response to mi-
crodialysis probe insertion, in terms of the vascular response, proteins recovered, and
the time-course over which they were collected. It measured the recovery of a panel of
cytokines, both those which have previously been reported in human dermal dialysate
(IL-6, IL-10, IFN-γ), and those which have not (MCP-1, MIP-1α, OSM, VEGF). Fur-
thermore, the use of 30-minute collection periods enabled a greater temporal resolution
than previously reported. This gives a clearer understanding of the order in which the
different cytokines are released and diffuse into the probe in large enough quantities
to be detected, shedding light on the activation of the resident and infiltrating cells.
However, there is a limit to the information that can be gained from characterising
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cytokine responses, as these are not the only mediators active during this time.
By investigating the different types of proteins that can be recovered from the injury
environment, a broader characterisation of the processes involved has been achieved.
While none of the proteins identified within the dermal dialysate samples were par-
ticularly surprising, or obvious candidates for novel markers, these data show that
microdialysis samples relevant interstitial fluid components from the tissue. It also
brings together the wider injury literature by linking together a range of processes,
such as iron metabolism, which may not be immediately associated with the response
to injury. Thus the research conducted during the present study represents a base for
further, targeted investigations into the expression of these proteins over the course of
the response to an injury in both healthy and diseased skin. From those studies, it
should become possible to select appropriate biomarker candidates.
The types of proteins identified were mostly highly abundant plasma proteins, re-
flecting both the infiltration of plasma into the wound and also the limits of detection
that are experienced with shotgun proteomics using GeLC-MS/MS. Different proteomic
analysis techniques are certain to expand on the dermal dialysate proteome presented
in this study, providing additional scope for potential targets.
Quantitative analysis of the changes in protein concentration between timed dialysate
samples has been performed, as part of another project within the CPR. Furthermore,
because the proteins identified in the present study were predominantly highly abun-
dant plasma proteins, it is unlikely that the concentrations will change significantly
within the study period while vascular permeability to protein remains elevated. This
permeability is maximal by three days after an injury and remains elevated until ap-
proximately seven days (Brown et al., 1992), much longer than the study period.
Instead, the present study took an alternative, complementary approach to improve
the characterisation of this proteome - namely, the analysis of protein phosphorylation.
This area of the research was perhaps the most fruitful in terms of novel information,
identifying potentially novel phosphorylation sites in two common plasma proteins.
These data suggest that future investigations into the post-translational modifications
of proteins involved in the response to injury will be highly informative. While the
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functions of these novel phosphorylation sites are as yet unknown, their discovery in
proteins collected from the interstitial fluid space rather than directly from the vascu-
lar compartment leads to the speculation that these modifications could be location-
or response- specific. Further experiments to characterise protein phosphorylation in
larger or depleted dermal dialysate samples could potentially lead to the identification
of further novel phosphorylation sites in a greater number of proteins. Additionally, it
could define more precisely the roles of phosphorylated residues known to have a regu-
latory function within the injury response, such as serpin F1 and others mentioned in
Section 5.1.1.
6.4 Is the microdialysis probe insertion model ap-
propriate for the study of inflammation in other
tissues or disease states?
The insertion of microdialysis probes causes an inflammatory response in the target
tissue, making it an ideal method by which to study injury without the complications
of additional stimuli. Microdialysis is certainly compatible for sampling interstitial
fluid components from tissues other than skin, including muscle and adipose tissue
(Rosdahl et al., 1993), liver (Yang et al., 1995) and the eye (Wei et al., 2006). It has
also been used to sample solutes from tumour micro-environments (Garvin & Dabrosin,
2008) and several skin diseases including psoriasis (Krogstad et al., 1997) and cold
urticaria (Nuutinen, Harvima & Ackermann, 2007). However, very few microdialysis
experiments in these tissues have looked at the recovery of a panel of inflammatory
mediators and none have used shotgun proteomics to characterise the response to
insertion.
Taken at face value, the dermal dialysate proteome appears very similar to that
reported for cerebral dialysate (Maurer et al., 2003), which would suggest that this
cutaneous injury model is appropriate for studying injury in other tissues. However,
the proteomic studies primarily identified relatively highly abundant proteins released
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from plasma as a result of vascular damage. This means that the proteomic profile will
appear very similar, regardless of the tissue studied. Further research is required to
determine whether these highly abundant proteins are suitable markers of the response
to injury in skin and other tissues. This is more likely to be determined by changes
in their modifications, rather than their concentration. Studies comparing healthy and
diseased skin, such as psoriatic lesions, could potentially complement these observations
by identifying proteins that are differentially modified or regulated.
Together, the data from the present study show that the microdialysis probe inser-
tion injury model generates a sufficient degree of inflammation and provides relevant
proteins for further study. However, while the inflammatory response generated by
probe insertion is of benefit to the present study and others investigating the injury
response, it is a concern for studies into the effects of additional stimuli over and above
the initial wounding. Understanding of the injury response to trauma is of particular
importance when it is considered that investigators frequently cite that one hour was
allowed for the trauma to subside before samples were collected (e.g. Flannery et al.,
2007). However, the present study, and indeed several others, show that this is only
the beginning of the response to injury and the associated inflammation.
Many investigations into inflammation have been conducted in which microdialysis
has been used to sample the response to an experimental stimulus (e.g. Iversen et
al., 2003; Schmelz et al., 1997; Toriyabe et al., 2004). While these studies compare
the test conditions to an unstimulated control to measure the effect over and above
this injury response, its influence on the experimentally-induced inflammation is often
overlooked even when the effect of cell damage is of particular interest (Fairweather
et al., 2004). Longer-term experiments have shown that the inflammatory response
to probe insertion alone lasts for at least 24 hours (Averbeck et al., 2006) and it is
unclear whether a secondary stimulus receives a dampened or enhanced response as a
result. It is also plausible that the removal of mediators into the dialysate attenuates
the response, although further research is required to confirm or refute this hypothesis.
In conclusion, microdialysis gives the means by which to injure and subsequently
explore the response to tissue damage in a variety of organs, through the recovery
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of relevant solutes. While the shotgun proteomics technique used was not sensitive
enough to identify any skin-specific markers, the analysis of protein phosphorylation
and detection of potentially novel modification sites is likely to be highly informative
and should shed light on cellular processes both in health and in disease.
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Y
R
4
65
1.
83
13
01
.6
4
13
01
.7
1
SL
D
LD
SI
IA
E
V
K
7
67
9.
32
13
56
.6
2
13
56
.6
9
LN
D
LE
D
A
LQ
Q
A
K
11
69
2.
31
13
82
.6
1
13
82
.6
8
SL
N
N
Q
FA
SF
ID
K
7
73
8.
34
14
74
.6
7
14
74
.7
4
W
E
LL
Q
Q
V
D
T
ST
R
8
73
8.
35
14
74
.6
8
14
74
.7
8
F
LE
Q
Q
N
Q
V
LQ
T
K
4
82
9.
37
16
56
.7
3
16
56
.7
9
SG
G
G
F
SS
G
SA
G
II
N
Y
Q
R
5
85
8.
89
17
15
.7
7
17
15
.8
4
Q
IS
N
LQ
Q
SI
SD
A
E
Q
R
6
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. APPENDIX TWO: DEPLETED DIALYSATE DATA
gi
n
o.
P
ro
te
in
N
am
e
P
ro
t
P
ro
t
em
P
A
I
U
n
i.
E
xp
.
E
xp
.
C
al
c.
P
ep
ti
d
e
N
o.
P
ep
t.
S
co
re
M
at
ch
es
P
ep
.
m
/
z
M
r
M
r
S
eq
u
en
ce
M
at
ch
es
88
3.
31
17
64
.6
2
17
64
.7
3
F
SS
C
G
G
G
G
G
SF
G
A
G
G
G
F
-
G
SR
2
66
5.
29
19
92
.8
5
19
92
.9
7
T
H
N
LE
P
Y
F
E
SF
IN
N
LR
5
86
1.
00
25
79
.9
8
25
80
.1
5
M
SG
E
C
A
P
N
V
SV
SV
ST
SH
T
-
T
IS
G
G
G
SR
5
45
57
48
5
ce
ru
lo
pl
as
m
in
59
3
50
0.
41
22
58
7.
77
11
73
.5
2
11
73
.5
4
M
Y
Y
SA
V
D
P
T
K
4
61
3.
27
12
24
.5
3
12
24
.5
1
D
D
E
E
F
IE
SN
K
2
68
6.
38
13
70
.7
4
13
70
.7
6
G
A
Y
P
LS
IE
P
IG
V
R
7
71
6.
31
14
30
.6
1
14
30
.6
3
Q
SE
D
ST
F
Y
LG
E
R
4
73
5.
41
14
68
.8
1
14
68
.8
3
D
IA
SG
LI
G
P
LI
IC
K
10
73
5.
85
14
69
.6
9
14
69
.7
2
E
V
G
P
T
N
A
D
P
V
C
LA
K
9
76
0.
36
15
18
.7
0
15
18
.7
4
A
LY
LQ
Y
T
D
E
T
F
R
7
78
8.
41
15
74
.8
1
15
74
.8
5
D
LY
SG
LI
G
P
LI
V
C
R
5
79
4.
36
15
86
.7
1
15
86
.7
3
R
Q
SE
D
ST
F
Y
LG
E
R
12
82
0.
38
16
38
.7
5
16
38
.7
8
A
G
LQ
A
F
FQ
V
Q
E
C
N
K
5
82
4.
41
16
46
.8
1
16
46
.8
3
K
A
LY
LQ
Y
T
D
E
T
F
R
7
72
4.
32
21
69
.9
4
21
70
.0
7
LI
SV
D
T
E
H
SN
IY
LQ
N
G
P
D
R
8
75
1.
29
22
50
.8
6
22
50
.9
0
M
H
SM
N
G
F
M
Y
G
N
Q
P
G
LT
-
M
C
K
6
56
4.
78
22
55
.1
0
22
55
.1
5
K
A
E
E
E
H
LG
IL
G
P
Q
LH
A
D
V
-
G
D
K
6
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. APPENDIX TWO: DEPLETED DIALYSATE DATA
gi
n
o.
P
ro
te
in
N
am
e
P
ro
t
P
ro
t
em
P
A
I
U
n
i.
E
xp
.
E
xp
.
C
al
c.
P
ep
ti
d
e
N
o.
P
ep
t.
S
co
re
M
at
ch
es
P
ep
.
m
/
z
M
r
M
r
S
eq
u
en
ce
M
at
ch
es
76
7.
05
22
98
.1
2
22
98
.1
6
K
LI
SV
D
T
E
H
SN
IY
LQ
N
G
P
D
-
R
20
78
8.
38
23
62
.1
3
23
62
.1
6
M
Y
Y
SA
V
D
P
T
K
D
IF
T
G
LI
G
P
-
M
K
7
80
0.
03
23
97
.0
6
23
97
.0
9
H
Y
Y
IG
II
E
T
T
W
D
Y
A
SD
H
G
-
E
K
10
82
5.
31
24
72
.9
1
24
73
.0
6
M
F
T
TA
P
D
Q
V
D
K
E
D
E
D
FQ
-
E
SN
K
5
82
9.
76
24
86
.2
5
24
86
.2
8
G
P
E
E
E
H
LG
IL
G
P
V
IW
A
E
V
-
G
D
T
IR
4
83
5.
70
25
04
.0
8
25
04
.1
2
SG
A
G
T
E
D
SA
C
IP
W
A
Y
Y
ST
-
V
D
Q
V
K
9
84
4.
41
25
30
.2
1
25
30
.2
4
SV
P
P
SA
SH
VA
P
T
E
T
F
T
Y
E
W
-
T
V
P
K
11
89
5.
74
26
84
.2
1
26
84
.2
5
G
V
Y
SS
D
V
F
D
IF
P
G
T
Y
Q
T
LE
-
M
F
P
R
4
45
57
32
1
ap
ol
ip
op
ro
te
in
A
-
I
53
8
46
2.
09
17
51
6.
24
10
30
.4
7
10
30
.5
1
LS
P
LG
E
E
M
R
3
61
5.
83
12
29
.6
5
12
29
.7
0
Q
G
LL
P
V
LE
SF
K
8
61
8.
32
12
34
.6
3
12
34
.6
8
D
LA
T
V
Y
V
D
V
LK
9
62
6.
78
12
51
.5
4
12
51
.6
1
V
Q
P
Y
LD
D
FQ
K
4
64
2.
26
12
82
.5
1
12
82
.5
7
W
Q
E
E
M
E
LY
R
8
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gi
n
o.
P
ro
te
in
N
am
e
P
ro
t
P
ro
t
em
P
A
I
U
n
i.
E
xp
.
E
xp
.
C
al
c.
P
ep
ti
d
e
N
o.
P
ep
t.
S
co
re
M
at
ch
es
P
ep
.
m
/
z
M
r
M
r
S
eq
u
en
ce
M
at
ch
es
65
1.
30
13
00
.5
9
13
00
.6
4
T
H
LA
P
Y
SD
E
LR
8
65
1.
84
13
01
.6
7
13
01
.6
4
LS
P
LG
E
E
M
R
D
R
3
69
0.
83
13
79
.6
4
13
79
.7
1
V
Q
P
Y
LD
D
FQ
K
K
3
69
3.
83
13
85
.6
4
13
85
.7
1
V
SF
LS
A
LE
E
Y
T
K
7
70
0.
80
13
99
.5
9
13
99
.6
6
D
Y
V
SQ
F
E
G
SA
LG
K
10
73
1.
90
14
61
.7
8
14
61
.8
4
V
K
D
LA
T
V
Y
V
D
V
LK
6
75
7.
88
15
13
.7
4
15
13
.8
0
V
SF
LS
A
LE
E
Y
T
K
K
4
80
6.
85
16
11
.6
9
16
11
.7
8
LL
D
N
W
D
SV
T
ST
F
SK
5
82
5.
89
16
49
.7
6
16
49
.8
6
D
LA
T
V
Y
V
D
V
LK
D
SG
R
2
60
5.
93
18
14
.7
6
18
14
.8
4
D
SG
R
D
Y
V
SQ
F
E
G
SA
LG
K
10
96
6.
93
19
31
.8
5
19
31
.9
3
E
Q
LG
P
V
T
Q
E
F
W
D
N
LE
K
10
73
4.
68
22
01
.0
1
22
01
.1
1
LR
E
Q
LG
P
V
T
Q
E
F
W
D
N
LE
-
K
19
11
32
15
61
he
m
op
ex
in
43
2
65
0.
84
16
48
7.
26
97
2.
51
97
2.
54
LW
W
LD
LK
5
50
9.
25
10
16
.4
9
10
16
.5
3
V
W
V
Y
P
P
E
K
4
56
5.
29
11
28
.5
6
11
28
.6
4
R
LW
W
LD
LK
2
57
1.
27
11
40
.5
2
11
40
.5
8
G
G
Y
T
LV
SG
Y
P
K
8
57
9.
71
11
57
.4
1
11
57
.4
6
D
Y
F
M
P
C
P
G
R
7
61
0.
78
12
19
.5
4
12
19
.6
0
N
F
P
SP
V
D
A
A
F
R
5
63
4.
81
12
67
.6
1
12
67
.6
7
F
D
P
V
R
G
E
V
P
P
R
4
70
2.
80
14
03
.5
9
14
03
.6
6
SW
PA
V
G
N
C
SS
A
LR
5
74
2.
83
14
83
.6
4
14
83
.6
8
E
W
F
W
D
LA
T
G
T
M
K
5
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gi
n
o.
P
ro
te
in
N
am
e
P
ro
t
P
ro
t
em
P
A
I
U
n
i.
E
xp
.
E
xp
.
C
al
c.
P
ep
ti
d
e
N
o.
P
ep
t.
S
co
re
M
at
ch
es
P
ep
.
m
/
z
M
r
M
r
S
eq
u
en
ce
M
at
ch
es
74
8.
30
14
94
.5
9
14
94
.6
7
Y
Y
C
FQ
G
N
Q
F
LR
10
75
0.
81
14
99
.6
0
14
99
.6
8
E
W
F
W
D
LA
T
G
T
M
K
6
85
6.
85
17
11
.6
8
17
11
.7
6
G
E
C
Q
A
E
G
V
LF
FQ
G
D
R
10
86
8.
41
17
34
.8
0
17
34
.8
7
A
LP
Q
P
Q
N
V
T
SL
LG
C
T
H
6
61
3.
27
18
36
.7
9
18
36
.8
8
SG
A
Q
A
T
W
T
E
LP
W
P
H
E
K
6
78
8.
67
23
62
.9
9
23
63
.1
6
LL
Q
D
E
F
P
G
IP
SP
LD
A
AV
E
C
-
H
R
3
83
3.
36
24
97
.0
7
24
97
.2
3
E
V
G
T
P
H
G
II
LD
SV
D
A
A
F
IC
-
P
G
SS
R
5
92
57
23
2
or
os
om
uc
oi
d
1
37
2
51
1.
2
7
49
7.
75
99
3.
48
99
3.
51
T
E
D
T
IF
LR
6
55
6.
72
11
11
.4
3
11
11
.5
2
SD
V
V
Y
T
D
W
K
5
58
0.
77
11
59
.5
2
11
59
.5
8
W
F
Y
IA
SA
F
R
5
72
3.
31
14
44
.6
0
14
44
.6
5
T
Y
M
LA
F
D
V
N
D
E
K
4
85
4.
90
17
07
.7
8
17
07
.8
5
N
W
G
LS
V
Y
A
D
K
P
E
T
T
K
5
87
1.
86
17
41
.7
0
17
41
.8
0
E
Q
LG
E
F
Y
E
A
LD
C
LR
4
58
4.
96
17
51
.8
7
17
51
.9
5
Y
V
G
G
Q
E
H
FA
H
LL
IL
R
6
45
57
38
5
co
m
pl
em
en
t
33
2
47
0.
23
24
41
7.
25
83
2.
49
83
2.
48
LP
Y
SV
V
R
4
co
m
po
ne
nt
3
44
3.
76
88
5.
50
88
5.
52
IS
LP
E
SL
K
4
51
2.
76
10
23
.5
0
10
23
.5
1
F
IS
LG
E
A
C
K
6
54
2.
28
10
82
.5
4
10
82
.5
5
G
Y
T
Q
Q
LA
F
R
6
54
6.
82
10
91
.6
2
10
91
.6
2
N
T
LI
IY
LD
K
6
63
3.
77
12
65
.5
2
12
65
.6
1
N
T
M
IL
E
IC
T
R
3
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gi
n
o.
P
ro
te
in
N
am
e
P
ro
t
P
ro
t
em
P
A
I
U
n
i.
E
xp
.
E
xp
.
C
al
c.
P
ep
ti
d
e
N
o.
P
ep
t.
S
co
re
M
at
ch
es
P
ep
.
m
/
z
M
r
M
r
S
eq
u
en
ce
M
at
ch
es
65
0.
77
12
99
.5
2
12
99
.5
8
A
C
E
P
G
V
D
Y
V
Y
K
4
66
8.
36
13
34
.7
1
13
34
.7
2
A
P
ST
W
LT
A
Y
V
V
K
7
68
5.
85
13
69
.6
8
13
69
.7
2
T
IY
T
P
G
ST
V
LY
R
5
70
1.
39
14
00
.7
6
14
00
.8
3
SS
LS
V
P
Y
V
IV
P
LK
5
73
5.
85
14
69
.6
9
14
69
.7
7
IP
IE
D
G
SG
E
V
V
LS
R
5
49
1.
23
14
70
.6
7
14
70
.7
4
A
AV
Y
H
H
F
IS
D
G
V
R
6
81
3.
93
16
25
.8
4
16
25
.8
7
R
IP
IE
D
G
SG
E
V
V
LS
R
6
82
0.
43
16
38
.8
4
16
38
.8
7
T
V
M
V
N
IE
N
P
E
G
IP
V
K
8
82
9.
38
16
56
.7
5
16
56
.7
6
A
G
D
F
LE
A
N
Y
M
N
LQ
R
7
83
4.
34
16
66
.6
8
16
66
.7
3
V
Y
A
Y
Y
N
LE
E
SC
T
R
4
85
1.
89
17
01
.7
8
17
01
.7
9
V
F
LD
C
C
N
Y
IT
E
LR
10
90
8.
90
18
15
.7
9
18
15
.8
8
SN
LD
E
D
II
A
E
E
N
IV
SR
5
62
4.
67
18
71
.0
0
18
71
.0
3
T
E
LR
P
G
E
T
LN
V
N
F
LL
R
5
63
1.
00
18
89
.9
8
18
90
.0
7
LS
IN
T
H
P
SQ
K
P
LS
IT
V
R
3
68
6.
03
20
55
.0
7
20
55
.0
9
V
RV
E
LL
H
N
PA
FC
SL
A
T
T
K
10
77
7.
37
23
29
.1
0
23
29
.1
3
SE
F
P
E
SW
LW
N
V
E
D
LK
E
P
P
-
K
11
86
5.
42
25
93
.2
4
25
93
.3
0
T
M
Q
A
LP
Y
ST
V
G
N
SN
N
Y
L-
H
LS
V
LR
7
91
9.
09
27
54
.2
5
27
54
.2
8
E
G
V
Q
K
E
D
IP
PA
D
LS
D
Q
V
P
-
D
T
E
SE
T
R
23
32
48
34
10
vi
ta
m
in
D
-b
in
di
ng
31
4
31
0.
7
15
45
8.
22
91
4.
43
91
4.
45
Y
T
F
E
LS
R
4
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gi
n
o.
P
ro
te
in
N
am
e
P
ro
t
P
ro
t
em
P
A
I
U
n
i.
E
xp
.
E
xp
.
C
al
c.
P
ep
ti
d
e
N
o.
P
ep
t.
S
co
re
M
at
ch
es
P
ep
.
m
/
z
M
r
M
r
S
eq
u
en
ce
M
at
ch
es
pr
ot
ei
n
57
8.
28
11
54
.5
4
11
54
.6
2
LP
D
A
T
P
T
E
LA
K
6
58
5.
81
11
69
.6
1
11
69
.6
4
T
H
LP
E
V
F
LS
K
5
62
7.
83
12
53
.6
5
12
53
.7
1
H
LS
LL
T
T
LS
N
R
4
44
2.
90
13
25
.6
8
13
25
.7
5
R
T
H
LP
E
V
F
LS
K
8
67
7.
87
13
53
.7
2
13
53
.7
5
A
K
LP
D
A
T
P
T
E
LA
K
6
76
5.
37
15
28
.7
2
15
28
.7
8
E
D
F
T
SL
SL
V
LY
SR
3
78
3.
89
15
65
.7
6
15
65
.8
1
F
P
SG
T
F
E
Q
V
SQ
LV
K
8
84
7.
92
16
93
.8
3
16
93
.9
0
K
F
P
SG
T
F
E
Q
V
SQ
LV
K
14
10
46
.8
9
20
91
.7
6
20
91
.8
2
SL
G
E
C
C
D
V
E
D
ST
T
C
F
N
A
K
10
75
5.
62
22
63
.8
3
22
63
.9
3
SC
E
SN
SP
F
P
V
H
P
G
TA
E
C
C
T
-
K
9
77
6.
71
23
27
.1
0
23
27
.1
8
E
F
SH
LG
K
E
D
F
T
SL
SL
V
LY
SR
3
78
9.
42
23
65
.2
4
23
65
.2
6
V
P
TA
D
LE
D
V
LP
LA
E
D
IT
N
I-
LS
K
10
79
0.
99
23
69
.9
5
23
70
.0
4
SY
LS
M
V
G
SC
C
T
SA
SP
T
V
C
F
-
LK
4
90
3.
04
27
06
.0
9
27
06
.2
0
H
Q
P
Q
E
F
P
T
Y
V
E
P
T
N
D
E
IC
E
-
A
F
R
13
67
78
23
58
co
m
pl
em
en
t
28
4
17
0.
3
12
57
8.
32
11
54
.6
2
11
54
.6
2
E
E
LL
PA
Q
D
IK
5
fa
ct
or
B
62
1.
85
12
41
.6
9
12
41
.7
0
V
K
D
IS
E
V
V
T
P
R
5
63
8.
29
12
74
.5
7
12
74
.6
5
Y
G
LV
T
Y
A
T
Y
P
K
3
65
3.
83
13
05
.6
5
13
05
.6
5
E
K
LQ
D
E
D
LG
F
L
6
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gi
n
o.
P
ro
te
in
N
am
e
P
ro
t
P
ro
t
em
P
A
I
U
n
i.
E
xp
.
E
xp
.
C
al
c.
P
ep
ti
d
e
N
o.
P
ep
t.
S
co
re
M
at
ch
es
P
ep
.
m
/
z
M
r
M
r
S
eq
u
en
ce
M
at
ch
es
75
4.
84
15
07
.6
7
15
07
.6
8
V
SE
A
D
SS
N
A
D
W
V
T
K
5
92
1.
97
18
41
.9
2
18
41
.9
1
E
A
G
IP
E
F
Y
D
Y
D
VA
LI
K
7
95
7.
88
19
13
.7
5
19
13
.8
4
F
LC
T
G
G
V
SP
Y
A
D
P
N
T
C
R
4
70
8.
35
21
22
.0
1
21
22
.0
3
Y
G
Q
T
IR
P
IC
LP
C
T
E
G
T
T
R
18
76
1.
01
22
80
.0
1
22
80
.0
3
A
IH
C
P
R
P
H
D
F
E
N
G
E
Y
W
P
R
9
81
3.
42
24
37
.2
3
24
37
.2
5
LP
P
T
T
T
C
Q
Q
Q
K
E
E
LL
PA
Q
-
D
IK
9
88
4.
74
26
51
.1
9
26
51
.1
9
W
SG
Q
TA
IC
D
N
G
A
G
Y
C
SN
-
P
G
IP
IG
T
R
22
93
9.
12
28
14
.3
4
28
14
.3
7
LL
Q
E
G
Q
A
LE
Y
V
C
P
SG
F
Y
P
-
Y
P
V
Q
T
R
6
45
57
28
7
an
gi
ot
en
si
no
ge
n
22
7
10
0.
35
5
54
2.
24
10
82
.4
6
10
82
.5
2
F
M
Q
AV
T
G
W
K
8
64
9.
32
12
96
.6
3
12
96
.7
1
D
P
T
F
IP
A
P
IQ
A
K
8
71
9.
32
14
36
.6
3
14
36
.7
0
SL
D
F
T
E
LD
VA
A
E
K
8
75
7.
35
15
12
.6
9
15
12
.7
6
A
A
M
V
G
M
LA
N
F
LG
F
R
6
86
1.
98
17
21
.9
5
17
22
.0
2
V
LS
A
LQ
AV
Q
G
LL
VA
Q
G
R
5
55
95
68
99
ke
ra
ti
n
9
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